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Background: In the UK, patients with one or two adenomas, of which at least one is ≥ 10 mm in size,
or three or four small adenomas, are deemed to be at intermediate risk of colorectal cancer (CRC) and
referred for surveillance colonoscopy 3 years post polypectomy. However, colonoscopy is costly, can cause
discomfort and carries a small risk of complications.
Objectives: To determine whether or not annual faecal immunochemical tests (FITs) are effective,
acceptable and cost saving compared with colonoscopy surveillance for detecting CRC and advanced
adenomas (AAs).
Design: Diagnostic accuracy study with health psychology assessment and economic evaluation.
Setting: Participants were recruited from 30 January 2012 to 30 December 2013 within the Bowel Cancer
Screening Programme in England.
Participants: Men and women, aged 60–72 years, deemed to be at intermediate risk of CRC following
adenoma removal after a positive guaiac faecal occult blood test were invited to participate. Invitees who
consented and returned an analysable FIT were included.
Intervention: We offered participants quantitative FITs at 1, 2 and 3 years post polypectomy. Participants
testing positive with any FIT were referred for colonoscopy and not offered further FITs. Participants testing
negative were offered colonoscopy at 3 years post polypectomy. Acceptibility of FIT was assessed using
discussion groups, questionnaires and interviews.
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Main outcome measures: The primary outcome was 3-year sensitivity of an annual FIT versus
colonoscopy at 3 years for detecting advanced colorectal neoplasia (ACN) (CRC and/or AA). Secondary
outcomes included participants’ surveillance preferences, and the incremental costs and cost-effectiveness
of FIT versus colonoscopy surveillance.
Results: Of 8008 invitees, 5946 (74.3%) consented and returned a round 1 FIT. FIT uptake in rounds 2
and 3 was 97.2% and 96.9%, respectively. With a threshold of 40 µg of haemoglobin (Hb)/g faeces
(hereafter referred to as µg/g), positivity was 5.8% in round 1, declining to 4.1% in round 3. Over three
rounds, 69.2% (18/26) of participants with CRC, 34.3% (152/443) with AAs and 35.6% (165/463) with
ACN tested positive at 40 µg/g. Sensitivity for CRC and AAs increased, whereas specificity decreased, with
lower thresholds and multiple rounds. At 40 µg/g, sensitivity and specificity of the first FIT for CRC were
30.8% and 93.9%, respectively. The programme sensitivity and specificity of three rounds at 10 µg/g were
84.6% and 70.8%, respectively. Participants’ preferred surveillance strategy was 3-yearly colonoscopy
plus annual FITs (57.9%), followed by annual FITs with colonoscopy in positive cases (31.5%). FIT with
colonoscopy in positive cases was cheaper than 3-yearly colonoscopy (£2,633,382), varying from £485,236
(40 µg/g) to £956,602 (10 µg/g). Over 3 years, FIT surveillance could miss 291 AAs and eight CRCs using a
threshold of 40 µg/g, or 189 AAs and four CRCs using a threshold of 10 µg/g.
Conclusions: Annual low-threshold FIT with colonoscopy in positive cases achieved high sensitivity for
CRC and would be cost saving compared with 3-yearly colonoscopy. However, at higher thresholds, this
strategy could miss 15–30% of CRCs and 40–70% of AAs. Most participants preferred annual FITs plus
3-yearly colonoscopy. Further research is needed to define a clear role for FITs in surveillance.
Future work: Evaluate the impact of ACN missed by FITs on quality-adjusted life-years.
Trial registration: Current Controlled Trials ISRCTN18040196.
Funding: National Institute for Health Research (NIHR) Health Technology Assessment programme, NIHR
Imperial Biomedical Research Centre and the Bobby Moore Fund for Cancer Research UK. MAST Group
Ltd provided FIT kits.
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Glossary
Cumulative test analyses Included only those participants who either completed the specified number
of rounds of faecal immunochemical tests or tested positive at a previous round. The two-test analysis
included participants who completed at least two rounds of faecal immunochemical tests or who tested
positive at round 1. The three-test analysis included participants who completed all three rounds of faecal
immunochemical tests or who tested positive at any round.
Programme analyses Included all participants who completed a faecal immunochemical test at round 1,
regardless of whether or not they participated at any further round. A participant was classed as positive
if their faecal immunochemical test was positive at any of the first two rounds at which they completed a
faecal immunochemical test (two-test analysis), or if their faecal immunochemical test was positive at any
round at which they completed a faecal immunochemical test (three-test analysis).
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Plain English summary
Bowel cancer typically develops from lesions called adenomas. Although common, most adenomas donot develop into cancer. Adenomas detected during a bowel examination, called a colonoscopy, are
usually removed during this procedure. However, even after adenoma removal, some patients are still at
greater risk of bowel cancer.
Depending on the number and size of adenomas found, patients are invited for a colonoscopy after 1,
3 or 5 years. Most of these additional colonoscopies will not detect cancer and they are expensive, often
uncomfortable and can harm the bowel.
Both bowel cancer and adenomas can cause bleeding in the bowel. This study examined whether or not a
test for blood in stool, completed at home [known as the faecal immunochemical test (FIT)], could be used
instead of colonoscopy to monitor patients following adenoma removal. Colonoscopy would then be
offered only to those who had a positive FIT result, indicating blood in the stool.
This study invited individuals for annual FITs for 3 years who, as part of the Bowel Cancer Screening
Programme, had one or two large adenomas or three or four small adenomas removed. If a FIT detected
blood in the stool at any of the tests, these individuals were immediately offered a colonoscopy. If a FIT did
not detect blood in the stool at any test, these individuals were offered a colonoscopy 3 years after their
adenomas were removed, as were participants who did not return their second or third FIT.
The study demonstrated that an annual FIT could identify 85 of every 100 cancers and 57 of every 100 patients
with adenomas if repeated over 3 years. Annual FITs were considerably cheaper than colonoscopy after 3 years.
Participants reported that the FIT was easy to use and provided reassurance. However, some were concerned
that the FIT would not be as effective as colonoscopy.
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Scientific summary
Background
Colorectal cancer (CRC) causes considerable morbidity and mortality in the UK and internationally. Most
CRCs develop from precursor lesions called adenomas. Adenoma removal through polypectomy reduces
CRC incidence; however, even after adenomas have been removed, many patients remain at increased
risk of CRC.
Given the increased risk of CRC in patients post polypectomy, national guidelines in the USA, the UK,
the European Union and elsewhere recommend surveillance of these patients at regular intervals using
colonoscopy. The length of the surveillance interval depends on the number and features of adenomas
found, including size and histology. Following polypectomy, the UK adenoma surveillance guidelines divide
patients into low-, intermediate- and high-risk groups. Low-risk patients, defined as those with one or two
small adenomas (i.e. sized < 10 mm), are recommended either no surveillance or surveillance every 5 years.
The Bowel Cancer Screening Programme (BCSP) in England currently adopts the no surveillance approach,
with low-risk patients returning to biennial guaiac faecal occult blood test (gFOBT) screening for as long as
they remain eligible. Intermediate-risk patients, namely, those with three or four small adenomas (i.e. sized
(< 10 mm), or one or two adenomas with at least one sized ≥ 10 mm, are recommended to undergo
surveillance every 3 years. High-risk patients, namely, those with five or more adenomas, or three or more
adenomas with at least one sized ≥ 10 mm, are recommended annual surveillance. Post-polypectomy
colonoscopy surveillance has been shown to reduce CRC incidence in several studies.
Although colonoscopy has a high sensitivity for CRC and advanced adenomas (AAs) (i.e. sized ≥ 10mm,
tubulovillous or villous histology, or high-grade dysplasia), it carries a small risk of complications, is time-consuming
and can cause discomfort for patients. Furthermore, demand on endoscopists and the cost of colonoscopies
to the NHS are increasing because of CRC screening and reductions in the referral threshold in primary care
for patients with suspected CRC. The National Institute for Health and Care Excellence (NICE) guidelines now
recommend referral for patients with symptoms and signs conferring a positive predictive value (PPV) for CRC
as low as 3% (National Institute for Health and Care Excellence (NICE). Suspected Cancer: Recognition and
Referral. London: NICE; 2015).
The majority of surveillance colonoscopies do not detect CRC. An alternative to colonoscopy for post-
polypectomy surveillance may be the faecal immunochemical test (FIT). Like gFOBT, a FIT detects haemoglobin
from blood in stool, although FITs detect species-specific globin rather than haem. Biennial gFOBT screening
has been demonstrated to reduce CRC mortality in randomised controlled trials. Compared with gFOBT, FITs
are less susceptible to dietary interference and more specific to lower gastrointestinal tract bleeding. Analysis
of FITs can be automated, is not subject to screener interpretation and, for quantitative FIT, the positivity
threshold can be modified to yield defined positivity rates. Furthermore, at low thresholds, FITs have higher
sensitivity than gFOBT for CRC and AAs. Given these advantages, FIT has been adopted by many screening
programmes and is set to replace gFOBT in the BCSP in England.
Although many studies have evaluated the diagnostic accuracy of FIT for CRC and AAs in screening, few have
examined FIT performance in surveillance. It was hypothesised that annual FITs could be a safe, effective and
cost-saving alternative to colonoscopy for surveillance of intermediate-risk patients post polypectomy.
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Objectives
The primary objective was to determine the 3-year programme sensitivity of annual FITs compared with
colonoscopy surveillance at 3 years for detecting CRC or AAs in intermediate-risk patients, following
polypectomy after a positive gFOBT.
Secondary objectives were to:
l estimate the diagnostic accuracy of FITs at first, second and third tests and over two or three tests
at various thresholds
l examine the acceptability of FITs, compared with colonoscopy, as a surveillance strategy for people
at increased risk of CRC
l calculate the incremental costs and cost-effectiveness of FITs versus colonoscopy surveillance.
Methods
Eligible individuals were those aged 60–72 years who were categorised as being at intermediate risk
following polypectomy at colonoscopy conducted < 1 year previously following a positive gFOBT in the
BCSP, and were scheduled for surveillance colonoscopy 3 years after initial colonoscopy in line with UK
guidelines [Atkin WS, Saunders BP, British Society for Gastroenterology. Surveillance guidelines after
removal of colorectal adenomatous polyps. Gut 2002;51(Suppl. 5):V6–9].
Consecutive individuals meeting the eligibility criteria were sent a FIT and invited to participate in the study
by the BCSP Southern Hub between January 2012 and December 2013. The FIT kit contained instructions,
an information sheet, a FIT sampling device (OC-AUTO Sampling Bottle 3, Eiken Chemical Co. Ltd, Tokyo,
Japan), a plastic zip-lock bag and a pre-paid envelope in which to return the completed kit and consent form.
Eligible individuals who returned a completed consent form and analysable FIT were included in the study.
Laboratory analysis of FITs was conducted using the OC-Sensor DIANA (Eiken Chemical Co. Ltd, supplied by
MAST Diagnostics Division, UK). The faecal haemoglobin threshold was initially 20 µg of haemoglobin/g
faeces(hereafter referred to as µg/g); however, as positivity was higher than expected in the pilot study, the
threshold was raised to 40 µg/g.
The study involved three rounds of FIT, conducted at 1, 2 and 3 years post baseline colonoscopy. Only participants
returning a round 1 FIT were invited to subsequent rounds. Participants testing positive at round 1 or 2 were
offered early colonoscopy and were not invited to further rounds. Participants testing negative at round 1 were
invited to round 2. A round 3 FIT was sent to participants testing negative at round 2, and to participants who did
not return an analysable round 2 FIT. Participants invited to round 3 were scheduled for colonoscopy at 3 years
post baseline colonoscopy, in line with UK guidelines (Atkin and Saunders 2002).
We calculated uptake and positivity of FIT at each round. We analysed sensitivity, specificity, PPVs and
negative predictive values (NPVs) of FIT for CRC, AAs and advanced colorectal neoplasia (ACN) (CRC
and/or AAs) at various thresholds (40 µg/g, 30 µg/g, 20 µg/g and 10 µg/g) and over multiple rounds. We
assumed that any ACN detected was present and would remain present and unchanged in the absence of
colonic examination at years 1, 2 and 3, and that the same neoplasia would be detected regardless of the
year at which examination occurred.
For analysis of multiple rounds, we performed a cumulative test analysis and a programme analysis. In the
programme analysis, we included all participants and categorised as positive anyone testing positive in
the first or second round (two-tests analysis), or in the first, second or third round (three-tests analysis). For the
cumulative test analysis, we included only participants who were compliant with testing (i.e. they completed the
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specified number of rounds, two for two-test analysis or three for three-test analysis, or tested positive at a
previous round).
Health psychology assessment
There were two components to the health psychology assessment: (1) a qualitative discussion group study
assessing attitudes towards FIT as an alternative to colonoscopy surveillance in adults with varied CRC risk
and experience of colonoscopy, and (2) an evaluation of the psychological impact and acceptability of
annual FIT and preferences for future surveillance using questionnaires and interviews.
For the discussion groups, 198 adults aged 60–74 years, with different levels of CRC risk and varying
amounts of experience with gFOBT and colonoscopy, were identified by the BCSP London Hub and
St Mark’s Hospital Endoscopy Unit.
Five discussion groups were held in 2011 using a comprehensive stepwise discussion guide. After each
section, participants were asked to ‘consider the information you have just seen about FIT replacing a
routine colonoscopy. How would you feel about the offer of a FIT every year instead of a 3-yearly
colonoscopy?’. Participants used an electronic device to select an option on a six-point scale from
‘very positive’ to ‘very negative’.
The views of FIT for Follow-Up study participants were gathered through questionnaires at baseline
and at each round. In addition, a subsample of participants underwent end-of-study interviews. In the
baseline questionnaire, participants were asked to rate their experience of baseline colonoscopy, level of
CRC-related worry and current emotional state using the Spielberger State–Trait Anxiety Inventory (STAI).
The questionnaires queried participants’ experience of completing FIT. Questionnaires at each round
queried emotional well-being and CRC-related worry.
Economic evaluation
We assessed incremental costs and cost-effectiveness of annual FIT with colonoscopy only for a positive
result, as an alternative to colonoscopy at 3 years, for the surveillance of intermediate-risk patients.
The cost of each surveillance regimen was estimated. Cost-effectiveness is presented as the incremental
cost-effectiveness (i.e. saving) per AA that was not detected by FIT versus colonoscopy surveillance, and
the incremental cost-effectiveness per CRC that was not detected by FIT versus colonoscopy surveillance.
Costs were restricted to those from surveillance and did not include treatment costs, other than the cost
of adenoma removal as a result of FIT positivity. Unit costs were obtained from the NHS Reference Costs
2014 to 2015 (Department of Health and Social Care. NHS Reference Costs 2014 to 2015. London:
Department of Health and Social Care; 2015). Sensitivity analyses explored the effect of different FIT
thresholds and diagnostic procedure costs on cost-effectiveness. We estimated the budget impact if
annual FIT surveillance was implemented nationally instead of 3-yearly colonoscopy surveillance.
Results
Of the 9851 individuals identified as potentially eligible, 296 were excluded and 1547 were not invited
because the target sample size had been reached. The remaining 8008 were invited to participate and
5948 (74.3%) consented and completed a FIT. Two individuals subsequently withdrew, leaving a cohort
of 5946 individuals in round 1. Uptake of FIT in rounds 2 and 3 was 97.2% (5350/5503) and 96.9%
(5058/5220), respectively.
With a threshold of 40 µg/g, FIT positivity was 5.8% (347/5946) in round 1, decreasing to 4.1% (206/5058)
in round 3. Positivity in each round was greater in men than in women (round 1: 6.6% vs. 4.3%, respectively)
and in older participants (> 65 years) than in younger participants (≤ 65 years) (round 1: 6.5% vs. 5.1%,
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respectively). Over all three rounds, cumulative attendance for colonic examination following a positive FIT
was 93.6% (744/795). Among participants with only negative FITs, attendance for end-of-study colonic
examination was 88.4% (4455/5039).
Among the 5199 participants who had a colonic examination, either following a positive FIT (n = 744) or at
the end of the study (n = 4455), CRC was identified in 0.5% (26/5199) and AAs in 8.5% (443/5199), with
both being identified in six participants. In total, 8.9% (463/5199) of participants were diagnosed with
ACN (CRC and/or AA). Over all three rounds, 69.2% (18/26) of participants with CRC, 34.3% (152/443)
with AAs and 35.6% (165/463) with ACN tested FIT positive with the 40 µg/g threshold.
FIT positivity increased at lower thresholds; for instance, 5.8% (344/5946) tested positive with the first FIT
at 40 µg/g, whereas 14.2% (844/5946) tested positive at 10 µg/g. Sensitivity increased, whereas specificity
decreased, with lower thresholds. Sensitivity and specificity of the first FIT for CRC were 30.8% (8/26) and
93.9% (4855/5173), respectively, at 40 µg/g, and 61.5% (16/26) and 86.0% (4447/5173), respectively,
at 10 µg/g.
Sensitivity for AAs was lower, and specificity higher, than for CRC. For example, sensitivity and specificity
of the first FIT for AAs were 17.6% (78/443) and 94.8% (4508/4756), respectively, at 40 µg/g, and 33.2%
(147/443) and 87.5% (4161/4756), respectively, at 10 µg/g.
Taking into account multiple FIT rounds, sensitivity increased but specificity decreased. In programme analysis,
sensitivity and specificity for CRC at 40 µg/g were, respectively, 61.5% (16/26) and 89.5% (4630/5173) over
two rounds, and 69.2% (18/26) and 86.0% (4450/5173) over three. Similarly, in cumulative test analysis,
sensitivity and specificity for CRC at 40 µg/g were, respectively, 66.7% (16/24) and 89.4% (4596/5139) for two
tests, and 81.8% (18/22) and 85.4% (4243/4966) for three tests.
Health psychology assessment
In total, 28 people with different levels of CRC risk took part in five qualitative discussion groups. Previous
experience of surveillance and level of CRC risk were associated with attitudes towards FIT. All groups
thought that FIT would be easier and safer as a surveillance method than colonoscopy. However, individuals
with prior experience of surveillance were concerned about the ability of FIT to detect lesions, and particularly
that single-sample FIT might not detect polyps that bleed intermittently.
FIT for Follow-Up study participants were invited to complete questionnaires during the study, and a subset of
FIT-positive participants was invited to be interviewed at the end of each round. A baseline questionnaire was
completed by 98.9% (5879/5946) of participants. Questionnaires were completed by 84.4% (5020/5946) of
participants at the end of round 1, 83.9% (4491/5350) at the end of round 2 and 83.5% (3881/4646) at the
end of round 3.
In the baseline questionnaire, the vast majority of participants (95.8%, 5370/5604) were satisfied with
their baseline colonoscopy. Most participants reported that catching the bowel motion, removing the stick,
collecting the sample with the stick, reinserting the stick into the sampling bottle and closing the sampling
bottle (94.9%, 99.0%, 97.1%, 95.4% and 99.3%, respectively) was easy.
Of round 1 questionnaire responders, 26.8% (1307/4877) reported that doing FIT made them anxious
and 29.2% (1416/4856) reported that they were concerned about the ability of FIT to detect new polyps.
Examining STAI scores, anxiety was higher at baseline than at rounds 1, 2 and 3. Participants reported high
levels of reassurance, feeling more hopeful and less anxious as a result of participating in the study.
Participants’ preferred surveillance strategy was 3-yearly colonoscopy plus annual FIT (57.9%, 2478/4279),
followed by annual FIT with colonoscopy only for a positive result (31.5%, 1347/4279). The least preferred
strategies included 3-yearly colonoscopy and no FIT (8.9%, 379/4279), and no surveillance (1.8%, 75/4279).
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In end-of-study interviews, participants generally reported being very satisfied with taking part in the study.
They reported that a FIT was easier to complete than a gFOBT and they appreciated the reassurance that
annual FIT provided.
Economic evaluation
Among the 5946 study participants, we estimated the cost of colonoscopy surveillance at 3 years to be
£2,633,382, whereas the cost of annual FIT surveillance using a threshold of 40 µg/g was £485,236.
However, FITs were also less effective at detecting ACN. Using a threshold of 40 µg/g, three rounds of FITs
missed 291 AAs and eight CRCs. The incremental cost-effectiveness (i.e. saving) from FITs was £7382 per
AA not detected and £268,518 per CRC not detected.
The estimated cost of FITs depended on the threshold, ranging from £485,236 using 40 µg/g to £956,602
using 10 µg/g. The incremental cost-effectiveness improved with lower thresholds because of fewer missed
lesions. At the lowest studied threshold, the incremental cost-effectiveness was £8872 per AA not detected
and £419,195 per CRC not detected. The budget impact of replacing colonoscopy surveillance with FIT
surveillance ranged from –£4.6M at a threshold of 40 µg/g to –£3.6M at a threshold of 10 µg/g.
Conclusions
This study demonstrated the potential utility of FITs in the surveillance of intermediate-risk patients post
polypectomy. Annual low-threshold FIT with colonoscopy in positive cases achieved high cumulative sensitivity
for CRC and would be cost saving compared with 3-yearly colonoscopy. However, at higher thresholds, this
strategy could miss 15–30% of CRCs and 40–70% of AAs. Participants’ preferred surveillance strategy was
annual FIT plus 3-yearly colonoscopy. Further research is needed to define a clear role for FITs in surveillance,
including evaluation of the implications of missed ACN, considering effects on quality-adjusted life-years.
Trial registration
This trial is registered as ISRCTN18040196.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR), the NIHR Imperial Biomedical Research Centre and the Bobby Moore
Fund for Cancer Research UK. MAST Group Ltd provided FIT kits.
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Chapter 1 Introduction
Colorectal cancer (CRC) is a UK health-care priority. It is estimated that 1 in 14 men and 1 in 19 womenwill develop the disease in their lifetime.1 CRC is the second most frequent cause of cancer death in
the UK, with 41,000 new diagnoses and 16,000 deaths in 2014. The estimated annual cost of CRC to the
NHS is more than £1B.1,2
Most CRCs develop from adenomas.3–6 Adenomas are common and their prevalence is around 30–40%
at 60 years.7 Most adenomas do not, however, become cancerous.8
Colorectal cancer screening
Screening enables the early detection of CRC and endoscopic removal of adenomas and is highly effective at
reducing CRC mortality rates.9–15 In England, the NHS Bowel Cancer Screening Programme (BCSP) offers CRC
screening to men and women aged between 60 and 74 years. Every 2 years, patients are invited to complete
a stool test, which is currently the guaiac faecal occult blood test (gFOBT). Among the first million people
tested by the BCSP, 2% (21,106/1,079,293) had an abnormal gFOBT result using a three-test-kit algorithm,
of whom 83% (17,518/21,106) had a follow-up colonoscopy or other investigative examination.16 Adoption
of an additional screening modality, flexible sigmoidoscopy at age 55 years, began in 2013.17
Adenoma surveillance
Adenomas detected through screening, surveillance or among patients presenting symptomatically,
are typically removed by polypectomy during colonoscopy, flexible sigmoidoscopy or surgery. Following
adenoma removal, a proportion of people remain at increased risk of developing advanced adenomas
(AAs) (i.e. sized ≥ 10 mm, tubulovillous or villous histology or high-grade dysplasia) or CRC, and are
recommended to undergo a surveillance colonoscopy at a later date.18–20 The risk of developing AAs or
CRC following polypectomy is dependent on the characteristics of the baseline colonoscopy, such as
completeness and quality of bowel preparation, and on the characteristics of adenomas found at baseline,
including number of adenomas, size and pathology.18–20 Based on the characteristics of adenomas found at
baseline, the UK adenoma surveillance guideline (UK-ASG) defines three risk groups with consequent
recommendations for surveillance colonoscopy following polypectomy (Figure 1).21
Low risk: patients with only one or two small adenomas (i.e. sized < 10 mm)
Low-risk patients identified after referral to hospital, because of symptoms or diagnostic test results, are
commonly offered surveillance at 5 years.24,25 In contrast, low-risk patients identified by the BCSP are not
offered surveillance but return to routine biennial gFOBT screening for as long as they remain within the
eligible age range.26
Among the first million individuals tested by the BCSP, 7514 out of the 17,518 (42.9%) individuals
attending colonic examination following positive gFOBT were found to have adenomas. Around 37%
(2743/7514) of patients with adenomas identified by the BCSP were considered as low risk.16
Intermediate risk: patients with three or four small adenomas (i.e. sized < 10 mm) or one
or two large adenomas (i.e. sized ≥ 10 mm)
This group constituted 41% (3050/7514) of adenoma patients identified by the BCSP among the first
million tested.16 Based on the UK-ASG, the BCSP recommends colonoscopy surveillance for the
intermediate-risk group at 3 years.
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High risk: patients with five or more small adenomas (i.e. sized < 10 mm) or three or
more adenomas, at least one of which is large (i.e. sized ≥ 10 mm)
This group constituted 23% (1721/7514) of adenoma patients identified by the BCSP among the first
million tested.16 Based on the UK-ASG, the BCSP recommends a clearing colonoscopy 1 year after first
diagnosis for high-risk patients. This recommendation is based on the high detection rate of AAs after
1 year and on the risk of missed or incompletely removed lesions when large or multiple adenomas
are removed.19,27,28
Colonoscopy in post-polypectomy surveillance
Colonoscopy is the most sensitive examination for CRC and adenomas. However, there are a number of
problems with its use as a surveillance method.
Colonoscopy is an expensive procedure because of the requirement for skilled endoscopists and the use
of sedation. The increased detection of adenomas requiring colonoscopy surveillance from the BCSP is
reaching the point at which demand is overwhelming the available endoscopy workforce.29 Currently,
post-polypectomy surveillance accounts for approximately 20% of colonoscopies in the UK, and this
figure will inevitably rise as more people enter surveillance.30
There are disadvantages to colonoscopy for the patient undergoing the examination. Bowel preparation is
typically unpleasant and the colonoscopy itself can be uncomfortable.31,32 There is a small risk of serious
complications (e.g. severe bleeding and colon perforation) and that risk increases with age.33 Attendance
for colonoscopy after a positive gFOBT is poor (around 80%), possibly because of procedural anxiety, in
addition to other patient-reported barriers such as fear of finding cancer and anticipated pain.16,34–36
Surveillance following adenoma removal
Baseline colonoscopy
Low risk
1 or 2 adenomas
AND
both small (i.e. sized 
< 1 cm)
Intermediate risk
3 or 4 small adenomas
OR
at least one sized ≥ 1 cm
High risk
≥ 5 small adenomas
OR
≥ 3, with at least one sized 
≥ 1 cm
A B C
Findings at follow-up
No adenomas
Low-risk adenomas
Intermediate-risk
adenomas
High-risk adenomas
Cease
follow-up
A
B
C
Findings at follow-up Findings at follow-up
No surveillance
or 5 yeara
3 year 1 year
One negative 
examination
Two consecutive
negative examinations
Low- or intermediate-
risk adenomas
High-risk adenomas
Cease
follow-upa
B
B
C
Negative-, low- or
intermediate-risk
adenomas
High-risk adenomas
B
C
FIGURE 1 The UK-ASG.21–23 a, Other considerations: age, comorbidity, family history, accuracy and completeness of
examination. Reproduced from surveillance guidelines after removal of colorectal adenomatous polyps, Atkins and
Saunders, vol. 51, pp. v6–9, 2002,21 with permission from BMJ Publishing Group Ltd.
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Colonoscopy is not 100% sensitive and sometimes lesions are missed. Studies suggest that > 50% of
post-colonoscopy CRCs result from missed lesions.37 Delayed diagnosis of CRC occurring as a result of the
surveillance interval could be detrimental to patient outcomes.38
The yield of CRC and AAs at each surveillance colonoscopy is low. Even in higher-risk groups, the yield is
< 20%, meaning that > 80% of colonoscopies will either be negative or detect only small adenomas of
low malignant potential.18,19,39,40 Negative colonoscopies provide no therapeutic benefit other than
reassurance while contributing to cost, discomfort and risk.
For these reasons, a different, more cost-effective, method of surveillance following adenoma removal
is urgently required. The faecal immunochemical test (FIT) for occult blood in stool may be an effective
alternative.
Faecal immunochemical tests and guaiac faecal occult blood tests
Many screening programmes use gFOBT. In randomised controlled trials (RCTs), CRC mortality rates
were reduced by 15%, on average, in people offered the gFOBT, and by 25% in those accepting the
gFOBT.13,41,42 However, an alternative stool test, FIT, which is due to replace gFOBT in the BCSP, has many
advantages over gFOBT.43,44
The FIT uses antibodies raised against the globin component of haemoglobin, whereas gFOBT is based on a
chemical reaction involving haem. Unlike gFOBT, FIT is not subject to interference from dietary haemoglobin
in red meat or peroxidases in vegetables.45 Reduced dietary interference with FIT enables its increased
analytical sensitivity to be exploited without diminution of analytical specificity. Furthermore, FIT is less
susceptible than gFOBT to false positives from upper gastrointestinal (GI) tract bleeding as the globin
component of haemoglobin is degraded by gastric proteases in the upper GI tract.
Quantitative FIT enables the selection of a preferred faecal haemoglobin threshold level for positivity,
allowing the adjustment of clinical sensitivity and specificity so that the test is clinically acceptable while not
overwhelming endoscopy resources.46–48 At a low haemoglobin threshold, FIT can detect lower levels of
bleeding than gFOBT and, therefore, has a higher sensitivity for CRC and AAs.49–51 Quantitative FIT provides
the opportunity to incorporate haemoglobin concentration into a multivariable CRC risk score, rather than
the binary risk (positive or negative) afforded by gFOBT.52
Test uptake is reported to be higher with FIT than gFOBT.53,54 Individuals may find FIT more acceptable than
gFOBT because the kit is typically simpler to use, less messy and usually requires only one stool sample
(unlike the widely used three-sample, six-window gFOBT).53
Given the advantages of FIT over gFOBT, many national screening programmes have started to use FIT to
screen average-risk populations.42 A systematic review examined the performance of FIT in the screening
context and found that at a threshold of 20 µg haemoglobin per gram of faeces (hereafter referred to as
µg/g), sensitivity for CRC approximated 90%.55 Sensitivity for AAs is reported to be lower, typically < 50%.56
Faecal immunochemical tests in post-polypectomy surveillance
Given the high sensitivity of low-threshold FIT for CRC in the screening setting, FIT could be useful for
post-polypectomy surveillance. However, few published studies have looked at the use of FIT for this
purpose and those few that have included patients undergoing surveillance for reasons other than
adenomas (e.g. family or personal history of CRC).46,57–62
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A number of studies have examined the performance of interval FIT in addition to colonoscopy
surveillance.58,60,61 In the first of these studies,58 1641 individuals enrolled in colonoscopy surveillance (538 of
whom were undergoing surveillance because of a personal history of neoplasia) were invited to complete
a qualitative FIT [Inform, Enterix Pty Ltd, Sydney, NSW, Australia; Inform is known as InSure (Enterix Inc.,
Edison, NJ) in the USA] in the interval prior to colonoscopy. Among the 792 who responded and completed
a FIT, 57 (7.2%) tested positive. Of the 57 who tested positive, six (10.5%) were diagnosed with CRC and
eight (14.0%) had a significant adenoma. The study authors suggested that using FIT in surveillance could
speed detection of interval CRCs. However, the study did not report the results of subsequent colonoscopy
in those testing FIT negative and, therefore, sensitivity and specificity of FIT could not be calculated.
A second study, by Cole et al.,60 is, to our knowledge, the only published study besides ours to have
examined the performance of annual FIT in surveillance. A total of 1736 individuals enrolled in colonoscopy
surveillance (984 of whom had prior adenomas) were invited to complete annual qualitative FIT (InSure) in
the interval prior to surveillance colonoscopy. Of these 1736 individuals, 1071 (61.7%) completed at least
one FIT (the median number completed was two) in the interval prior to surveillance colonoscopy, of whom
379 (35.4%) tested positive at least once. Colonoscopy was performed either following positive FIT or,
in those testing FIT negative, after the designated surveillance interval. Sensitivity of repeated FIT was
85.7% (12/14) for CRC and 62.5% (60/96) for AAs. In cases in which CRC and AAs were diagnosed
following a positive test, it is estimated that FIT brought forward colonoscopy by a median of 25 months
and 24 months, respectively.
Most recently, Cole et al.61 examined the performance of two-sample interval quantitative FIT (OC-Sensor,
Eiken Chemical Co. Ltd, Tokyo, Japan; 20 µg/g threshold) in addition to colonoscopy surveillance. In total,
804 colonoscopies were performed early bacause of a positive FIT. As a result, nine (1.1%) patients were
diagnosed with CRC and 162 (20.1%) patients were diagnosed with AAs. The results of subsequent
surveillance colonoscopy in those patients testing negative were not reported and, therefore, sensitivity
could not be calculated. However, the findings indicate that FITs could bring forward detection of
significant neoplasia if used in combination with colonoscopy surveillance.
In addition to these studies, there have been a number of others that have tested the performance of one
round of FIT directly prior to surveillance colonoscopy. Robinson et al.57 invited 919 individuals (420 of whom
had prior adenomas) to complete a qualitative FIT (HemeSelect, SmithKline Diagnostics, San Jose, CA, USA)
before surveillance colonoscopy. In the 808 who complied, sensitivity for CRC was 70.0% (7/10) and sensitivity
for large adenomas (i.e. sized ≥ 10mm) was 44.4% (16/36). Hazazi et al.59 invited 1469 individuals to complete
three FITs (OC-Micro, Eiken Chemical Co. Ltd) prior to colonoscopy. Of 1469 invited, 1000 completed a FIT
(337 of whom had prior polyps). Sensitivity of the first of three FITs at 10 µg/g was 100.0% (8/8) for CRC and
44.4% (32/72) for advanced colorectal neoplasia (ACN) (CRC and/or AAs). Using the highest haemoglobin
concentration of all three FITs, sensitivity for ACN increased to 65.3% (47/72).
Although the study by Hazazi et al.59 indicated that low-threshold quantitative FITs had high accuracy for ACN,
a more recent study by Terhaar sive Droste et al.46 of quantitative FIT (OC-Sensor) reported lower sensitivity. At a
threshold of 10 µg/g, sensitivity was 80.0% (4/5) for CRC and 30.2% (32/106) for ACN. Both studies, however,
had limited sample sizes and did not test the performance of multiple rounds of FIT.
These studies provide some evidence to suggest that FIT could be a useful tool for surveillance following
adenoma removal. However, further research is needed on the accuracy, acceptability and cost-effectiveness
of repeated FIT for detecting CRC and AAs in a large cohort of individuals. For this reason we developed the
FIT for Follow-Up study.
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Study aim
The aim of the FIT for Follow-Up study was to determine whether or not annual FIT is a feasible, safe,
acceptable and cost-saving alternative to colonoscopy surveillance for the detection of CRC and AAs
following adenoma removal. We proposed to offer annual FIT to people deemed at intermediate risk
because of adenomas (see Figure 1) detected following a positive gFOBT completed as part of the BCSP in
England. As is standard UK practice,21 these individuals were scheduled to have a surveillance colonoscopy
at 3 years. In the BCSP, intermediate-risk patients account for approximately 40% of all patients diagnosed
with adenomas, and approximately 5000 intermediate-risk patients a year are identified.16 We hypothesised
that, by using FIT as an alternative to colonoscopy surveillance, the number of colonoscopies could be
greatly reduced, with minimal loss of sensitivity.
Primary objective
To determine the 3-year programme sensitivity of annual FITs compared with colonoscopy surveillance
at 3 years, for the detection of CRC or AAs in patients categorised as at intermediate risk because of
adenomas detected at colonoscopy following a positive gFOBT completed as part of the BCSP.
Secondary objectives
l To estimate the diagnostic accuracy of FIT at first, second and third tests and over two or three tests at
various thresholds.
l To examine the acceptability of FIT, compared with colonoscopy, as a method of surveillance for people
at increased risk of CRC.
l To calculate the incremental costs and cost-effectiveness of FIT versus colonoscopy surveillance.
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Chapter 2 Methods
The FIT for Follow-Up study compared the accuracy, acceptability and cost-effectiveness of three annualFITs compared with colonoscopy at 3 years for surveillance of intermediate-risk patients following
the removal of adenomas. The reporting of this study is in accordance with Standards of Reporting of
Diagnostic Accuracy (STARD) guidelines.63
Literature search
We searched MEDLINE and EMBASE, using text words and medical subject heading (MeSH)/EMTREE terms,
to identify studies using FIT in a surveillance setting published on or before 6 April 2017. Reference lists of
relevant articles were also reviewed to identify further pertinent studies.
Research governance and ethics arrangements
The FIT for Follow-Up study was prospectively registered in the International Standard Randomised
Controlled Trial Number (ISRCTN) registry (ISRCTN18040196). Imperial College London was the nominated
sponsor of the study. A trial steering committee provided independent oversight and advice.
In line with Imperial College London research governance procedures, relevant approvals were obtained
before the study commenced, and appropriate regulations and guidelines were followed. The BCSP
Research Committee granted support for the study on 7 October 2009. The London – City and East
Research Ethics Committee approved the study on 17 May 2011 (reference number 11/LO/0326). Further
approval was granted for substantial amendments to (1) invite a subset of participants to an end-of-study
interview, (2) add a ‘health and lifestyle’ questionnaire to round 3 of testing and increase the FIT positivity
threshold from 20 µg/g to 40 µg/g and (3) include a reminder letter to be sent to participants who had
not yet attended their routine 3-year surveillance colonoscopy. The Ethics and Confidentiality Committee
(ECC) of the National Information Governance Board (now known as the Health Research Authority
Confidentiality Advisory Group) granted approval [reference number ECC 3-04(p)/2011] to access patient
identifiers and contact details on 10 June 2011, allowing the identification of eligible participants and
invitation by the BCSP.
Participant recruitment
Individuals who had been identified as being at intermediate risk (one or two adenomas of ≥ 10 mm in
size, or three or four adenomas of < 10 mm in size, no CRC) within the previous 12 months were
identified from those who had attended colonoscopy after positive gFOBT in the English BCSP.
Individuals meeting the eligibility criteria were identified by NHS Digital (formerly known as the Health and
Social Care Information Centre) using the BCSP’s database, the Bowel Cancer Screening System (BCSS).
NHS Digital sent encrypted information on potentially eligible individuals to the BCSP Southern Hub. In the
BCSP, there are five regional hubs (Southern Hub, Eastern Hub, Midlands and North West Hub, London
Hub and North East Hub) that receive and analyse gFOBT kits.16 However, for the purpose of this study,
analysis and distribution of kits were centralised; kits were sent and analysed from one hub, the BCSP
Southern Hub, regardless of the invitee’s location. The BCSP Southern Hub sent an invitation letter, a
detailed participant information sheet, a consent form, a short baseline questionnaire and a FIT kit to
eligible individuals between January 2012 and December 2013 (see Report Supplementary Material 1 for
study documentation). Individuals who returned a completed consent form and an analysable FIT
constituted the study cohort.
DOI: 10.3310/hta23010 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 1
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Atkin et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
7
Eligibility criteria
Criteria for inclusion were:
l aged 60–72 years at recruitment
l diagnosed < 1 year previously with intermediate-risk adenomas at colonoscopy following positive
gFOBT in the BCSP
l scheduled for surveillance colonoscopy 3 years after initial colonoscopy, in line with BCSP guidelines for
post-polypectomy surveillance of intermediate-risk patients.
Although individuals aged 72–74 years are invited to gFOBT screening in the BCSP, this group was excluded
from this study. Given that they would be ≥ 75 years by the end of the study, they would not be eligible for
a surveillance colonoscopy according to BCSP guidelines.
After study initiation, it was found that some potentially eligible individuals had received multiple baseline
colonoscopies. These individuals were excluded from the study to prevent patient overinvestigation from a
further colonoscopy at years 1 or 2 because of a positive FIT result.
Faecal immunochemical test kit processing
The FIT kit comprised a step-by-step instruction wallet, the FIT sampling device (OC-Sensor sampling
device, Eiken Chemical Co. Ltd), a plastic zip-lock bag with absorbent material in case of leakage and a
foil-lined pre-paid envelope in which to return the completed kit. The distribution of FIT kits and analysis of
returned tests was conducted by the BCSP Southern Hub through the patient management system (PMS)
(see Data processing and information governance).
Laboratory analysis of the FIT was carried out at the BCSP Southern Hub, using the OC-Sensor DIANA
analyser (Eiken Chemical Co. Ltd) in accordance with the manufacturer’s instructions. Samples were
refrigerated on receipt and analysis took place within 7 days. Results were uploaded onto the PMS as
comma-separated values (CSV) files. Any samples that were > 10 days old on receipt were not analysed.
If the sample was spoilt in any other way [damaged packaging, technical fail, non-technical fail (e.g.
insufficient sample to analyse)], then a replacement kit was sent to the participant. The coefficient of
variation for FIT was 4.5% at a concentration of 20 µg/g and 3.3% at a concentration of 90 µg/g.64
In the pilot study, the threshold for a FIT positive result was set at 20 µg/g. However, as the percentage
of participants testing positive in this pilot was higher than expected, the threshold was subsequently
increased to 40 µg/g. This change of threshold was made to ensure that the range of predicted positivity
rates would not lead to unsustainable numbers of colonoscopies that would swamp screening centres.
The threshold was not changed retrospectively for participants screened within the pilot study (see
Pilot study).
Study design
The study was divided into three annual FIT rounds at 1, 2 and 3 years after baseline colonoscopy
(i.e. colonoscopy at which intermediate-risk adenomas were detected), as shown in the study flow
diagram (Figure 2).
Participants who tested FIT positive at round 1 or 2 were offered an early surveillance colonic examination
(typically colonoscopy) and were not invited to further FIT rounds. For participants who accepted the offer,
the early colonic examination was the reference standard. If the participant declined the offer in round 1
METHODS
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or 2, they were still invited to an end-of-study colonic examination at 3 years after baseline colonoscopy,
which served as the reference standard.
Participants who tested FIT negative in rounds 1 and 2 were eligible for further FIT rounds. All participants
offered a round 3 FIT were invited to the routine 3-year surveillance colonic examination, which again
served as the reference standard. Those who attended a colonic examination following positive FIT,
because of symptoms or at the end of the study, returned to the appropriate surveillance pathway
according to the outcomes of the examination (see Figure 1).
Intervention round 1 (year 1)
Eligible individuals were invited to take part in the study approximately 10 weeks before the first
anniversary of their baseline colonoscopy. Individuals who did not respond within 3 weeks were sent a
reminder to participate.
We decided that the interval between FIT rounds should be at least 9 months. If the participant returned
a round 1 negative FIT late, and a round 2 FIT invite would have meant an interval between rounds of
Year 0 colonoscopy for positive gFOBT in BCSP
Intermediate-risk adenomas detected
Year 1 FIT kit
(plus consent form and
baseline questionnaire)
Year 2 FIT kit
Kit and consent
returned
Kit returned
FIT+ Immediate
colonoscopy
Immediate
colonoscopy
ColonoscopyKit returned
Kit not
received
Kit not 
received
ROUND 1
ROUND 2
ROUND 3
R1 PEQ after
colonoscopy
FIT–
R1-negative FIT PEQ
R2 PEQ after
colonoscopy
FIT–
R2-negative FIT PEQ
Year 3 FIT kit
FIT+
FIT+
FIT–
R3 PEQ after
colonoscopy
FIGURE 2 The FIT for Follow-Up study flow diagram. PEQ, participant experience questionnaire; R1, round 1;
R2, round 2; R3, round 3 (intervention rounds).
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< 9 months, then the participant was classed as a round 1 late responder. These participants were not
invited to complete a FIT in round 2 but were invited in round 3.
Intervention round 2 (year 2)
Participants who tested FIT negative in round 1 and who were not round 1 late responders were sent a FIT
kit in round 2. As in round 1, participants who did not reply within 3 weeks were sent a reminder letter.
Intervention round 3 (year 3)
Participants who tested FIT negative in round 2, who were round 1 late responders and who did not return
an analysable round 2 FIT were sent a round 3 FIT. As in rounds 1 and 2, participants who did not reply
within 3 weeks were sent a reminder letter.
Throughout the study, the participants and their general practitioners (GPs) were informed of the results
of each completed FIT. A dedicated freephone helpline managed by the BCSP Southern Hub was available
to participants, GPs and screening centre staff. A study website was also available.65
Questionnaires and interviews
Participant experience questionnaires were sent by post (1) with the consent form in round 1 (baseline
questionnaire), (2) with FIT-negative results letters in rounds 1 and 2 (round 1 negative questionnaire,
round 2 negative questionnaire), (3) after attending/declining an early surveillance colonoscopy after a
FIT positive result in rounds 1 and 2 (round 1 positive questionnaire, round 2 positive questionnaire) and
(4) after the participant had attended their year 3 end-of-study colonic examination (round 3 end-of-study
questionnaire) (see Report Supplementary Material 2 for study questionnaires). To avoid unnecessary
distress, participants diagnosed with cancer were not sent questionnaires.
End-of-study phone interviews were conducted with a subsample of participants in order to better
understand attitudes towards the use of FIT in surveillance (see Chapter 4).
Colonic examinations
The default colonic examination was colonoscopy. However, as is current practice in the BCSP, computed
tomographic (CT) colonography or flexible sigmoidoscopy were alternative options when colonoscopy
was not deemed appropriate. In the BCSP, only a minority of patients (typically < 3%) are deemed unfit
for colonoscopy.16
If participants tested FIT positive in round 1 or 2, the participant’s affiliated BCSP screening centre was
informed that the participant had consented to take part in the study, had tested FIT positive and should
be offered an early colonic examination.
Before commencement of the study, all screening centre directors and nominated specialist screening
practitioners at the 64 English screening centres were encouraged to support the study, and to contact
FIT-positive participants to discuss arranging an earlier colonic examination in a timely manner to reduce
participant anxiety. Collaborators at NHS Digital modified the BCSS to allow specialist screening practitioners
to amend a participant’s surveillance due date, bring forward the date of the colonic examination and
indicate that this was as a result of them taking part in the study and testing FIT positive. The Imperial
College London study team contacted the appropriate screening centre on a case-by-case basis for all those
who tested FIT positive, retrieved the relevant colonic examination and histology reports for those who
attended and updated the PMS to show that the participant had declined an earlier examination.
METHODS
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All participants who did not attend (DNA) an early colonic examination as a result of a positive FIT were still
invited for their year 3 surveillance examination. To manage the timely collection of the year 3 surveillance
examination reports for participants who tested FIT negative, monthly data downloads from the BCSS with
information on participants’ scheduled and attended colonic examinations were sent by NHS Digital to the
Imperial College London study team. The team were responsible for contacting the screening centres to
determine whether colonic examinations had been arranged or declined and, once colonic examinations had
occurred, to retrieve copies of the relevant colonic examination and histology reports. Colonic examination
and histology reports were sent directly to data clerks at the Imperial College London central study office by
encrypted NHS.net e-mail or secure fax, and were immediately logged on receipt.
Data clerks entered data according to a standard operating procedure (see Report Supplementary Material 3).
All data entered were audited by a second data clerk.
Colonic examination data entered included:
l date of examination
l type of examination
l pre-medications used (if any)
l name of the endoscopist
l bowel preparation used
l segment of the bowel reached
l whether or not the examination was completed
l the final results of the examination
l details of polyps discovered in the bowel
l whether or not a polyp was removed and successfully retrieved
l polyp pathology (if known)
l evidence of CRC or AA.
Data processing and information governance
The study was co-ordinated through a purpose-built PMS. The PMS was hosted in an ISO 27001 high-security
data centre by ioko365 (Piksel Ltd, York, UK). The Clinical Informatics Research Unit at the University of
Southampton processed the data, and was responsible for the development, maintenance and security of the
PMS and had policies in place for information governance (IG) that were compliant with the Data Protection
Act and the European Clinical Trials Directive.
Every aspect of the study was conducted through the PMS, creating a complete record of each individual’s
passage through the study. The PMS was used by the following organisations that collaborated on
this study:
l The BCSP Southern Hub (based at Royal Surrey County Hospital NHS Trust).
¢ Nominated members of the BCSP Southern Hub had access to the PMS in order to upload
information about potentially eligible individuals and for patient management purposes.
¢ The IG toolkit organisation code was RA2.
l Cancer Screening and Prevention Research Group (CSPRG), Imperial College London.
¢ Nominated members of the CSPRG could receive paper records from study participants and NHS
sites involved with participants’ medical care. All records were stored in secure locked cabinets.
¢ Nominated members of the CSPRG received pseudonymised electronic BCSS data, which were
stored in a managed and secure area on the server.
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¢ Nominated members of the CSPRG had access to the PMS in order to carry out trial management
duties, record the information received and extract information on consented participants
for analysis.
¢ The CSPRG held a level 3 IG certificate that was subsequently superseded by the IG toolkit version
14 (CSPRG organisational code: 8HL46-FOM-CSPRG).
¢ The PMS was hosted and developed outside Imperial College London but complied with Imperial
College London’s policy on data handling and data storage. ioko365 (Piksel Ltd, York, UK), the
company that hosted the PMS, held an IG toolkit (IG Toolkit Organisation Code 8GX09). The Head
of the CSPRG was the data controller.
l Department of Behavioural Science and Health, University College London.
¢ Selected members had limited access to the PMS in order to record the questionnaires. They could
not access participant-identifiable information. Access to the system was from the CSPRG office
with a guest user account valid for a limited time period.
Statistical methods
Primary outcome
To determine the 3-year sensitivity of annual FIT for the detection of CRC or AAs compared with
colonoscopy undertaken at 3 years.
Secondary outcomes
l Uptake and positivity of FIT in rounds 1, 2 and 3.
l Positive predictive value (PPV) of FIT for ACN, CRC or AAs in rounds 1, 2 and 3 in participants
attending colonic examination following positive FIT.
l Diagnostic yield of ACN, CRC or AAs in participants attending colonic examination following negative
FIT in rounds 1, 2 and 3.
l Positivity, sensitivity, specificity, PPV and negative predictive value (NPV) of FIT for ACN, CRC or AAs at
first, second and third tests and over two or three tests at various thresholds.
l Subjective physical and mental well-being following each FIT round (see Chapter 4).
l Participant preference for annual FIT versus 3-yearly colonoscopy for surveillance, and participant
satisfaction with FIT at the 3-year assessment (see Chapter 4).
l Incremental costs and cost-effectiveness of annual FIT versus 3-yearly colonoscopy surveillance
(see Chapter 5).
Sample size
The sample size calculation was based on the estimation of the relative sensitivity of three annual FITs
compared with 3-yearly colonoscopy to detect ACN. Under conservative assumptions of a prevalence of
ACN of 2.5%, and a relative FIT sensitivity of 75%, we required 72 cases and 2881 adherent participants
in order to provide an estimate of the sensitivity with a 95% confidence interval (CI) within ± 10% among
adherent participants. Allowing for a conservative estimate of compliance with all tests of 40%, we
calculated that we would need 7203 invitees. Given a ± 10% margin of error, this led to the calculated
required sample size of 8000.
Outcome definitions
Outcomes of CRC and AA were ascertained from colonic examination and histology reports. Participants
may have had more than one colonic examination (colonoscopy, flexible sigmoidoscopy or CT colonography)
performed and may have also had surgery. All colonic procedures performed were considered when
defining outcomes.
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The CRC sites were defined by the International Classification of Diseases, Tenth Edition, and we included
codes C18-C20. CRC morphology was coded with ICD-O2 codes and we included cancers with codes of
8140/3, 8211/3, 8246/3, and 8263/3.
Polyp size was determined by the maximum of the microscopic size at pathology, endoscopy or surgery for
each polyp. An AA was defined as an adenoma meeting one of the following criteria: ≥ 10mm, tubulovillous
or villous histology, or high grade dysplasia. Adenocarcinomas were not classed as adenomas; therefore,
participants with CRC were included as having an AA detected only if they had a separate lesion which met
the criteria of an AA. ACN was defined as CRC and/or AAs.
Data analyses
In order to estimate the diagnostic accuracy of FIT, we made the important assumption that any colorectal
neoplasia detected at year 1, 2 or 3 was present at year 1 and remained present and unmodified, in the
absence of colonic examination, to year 3. We also assumed that the same colorectal neoplasia would be
detected in each participant regardless of the year in which colonic examination was performed. Under
these assumptions, AAs or CRCs detected at year 2 or 3 were considered missed by previous FITs and it
was assumed that any colorectal neoplasia found at early colonic examination (year 1 or 2) would have
been found at year 3. Furthermore, these assumptions allowed us to estimate the sensitivity and specificity
of FIT at multiple FIT thresholds (10 µg/g, 20 µg/g, 30 µg/g and 40 µg/g). Under these assumptions, if a
participant would have tested positive at a lower threshold (e.g.10 µg/g) than that used (40 µg/g), the
resulting early colonic examination would have found what was actually found at a later examination.
For the outcomes of ACN, CRC and AA, we calculated positivity, sensitivity, specificity, PPV and NPV
at each round and for different FIT thresholds. In order to perform calculations at each round for the
thresholds lower than 40 µg/g used in the study, any of a participant’s FIT results from later rounds were
ignored in the analysis once the participant had a FIT result above the threshold being analysed, analogous
to participants being excluded from further FIT rounds once testing positive during the trial. For example,
in the analysis considering a threshold of 20 µg/g, a participant who had a FIT result of 22 µg/g at year 1
would be considered positive at year 1, and any FIT results from year 2 or 3 would be ignored, despite the
fact that they may have completed additional rounds of FIT. For calculations of sensitivity, specificity, PPV
and NPV, we included only participants who had at least one colonic examination.
As well as estimating positivity, sensitivity, specificity, PPV and NPV for each round, we also calculated
these figures for a combination of two tests and for a combination of three tests.
In ‘cumulative test analyses’, we included only those participants who either completed the specified
number of rounds of FIT or tested positive at a previous round. The two-test analysis included participants
who completed at least two rounds of FIT or who tested positive at round 1. The three-test analysis
included participants who completed all three rounds of FIT or who tested positive at any round.
‘Programme analyses’ included all participants who completed FIT at round 1, regardless of whether or not
they participated at any further round. A participant was classed as positive if their FIT was positive at any
of the first two rounds at which they completed FIT (two-test analysis), or if their FIT was positive at any
round at which they completed FIT (three-test analysis).
Results were presented by sex and by age group (≤ 65 years and > 65 years). We compared sex and age in
individuals who did and did not participate using chi-squared tests. A number of methods for computing
CIs for binomial proportions were considered, including asymptotic CI calculated assuming a normal
approximation of the sampling distribution. However, accuracy suffers when these methods are used for
proportions very close to zero or 1. For the asymptotic method to be appropriate, Bland66 anticipated that
both the number of tests giving a negative result and the number giving a positive result should exceed
five. Given the low number of CRC cases identified in this study, and given the capability to make use of
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more accurate methods [using the statistical software package Stata® (StataCorp LP, College Station, TX,
USA)], exact Clopper–Pearson CIs were used.
All data analyses were performed in Stata/IC 13.
Patient and public involvement
Patient and public representatives were involved throughout this study by means of workshops, individual
consultations (e.g. to co-participate in designing patient materials and questionnaires) and as members of
the independent steering committee. We consulted a range of representatives, some of whom had no
history of colorectal investigations, some of whom had tested negative in the BCSP and had no experience
of colonoscopy, some of whom had tested positive in the BCSP and had experienced an investigative
colonoscopy, and some of whom were in an active adenoma surveillance programme.
While planning the study, we took advice from a panel of patient experts on contacting individuals prior
to consent. The panel felt that, given the importance of the research, this was acceptable, as long as the
details of individuals who had not given explicit consent to take part in the study were not shared outside
the BCSP Southern Hub. Personnel at the BCSP Southern Hub were the only members of the study team
who could view unconsented individuals’ personal details, in order to produce the initial invitation letters.
Representatives were consulted in the pre-pilot phase (see Preparation for the study), during which the
PMS and study materials (e.g. flyer, letter, consent form, baseline questionnaire, FIT kit instructions,
participant information sheet) were being developed. Representatives’ feedback strongly influenced the
type of study materials that were used and their layout and content.
Service users were also interviewed to assess the likely acceptability of FIT as a CRC surveillance tool.
A discussion group was convened in November 2011 to discuss the practicalities of using FIT, the
implications of the results and the possible risks associated with FIT. As a result of users’ feedback about
the psychological implications of receiving a false-positive test result, patient materials were modified to
clearly demonstrate the possibility of testing false positive (see Chapter 4 and Bowyer et al.67 for full details
and results).
Users were also involved in assessment of the pilot study (see Pilot study), the aim of which was to test
the processes for invitation, analysis and transmission of results, and storage of information on the PMS.
A number of modifications to the PMS and to the study materials were made as a result of the pilot study.
Health psychology assessment
A secondary objective of the FIT for Follow-Up study was to examine the acceptability of FIT compared
with colonoscopy as a surveillance mechanism for people at increased risk of developing CRC. Participant
experience questionnaires after each round of FIT allowed us to assess various aspects of the study,
including the FIT kit instructions, how easy participants found it to use the FIT kit, how they felt when
receiving the results, how any subsequent colonoscopy affected them, and their screening preferences
(see Chapter 4).
We assessed the psychological consequences of annual surveillance over time using an itinerary of
questions, including a short version of the Spielberger State–Trait Anxiety Inventory (STAI)68 and more
specific measures of CRC-related worry.69 We also investigated the emotional impact of FIT outcomes
(e.g. false-negative and false-positive results) through telephone interviews. Participants suspected of
having cancer were not sent questionnaires to avoid causing unnecessary distress. Chapter 4 fully
documents the methods and analyses pertaining to the health psychology assessment.
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Economic evaluation
We assessed the cost and cost-effectiveness of annual FIT with colonoscopy only for a positive result versus
3-yearly colonoscopy surveillance. Further details are in Chapter 5.
Preparation for the study
In July 2011, we conducted a pre-pilot study to review study materials and to assess PMS functionality.
Volunteers were asked to review and comment on the flyer introducing the study, invitation letter,
participant information sheet, consent form, baseline questionnaire, FIT kit instruction wallet and foil-lined
sample return envelope.
Feedback on the study materials was received from 27 age-appropriate volunteers (60–71 years), six other
volunteers (< 60 years) and 13 members of the research teams.
It was decided that a flyer, designed to introduce potential participants to the study, should not be used in
the main study, as feedback indicated that it did not contain enough information about the study and
would be likely to confuse potential participants. Other feedback warranted changes to the invitation letter
and the participant information sheet.
A qualitative study with discussion groups was conducted (November 2011) to gain an understanding of
public attitudes towards FIT, identify potential issues for the main study and facilitate the design of study
materials. Details of this study are further described in Chapter 4, Study 1: patient attitudes towards the
faecal immunochemical test as an alternative to colonoscopy surveillance of groups at increased risk of
colorectal cancer – a qualitative discussion group study.
Pilot study
The aim of the pilot study was to test the processes for invitation, analysis, transmission of results and
storage of information on the PMS. It also enabled us to examine uptake, requirements for reminders,
attendance for colonic examination of those with a positive FIT and the frequency and nature of calls to
the freephone helpline. Following the pilot study, a number of modifications to the PMS and to the
information and study materials were made. A major change was to the haemoglobin threshold set to
define a positive FIT result. Initially, the threshold was set at 20 µg/g, as this is commonly used in screening
programmes and has been used frequently by other studies.70–76 It was subsequently changed to 40 µg/g
as the proportion positive at a threshold of 20 µg/g was 6.5%, which was higher than we expected given
the literature.77 We were concerned that this level of positivity had the potential to cause an excess of
colonoscopies, with consequences on patient risk and endoscopist workload.
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Chapter 3 Results
Invitation to participate in the study
In total, 9851 individuals were identified as potentially eligible for the study. Of these, 296 were excluded after
eligibility assessment for the following reasons: 187 individuals had received more than one colonoscopy prior to
invitation and were therefore excluded to prevent patient overinvestigation, and 109 individuals were excluded
by the BCSP for clinical reasons, or because of informed dissent, death or emigration. A further 1547 were
not invited as the recruitment target of 8000 participants had been met. The remaining 8008 individuals were
invited to participate in the study between 30 January 2012 and 30 December 2013 (Figure 3). The mean age
of these invited individuals was 65.7 years (standard deviation 3.4 years; 49.3% were aged ≤ 65 years and
50.7% were aged > 65 years), and 65.3% were men (Table 1).
Participation in surveillance by round
Round 1
Following the invitation to participate, 5948 out of 8008 invitees returned a completed consent form
and an analysable FIT. Of the 2060 invitees not recruited, 2055 did not provide consent and five consented
but did not return an analysable FIT. Of the 5948 invitees who returned a completed consent form and an
analysable FIT, two individuals subsequently withdrew consent. The remaining 5946 participants (74.3% of
the 8008 invited) formed the study cohort.
Participation was slightly higher in male (74.6%, 3898/5227) than in female (73.6%, 2048/2781) invitees,
although the difference was not significant (p = 0.364) (see Table 1). Older men were more likely to
participate than younger men (76.9% of men aged > 65 years participated vs. 72.2% of men aged
≤ 65 years; p < 0.001). However, among women, the proportion who participated was similar across age
groups (73.1% of women aged > 65 years participated vs. 74.2% of women aged ≤ 65 years; p = 0.498).
In the study cohort of 5946 participants, 347 (5.8%) tested FIT positive and 5599 (94.2%) tested FIT
negative in round 1 (Table 2 and see Figure 3). Most FIT-positive participants (94.8%, 329/347) attended a
colonic examination (colonoscopy, CT colonography or flexible sigmoidoscopy). Reasons for non-attendance
were that the participant declined colonic examination (n = 12), the participant could not be contacted
(n = 3) or the participant was lost to follow-up and not contacted again (n = 3).
Round 2
Round 2 FIT kits were sent to 5503 out of 5599 (98.3%) participants who tested FIT negative in round 1.
There were 96 round 1 FIT-negative participants who were not sent a round 2 FIT, for the following
reasons: 68 were late responders to round 1, 22 were lost to follow-up (deceased, n = 15; moved away,
n = 6; clinical reason, n = 1) and were not contacted again, and six missed subsequent FITs because of an
administrative error or investigation of symptoms, but did have a colonic examination performed during
the study period.
In total, 5350 out of 5503 (97.2%) participants sent a round 2 FIT returned an analysable test. Of the
153 participants who did not return an analysable FIT, 29 were lost to follow-up (deceased, n = 15; moved
away, n = 1; clinical reason, n = 4; declined further participation, n = 9) and were not contacted again,
122 did not return an analysable FIT but were sent a FIT in round 3, and two were not sent a FIT in
round 3 as a result of an investigation of symptoms.
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Recruited
(n = 5948)
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(n = 8008)
Withdrew
consent
(n = 2)
Round 1 FIT
completed
(n = 5946)
Round 1 FIT 
negative
(n = 5599)
Round 2 FIT 
negative
(n = 5108)
Round 3 FIT 
negative
(n = 4852)
Offered study-end colonic examination
(n = 5039)
Round 2 FIT
completed
(n = 5350)
Round 3 FIT
completed
(n = 5058)
Round 3 FIT 
positive
(n = 206)
Round 2 FIT 
positive
(n = 242)
Round 1 FIT 
positive
(n = 347)
Round 1 FIT kit late responders
(n = 68)
Round 2 FIT kit late responders
(n = 32)
Round 2 not completed
(n = 122)
DNA diagnostic
examination
(n = 18)
Diagnostic examination
(n = 329)
• Colonoscopy, n = 321
• CTC (no colonoscopy), n = 7
• Flexible sigmoidoscopy
   (no colonoscopy or CTC), n = 1
DNA diagnostic
examination
(n = 18)
Sent round 2 FIT kit
(n = 5503)
Sent round 3 FIT kit
(n = 5220)
R
o
u
n
d
 3
R
o
u
n
d
 2
R
o
u
n
d
 1
Round 3 not completed
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(n = 15)
Diagnostic examination
(n = 224)
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(n = 21)
Had study-end colonic examination
(n = 4455)
No further participation in the study but had
a study-end colonic examination
(n = 6)
No further participation in the study but had
a study-end colonic examination
(n = 2)
No further participation in the study but had
a study-end colonic examination
(n = 6)
• Colonoscopy, n = 220
• CTC (no colonoscopy), n = 4
Diagnostic examination
(n = 191)
• Colonoscopy, n = 185
• CTC (no colonoscopy), n = 6
• Deceased, n = 12
• Moved away, n = 3
• Clinical reason, n = 3
• Declined participation, n = 3
• Colonoscopy, n = 4371
• CTC (no colonoscopy), n = 83
• Flexible sigmoidoscopy (no colonoscopy or CTC), n = 1
Lost to follow-up
(n = 29)
• Deceased, n = 15
• Moved away, n = 1
• Clinical reason, n = 4
• Declined participation, n = 9
Lost to follow-up
(n = 22)
• Deceased, n = 15
• Moved away, n = 6
• Clinical reason, n = 1
Lost to follow-up
(n = 40)
• Deceased, n = 25
• Moved away, n = 8
• Clinical reason, n = 7
FIGURE 3 Participant flow diagram from invitation through to end-of-study colonic examination. Invited: 9851 individuals
were identified as potentially eligible for the study and were ordered by surveillance due date; 8008 individuals were
invited to participate. A total of 1843 of the potentially eligible individuals were not invited to participate in the study;
296 were not invited as they were excluded after the eligibility assessment and a further 1547 individuals were not invited
as the recruitment target of 8000 had already been met. Not recruited: 2055 were because of lack of consent, one
consented but had not returned a FIT kit and four consented but returned a FIT kit that could not be analysed. DNA:
includes participants who (using data collected on 6 October 2016) were offered, but DNA, a diagnostic examination
after a positive kit, or DNA a study-end colonic examination after being offered such.
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Overall, 5108 out of 5350 (95.5%) participants completing a round 2 FIT tested negative, and 242 (4.5%)
tested positive. Of the 242 participants testing positive, 224 (92.6%) attended a colonic investigation.
Eighteen (7.4%) DNA the colonic examination (12 participants declined, one could not be contacted and
five were lost to follow-up and not contacted again).
Round 3
In round 3, 5220 participants were sent a FIT. This included 5030 participants who tested FIT negative
in round 2 and who were receiving their third consecutive FIT, 68 participants who were round 1 late
responders and had therefore not been invited to round 2, and 122 participants who had been invited in
round 2 but had not returned an analysable FIT. A number of round 2 FIT-negative participants were not
sent a round 3 FIT (n = 78), for the following reasons: 40 were lost to follow-up (deceased, n = 25; moved
away, n = 8; clinical reason, n = 7) and were not contacted again, 32 participants were late responders to
round 2, and six missed round 3 because of an administrative error. The 38 participants who were not lost
to follow-up were invited to an end-of-study colonic examination.
In total, 5058 out of 5220 (96.9%) participants who were sent a round 3 FIT returned an analysable test.
Of the 162 participants who did not return an analysable FIT, 21 were lost to follow-up (deceased, n = 12;
moved away, n = 3; clinical reason, n = 3; declined participation, n = 3) and were not contacted again;
141 participants did not return an analysable FIT but were invited to an end-of-study colonic examination.
For 60 out of 5058 (1.2%) participants completing a round 3 FIT, it was their second completed FIT, and
for 4998 (98.8%) participants it was their third. Of these 5058 round 3 participants, 4852 (95.9%) tested
negative and 206 (4.1%) tested positive. Not all participants testing positive attended colonic investigation:
15 out of 206 (7.3%) DNA, either because they declined (n = 3) or for reasons unknown (n = 12).
End-of-study colonic examination
Of the 5946 study participants who completed at least the round 1 FIT, 5039 (84.7%) were offered an end-of-study
colonic examination. There were 907 (15.3%) participants who were not offered an end-of-study colonic
examination: 795 (13.4%) because of a prior positive FIT and 112 (1.9%) because the participant had been
lost to follow-up.
TABLE 1 Baseline characteristics of invited individuals by participation
Sex and age (years) at invite
Participation, n (%)
p-valuecInviteda Participatedb Did not participateb
All
All ages 8008 (100) 5946 (74.3) 2062 (25.7)
≤ 65 3950 (49.3) 2880 (72.9) 1070 (27.1) 0.007
> 65 4058 (50.7) 3066 (75.6) 992 (24.4)
Men
All ages 5227 (65.3) 3898 (74.6) 1329 (25.4)
≤ 65 2634 (32.9) 1903 (72.2) 731 (27.8) < 0.001
> 65 2593 (32.4) 1995 (76.9) 598 (23.1)
Women
All ages 2781 (34.7) 2048 (73.6) 733 (26.4)
≤ 65 1316 (16.4) 977 (74.2) 339 (25.8) 0.498
> 65 1465 (18.3) 1071 (73.1) 394 (26.9)
a Percentage of the invited cohort of 8008.
b Participation was defined as having provided consent, returned an analysable round 1 FIT kit, and not subsequently
withdrawn from the study.
c p-value for the comparison of age at invite for those who participated and those who did not, overall and by sex.
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TABLE 2 Uptake, test positivity and diagnostic yield of the FIT overall and at rounds 1, 2 and 3
Findings
Round
End-of-study colonic examination
Entire study
findings1 2 3 Cumulative (across all rounds)
n
% of
round 1
% of entire
study
findings n
% of
round 2
% of entire
study
findings n
% of
round 3
% of entire
study
findings n
% of all
rounds
% of entire
study
findings n
% of
end-of-study
colonic exam
% of entire
study
findings n
% of entire
study
findings
Invited 8008 5503 5220 8008
Completed FIT
a
5946 74.3 5350 97.2 5058 96.9 5946 74.3
Tested positive 347
b
5.8
c
242 4.5
c
206 4.1
c
795
d
13.4
c
Invited for colonic examination – – – – – – – – – – – –
Colonic examination performed 329 94.8
e
6.3
f
224 92.6
e
4.3
f
191 92.7
e
3.7
f
744 93.6
e
14.3
f
4455 – 85.7
f
5199
Colonoscopy 321 97.6
g
6.3
f
220 98.2
g
4.3
f
185 96.9
g
3.6
f
726 97.6
g
14.2
f
4371 98.1
g
85.8
f
5097 98.0
g
CTC (no colonoscopy) 7 2.1
g
7.0
f
4 1.8
g
4.0
f
6 3.1
g
6.0
f
17 2.3
g
17.0
f
83 1.9
g
83.0
f
100 1.9
g
FS (no colonoscopy or CTC) 1 0.3
g
50.0
f
0 0
g
0
f
0 0
g
0
f
1 0.1
g
50.0
f
1 0.02
g
50.0
f
2 0.04
g
Diagnostic yield
ACN
h
83 25.2
i
17.9
f
43 19.2
i
9.3
f
39 20.4
i
8.4
f
165 22.2
i
35.6
f
298 6.7
i
64.4
f
463 8.9
i
CRC 8 2.4
i
30.8
f
8 3.6
i
30.8
f
2 1.0
i
7.7
f
18 2.4
i
69.2
f
8 0.2
i
30.8
f
26 0.5
i
AAs 78 23.7
i
17.6
f
37 16.5
i
8.4
f
37 19.4
i
8.4
f
152 20.4
i
34.3
f
291 6.5
i
65.7
f
443 8.5
i
CTC, computed tomography colonography; FS, flexible sigmoidoscopy.
a Completion of FIT was defined as having provided consent, returned an analysable round 1 FIT kit and not subsequently withdrawn from the study.
b Three participants were defined as ‘FIT positive’ in round 1 during the pilot phase based on a threshold of 20 µg/g with a reading that was < 40 µg/g (i.e. that did not meet the positivity
threshold used in the rest of the study).
c Percentages calculated using the number of those who completed FIT as the denominator. Positivity was defined as ≥ 40 µg Hb/g faeces for the majority of the study, with the exception
of the pilot phase when a threshold of 20 µg Hb/g faeces was used.
d Participants who tested positive at any round, regardless of whether or not they completed FIT at all rounds to which they were invited.
e Percentages calculated using the number of those who tested positive as the denominator.
f Percentages calculated using the row total from the entire study findings as the denominator.
g Percentages calculated using the number of those who had a colonic examination performed as the denominator.
h ACN was defined as CRC or AA. Six participants in the entire study had both CRC and AA.
i Diagnostic yield in participants who had a colonic examination performed.
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The 5039 participants offered an end-of-study colonic examination were composed of 4852 (96.3%)
round 3 FIT-negative participants, 32 (0.6%) round 2 late responders, 141 (2.8%) participants who did
not return a completed round 3 FIT and 14 participants who ceased participation in FIT prior to round 3
(because of an investigation of symptoms or an administrative error) but who did have an end-of-study
colonic examination. Among the 5039 invited to an end-of-study colonic examination, 584 (11.6%) DNA.
Participants DNA for the following reasons: they declined (n = 298), they could not be contacted (n = 172),
they postponed (n = 107) or for clinical reasons (n = 7).
Uptake and test positivity
Uptake of faecal immunochemical test overall and by round
In round 1, 5946 out of 8008 (74.3%) invited individuals returned a completed consent form and an
analysable FIT (see Table 2). Only individuals who returned a completed consent form and negative FIT in
round 1 were eligible for round 2. Uptake of FIT was 97.2% (5350/5503) in round 2 and 96.9% (5058/5220)
in round 3. Uptake was marginally higher in men than in women in round 1 (74.6% vs. 73.6%), round 2
(97.3% vs. 97.0%) and round 3 (97.3% vs. 96.1%) (see Report Supplementary Material 4, Table 1).
Although participation in the study in round 1 was greater in participants aged > 65 years than in
those aged ≤ 65 years (75.6% vs. 72.9%), subsequent uptake of FIT in rounds 2 and 3 did not differ
considerably by age category (see Report Supplementary Material 5, Table 2). Uptake in round 2 was
97.3% in participants aged > 65 years and 97.1% in those aged ≤ 65 years. In round 3, uptake was
96.8% in participants aged > 65 years and 97.0% in those aged ≤ 65 years.
Faecal immunochemical test positivity overall and by round
Faecal immunochemical test positivity decreased from 5.8% (347/5946) in round 1 to 4.5% (242/5350) in
round 2, and 4.1% (206/5058) in round 3 (see Table 2). The cumulative test positivity over all three rounds
was 13.4% (795/5946).
Positivity at each round was greater in men than in women (see Report Supplementary Material 4, Table 1).
At round 1, positivity was 6.6% in men and 4.3% in women. At round 2, positivity was 4.9% in men and
3.8% in women. At round 3, positivity was 4.5% in men and 3.2% in women. The cumulative positivity
over all three rounds was 14.8% in men and 10.6% in women.
Positivity was greater, in every round, in older (> 65 years) participants than in younger participants
(see Report Supplementary Material 5, Table 2). Cumulative positivity over all three rounds was 12.2%
in participants aged ≤ 65 years and 14.4% in participants aged > 65 years.
Attendance for colonic examination and yield of colorectal cancer,
advanced adenomas and advanced colorectal neoplasia
Attendance for colonic examination
Attendance for colonic examination following a positive FIT was 94.8% (329/347) in round 1, 92.6% (224/242)
in round 2 and 92.7% (191/206) in round 3 (see Table 2). Over all three rounds, cumulative attendance for
colonic examination following a positive FIT was 93.6% (744/795). The majority of participants attending
colonic examination following a positive FIT received a colonoscopy (97.6%, 726/744). Of the 18 who did not
receive a colonoscopy, 17 received CT colonography and one received a flexible sigmoidoscopy.
Among all FIT-positive participants, a greater proportion of men (95.0%, 549/578) than in women (89.9%,
195/217) attended a colonic examination (see Report Supplementary Material 4, Table 1). There was little
difference in attendance by age category (93.5% of participants aged ≤ 65 years attended vs. 93.7% of
those aged > 65 years) (see Report Supplementary Material 5, Table 2).
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Attendance for an end-of-study colonic examination following prior negative FITs was 88.4%
(4455/5039). Most participants attending an end-of-study colonic examination received a colonoscopy
(98.1%, 4371/4455).
Diagnostic yield of colorectal cancer, advanced adenomas and advanced
colorectal neoplasia
In total, 5199 out of 5946 (87.4%) participants had a colonic examination at some point during the study
(see Table 2). Among these 5199 participants, CRC was found in 26 (0.5%), AAs in 443 (8.5%) and ACN
in 463 (8.9%); there were six individuals with an AA and a CRC.
Among the 744 participants who, in any round, attended colonic examination following a positive FIT,
the diagnostic yields of CRC, AA and ACN were 2.4% (18/744), 20.4% (152/744) and 22.2% (165/744),
respectively (see Table 2). The diagnostic yield of CRC was greater in rounds 1 (2.4%, 8/329) and 2 (3.6%,
8/224) than in round 3 (1.0%, 2/191). The diagnostic yield of AA was greatest in round 1 (23.7%, 78/329)
and lower in rounds 2 (16.5%, 37/224) and 3 (19.4%, 37/191).
The diagnostic yield of ACN from colonic examination was slightly higher in men (9.3%, 321/3454) than
in women (8.1%, 142/1745), and in participants aged > 65 years (9.4%, 252/2667) than in those aged
≤ 65 years (8.3%, 211/2532) (see Report Supplementary Material 4, Table 1 and Report Supplementary
Material 5, Table 2). Furthermore, the mean number of adenomas per patient with ACN was slightly
greater in men than women (2.20 vs. 1.92 – data not presented). The mean number of adenomas in
participants aged > 65 years with ACN was similar to that in those aged ≤ 65 years (2.13 vs. 2.09 – data
not presented).
The diagnostic yield of CRC from colonic examination following a positive FIT, over all three rounds, was
greater in female (4.6%, 9/195) than in male (1.6%, 9/549) participants (see Report Supplementary
Material 4, Table 1). There was little difference between men and women in the diagnostic yield of AA
(20.4% vs. 20.5%). The diagnostic yield of CRC and AA was greater in participants aged > 65 years (2.7%
and 21.0%, respectively) than in those aged ≤ 65 years (2.1% and 19.8%, respectively) (see Report
Supplementary Material 5, Table 2).
Among the 4455 participants attending an end-of-study colonic examination, eight (0.2%) were found
to have CRC, 291 (6.5%) had AAs and 298 participants (6.7%) had ACN (see Table 2).
Performance of the faecal immunochemical test at different faecal
haemoglobin thresholds
Faecal immunochemical test positivity at different thresholds
We calculated FIT positivity, by number of completed FITs, at different faecal haemoglobin thresholds
among the 5946 study participants (Table 3). FIT positivity rates with thresholds of < 40 µg/g were
estimated on the assumption that following a positive test at a given threshold, the participant would not
have been offered further FITs. With higher positivity rates expected at lower thresholds, the number
available for subsequent rounds of FIT would be lower.
Faecal immunochemical test positivity was higher with lower faecal haemoglobin thresholds. At 40 µg/g,
positivity was 5.8% (344/5946), 4.6% (251/5481) and 4.0% (197/4927) for the first, second and third
completed FIT, respectively. At a lower threshold of 30 µg/g, positivity was greater, at 7.0% (416/5946),
5.5% (299/5415) and 5.0% (241/4820). Positivity increased further with a threshold of 20 µg/g to 9.2%
(546/5946), 6.8% (362/5294) and 6.3% (295/4649). At the lowest studied threshold of 10 µg/g, the
highest positivity was observed: 14.2% (844/5946), 9.8% (491/5004) and 9.1% (388/4254) for the first,
second and third completed FIT, respectively.
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TABLE 3 Faecal immunochemical test positivity rate at various thresholds in participants who completed 1–3 tests,
overall and by sex
FIT threshold (µg/g) and
test
All
Sex
Men Women
Completed
a test,a n
Tested +ve,
n (%)
Completed
a test,a n
Tested +ve,
n (%)
Completed
a test,a n
Tested +ve,
n (%)
40
First 5946 344b (5.8) 3898 256 (6.6) 2048 88 (4.3)
Secondc 5481 251 (4.6) 3571 178 (5.0) 1910 73 (3.8)
Thirdd 4927 197 (4.0) 3194 142 (4.4) 1733 55 (3.2)
Cumulative test analysis
Two testse 5825 595 (10.2) 3827 434 (11.3) 1998 161 (8.1)
Three testsf 5522 792 (14.3) 3628 576 (15.9) 1894 216 (11.4)
Programme analysis
Two testsg 5946 595 (10.0) 3898 434 (11.1) 2048 161 (7.9)
Three testsh 5946 792 (13.3) 3898 576 (14.8) 2048 216 (10.5)
30
First 5946 416 (7.0) 3898 309 (7.9) 2048 107 (5.2)
Secondc 5415 299 (5.5) 3522 217 (6.2) 1893 82 (4.3)
Third 4820 241 (5.0) 3111 171 (5.5) 1709 70 (4.1)
Cumulative test analysis
Two testse 5831 715 (12.3) 3831 526 (13.7) 2000 189 (9.5)
Three testsf 5535 956 (17.3) 3637 697 (19.2) 1898 259 (13.6)
Programme analysis
Two tests
g
5946 715 (12.0) 3898 526 (13.5) 2048 189 (9.2)
Three testsh 5946 956 (16.1) 3898 697 (17.9) 2048 259 (12.6)
20
First 5946 546 (9.2) 3898 399 (10.2) 2048 147 (7.2)
Secondc 5294 362 (6.8) 3438 259 (7.5) 1856 103 (5.5)
Third 4649 295 (6.3) 2994 212 (7.1) 1655 83 (5.0)
Cumulative test analysis
Two testse 5840 908 (15.5) 3837 658 (17.1) 2003 250 (12.5)
Three testsf 5557 1203 (21.6) 3652 870 (23.8) 1905 333 (17.5)
Programme analysis
Two testsg 5946 908 (15.3) 3898 658 (16.9) 2048 250 (12.2)
Three testsh 5946 1203 (20.2) 3898 870 (22.3) 2048 333 (16.3)
10
First 5946 844 (14.2) 3898 598 (15.3) 2048 246 (12.0)
Secondc 5004 491 (9.8) 3243 343 (10.6) 1761 148 (8.4)
Third 4254 388 (9.1) 2729 272 (10.0) 1525 116 (7.6)
continued
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Higher positivity at lower thresholds was reflected in cumulative test analysis and programme analysis. In
cumulative test analysis, examining only individuals who completed all three tests or who tested positive
prior to the third test, positivity was 14.3% (792/5522) at a threshold of 40 µg/g, 17.3% (956/5535) at a
threshold of 30 µg/g, 21.6% (1203/5557) at a threshold of 20 µg/g and 30.8% (1723/5589) at a threshold
of 10 µg/g. Cumulative test positivity of two, rather than three, tests was lower: 10.2% (595/5825) at a
threshold of 40 µg/g, 12.3% (715/5831) at a threshold of 30 µg/g, 15.5% (908/5840) at a threshold of
20 µg/g and 22.8% (1335/5848) at a threshold of 10 µg/g.
Similarly, in programme analysis, examining all 5946 participants completing a test at round 1 regardless
of subsequent participation in further rounds, positivity was higher at lower thresholds. Over three rounds,
13.3% (792/5946) tested positive at a threshold of 40 µg/g, 16.1% (956/5946) at a threshold of 30 µg/g,
20.2% (1203/5946) at a threshold of 20 µg/g and 29.0% (1723/5946) at a threshold of 10 µg/g. Positivity
was lower after up to two, rather than up to three, tests: 10.0% (595/5946) at a threshold of 40 µg/g,
12.0% (715/5946) at a threshold of 30 µg/g, 15.3% (908/5946) at a threshold of 20 µg/g and 22.5%
(1335/5946) at a threshold of 10 µg/g.
Regardless of threshold and number of tests performed, positivity was higher in men than in women. In
programme analysis, after three rounds of testing using a threshold of 40 µg/g, 14.8% (576/3898) of men
and 10.5% (216/2048) women were FIT positive; and at a threshold of 10 µg/g, 31.1% (1213/3898) of
men and 24.9% (510/2048) of women tested positive (see Table 3). Positivity was in general, although not
in all cases, higher in participants aged > 65 years than in those aged ≤ 65 years (see Report Supplementary
Material 6, Table 3). At a threshold of 40 µg/g, in programme analysis after up to three tests, 12.2%
(350/2880) of participants aged ≤ 65 years and 14.4% (442/3066) of those aged > 65 tested positive; at
a threshold of 10 µg/g, 27.6% (795/2880) of participants aged ≤ 65 years and 30.3% (928/3066) of those
aged > 65 years tested positive.
TABLE 3 Faecal immunochemical test positivity rate at various thresholds in participants who completed 1–3 tests,
overall and by sex (continued )
FIT threshold (µg/g) and
test
All
Sex
Men Women
Completed
a test,a n
Tested +ve,
n (%)
Completed
a test,a n
Tested +ve,
n (%)
Completed
a test,a n
Tested +ve,
n (%)
Cumulative test analysis
Two testse 5848 1335 (22.8) 3841 941 (24.5) 2007 394 (19.6)
Three testsf 5589 1723 (30.8) 3670 1213 (33.1) 1919 510 (26.6)
Programme analysis
Two tests
g
5946 1335 (22.5) 3898 941 (24.1) 2048 394 (19.2)
Three testsh 5946 1723 (29.0) 3898 1213 (31.1) 2048 510 (24.9)
+ve, positive.
a Participants were not included as invited to any subsequent tests following a FIT positive test at the specified threshold.
b Three participants are defined in the participant flow diagram (see Figure 3) as ‘FIT positive’ in round 1 based on a
threshold of 20 µg/g with a reading that was < 40 µg/g, as they were recruited during the pilot phase; however, in this
table they appear as tested positive only based on meeting the stated thresholds.
c The round at which a participant completed their second FIT; for a particular participant this could be round 2 or round 3.
d The round at which a participant completed their third FIT; equivalent to round 3 in participants who completed FIT at
both prior rounds.
e Includes participants who completed at least two rounds of FIT or who were FIT positive at round 1; participants were
classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
f Includes participants who completed all three rounds of FIT or who were FIT positive at any round; participants were
classed as positive if FIT was positive at any of the three rounds.
g Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at
either of the first two rounds at which they completed FIT.
h Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at
any of the three rounds.
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Accuracy of the faecal immunochemical test at different faecal
haemoglobin thresholds
We estimated the sensitivity, specificity, PPV and NPV of FIT at different faecal haemoglobin thresholds
among the 5199 participants who underwent a colonic examination (see Tables 4–6).
Sensitivity, specificity, positive predictive value and negative predictive value of the
faecal immunochemical test for colorectal cancer
Of the 5199 participants who underwent a colonic examination, 26 (0.5%) were diagnosed with CRC
during the study (Table 4). For the first completed FIT, at a threshold of 40 µg/g, sensitivity for CRC was
30.8%, specificity was 93.9%, the PPV was 2.5% and the NPV was 99.6%.
Sensitivity increased and specificity decreased with lower faecal haemoglobin thresholds. For the first
completed FIT, sensitivity and specificity for CRC were, respectively, 38.5% and 92.7% at a threshold of
30 µg/g, 46.2% and 90.7% at a threshold of 20 µg/g, and 61.5% and 86.0% at a threshold of 10 µg/g.
Sensitivity also increased, and specificity decreased, when taking into account multiple FITs. In cumulative test
analysis, examining only individuals who completed all three tests or who tested positive prior to the third test,
sensitivity and specificity for CRC were, respectively, 81.8% and 85.4% at a threshold of 40 µg/g, 86.4% and
82.6% at a threshold of 30 µg/g, 91.3% and 78.5% at a threshold of 20 µg/g, and 91.7% and 69.8% at a
threshold of 10 µg/g (see Table 4). The highest observed sensitivity for CRC in the study was obtained using
the 10 µg/g threshold (91.7%).
Sensitivity of two FITs was lower, and specificity higher, than that of three FITs. In cumulative test analysis,
sensitivity and specificity for CRC after two FITs were, respectively, 66.7% and 89.4% at a threshold of
40 µg/g, 66.7% and 87.4% at a threshold of 30 µg/g, 72.0% and 84.4% at a threshold of 20 µg/g, and
80.8% and 77.4% at a threshold of 10 µg/g. In programme analysis, sensitivity and specificity for CRC
after two FITs were, respectively, 61.5% and 89.5% at a threshold of 40 µg/g, 61.5% and 87.5% at a
threshold of 30 µg/g, 69.2% and 84.4% at a threshold of 20 µg/g, and 80.8% and 77.5% at a threshold
of 10 µg/g (see Table 4).
In both cumulative test analysis and programme analysis, the PPV decreased at lower faecal haemoglobin
thresholds and with multiple tests, whereas the NPV remained the same. For instance, in cumulative analysis
after three tests, the PPVs and NPVs were, respectively, 2.4% and 99.9% at a threshold of 40 µg/g, 2.2% and
99.9% at a threshold of 30 µg/g, 1.9% and 99.9% at a threshold of 20 µg/g, and 1.4% and 99.9% at a
threshold of 10 µg/g (see Table 4).
Sensitivity, specificity, positive predictive value and negative predictive value of the
faecal immunochemical test for advanced adenomas
Of the 5199 participants who underwent a colonic examination, 443 (8.5%) participants were diagnosed
with AAs (Table 5).
Sensitivity of FIT for AAs was lower, and specificity higher, than for CRC. The sensitivity of the first completed
FIT for AAs was 17.6% at a threshold of 40 µg/g, 19.9% at a threshold of 30 µg/g, 25.1% at a threshold of
20 µg/g and 33.2% at a threshold of 10 µg/g. Specificity of the first completed FIT for AAs was 94.8% at
a threshold of 40 µg/g, 93.7% at a threshold of 30 µg/g, 92.0% at a threshold of 20 µg/g and 87.5% at a
threshold of 10 µg/g. Comparable sensitivities for CRC were 30.8%, 38.5%, 46.2% and 61.5% at each of
the thresholds and comparable specificities for CRC were 93.9%, 92.7%, 90.7% and 86.0% (see Table 4).
As with CRC, sensitivities for AAs were higher, and specificities lower, with multiple FITs and lower faecal
haemoglobin thresholds. In cumulative test analysis after three tests, sensitivity and specificity for AAs were,
respectively, 35.8% and 87.1% at a threshold of 40 µg/g, 42.8% and 84.7% at a threshold of 30 µg/g,
48.2% and 80.7% at a threshold of 20 µg/g, and 59.3% and 72.2% at a threshold of 10 µg/g. In
programme analysis after three tests, sensitivity and specificity were, respectively, 34.3% and 87.6% at a
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TABLE 4 Faecal immunochemical test sensitivity, specificity, PPV and NPV for CRC at various thresholds in participants who completed 1–3 tests and had at least one colonic
examination performed
FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
CRCs
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases, n
FIT +ve
cases, n
40
First 5199 326 (6.3) 26 8 30.8 (14.3 to 51.8) 93.9 (93.2 to 94.5) 2.5 (1.1 to 4.8) 99.6 (99.4 to 99.8)
Secondb 4837 233 (4.8) 16 8 50.0 (24.7 to 75.3) 95.3 (94.7 to 95.9) 3.4 (1.5 to 6.7) 99.8 (99.7 to 99.9)
Thirdc 4429 182 (4.1) 6 2 33.3 (4.3 to 77.7) 95.9 (95.3 to 96.5) 1.1 (0.1 to 3.9) 99.9 (99.8 to 100.0)
Cumulative test analysis
Two testsd 5163 559 (10.8) 24 16 66.7 (44.7 to 84.4) 89.4 (88.6 to 90.3) 2.9 (1.6 to 4.6) 99.8 (99.7 to 99.9)
Three testse 4988 741 (14.9) 22 18 81.8 (59.7 to 94.8) 85.4 (84.4 to 86.4) 2.4 (1.4 to 3.8) 99.9 (99.8 to 100.0)
Programme analysis
Two testsf 5199 559 (10.8) 26 16 61.5 (40.6 to 79.8) 89.5 (88.6 to 90.3) 2.9 (1.6 to 4.6) 99.8 (99.6 to 99.9)
Three testsg 5199 741 (14.3) 26 18 69.2 (48.2 to 85.7) 86.0 (85.0 to 87.0) 2.4 (1.4 to 3.8) 99.8 (99.6 to 99.9)
30
First 5199 386 (7.4) 26 10 38.5 (20.2 to 59.4) 92.7 (92.0 to 93.4) 2.6 (1.2 to 4.7) 99.7 (99.5 to 99.8)
Secondb 4778 276 (5.8) 14 6 42.9 (17.7 to 71.1) 94.3 (93.6 to 95.0) 2.2 (0.8 to 4.7) 99.8 (99.7 to 99.9)
Thirdc 4330 220 (5.1) 6 3 50.0 (11.8 to 88.2) 95.0 (94.3 to 95.6) 1.4 (0.3 to 3.9) 99.9 (99.8 to 100.0)
Cumulative test analysis
Two testsd 5164 662 (12.8) 24 16 66.7 (44.7 to 84.4) 87.4 (86.5 to 88.3) 2.4 (1.4 to 3.9) 99.8 (99.7 to 99.9)
Three testse 4992 882 (17.7) 22 19 86.4 (65.1 to 97.1) 82.6 (81.6 to 83.7) 2.2 (1.3 to 3.3) 99.9 (99.8 to 100.0)
Programme analysis
Two testsf 5199 662 (12.7) 26 16 61.5 (40.6 to 79.8) 87.5 (86.6 to 88.4) 2.4 (1.4 to 3.9) 99.8 (99.6 to 99.9)
Three tests
g
5199 882 (17.0) 26 19 73.1 (52.2 to 88.4) 83.3 (82.3 to 84.3) 2.2 (1.3 to 3.3) 99.8 (99.7 to 99.9)
20
First 5199 492 (9.5) 26 12 46.2 (26.6 to 66.6) 90.7 (89.9 to 91.5) 2.4 (1.3 to 4.2) 99.7 (99.5 to 99.8)
Secondb 4677 331 (7.1) 13 6 46.2 (19.2 to 74.9) 93.0 (92.3 to 93.7) 1.8 (0.7 to 3.9) 99.8 (99.7 to 99.9)
Thirdc 4182 267 (6.4) 5 3 60.0 (14.7 to 94.7) 93.7 (92.9 to 94.4) 1.1 (0.2 to 3.2) 99.9 (99.8 to 100.0)
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FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
CRCs
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases, n
FIT +ve
cases, n
Cumulative test analysis
Two testsd 5169 823 (15.9) 25 18 72.0 (50.6 to 87.9) 84.4 (83.3 to 85.3) 2.2 (1.3 to 3.4) 99.8 (99.7 to 99.9)
Three testse 5005 1090 (21.8) 23 21 91.3 (72.0 to 98.9) 78.5 (77.4 to 79.7) 1.9 (1.2 to 2.9) 99.9 (99.8 to 100.0)
Programme analysis
Two testsf 5199 823 (15.8) 26 18 69.2 (48.2 to 85.7) 84.4 (83.4 to 85.4) 2.2 (1.3 to 3.4) 99.8 (99.6 to 99.9)
Three testsg 5199 1090 (21.0) 26 21 80.8 (60.6 to 93.4) 79.3 (78.2 to 80.4) 1.9 (1.2 to 2.9) 99.9 (99.7 to 100.0)
10
First 5199 742 (14.3) 26 16 61.5 (40.6 to 79.8) 86.0 (85.0 to 86.9) 2.2 (1.2 to 3.5) 99.8 (99.6 to 99.9)
Secondb 4429 441 (10.0) 10 5 50.0 (18.7 to 81.3) 90.1 (89.2 to 91.0) 1.1 (0.4 to 2.6) 99.9 (99.7 to 100.0)
Thirdc 3837 347 (9.0) 3 1 33.3 (0.8 to 90.6) 91.0 (90.0 to 91.9) 0.3 (0.0 to 1.6) 99.9 (99.8 to 100.0)
Cumulative test analysis
Two testsd 5171 1183 (22.9) 26 21 80.8 (60.6 to 93.4) 77.4 (76.2 to 78.6) 1.8 (1.1 to 2.7) 99.9 (99.7 to 100.0)
Three testse 5020 1530 (30.5) 24 22 91.7 (73.0 to 99.0) 69.8 (68.5 to 71.1) 1.4 (0.9 to 2.2) 99.9 (99.8 to 100.0)
Programme analysis
Two testsf 5199 1183 (22.8) 26 21 80.8 (60.6 to 93.4) 77.5 (76.4 to 78.7) 1.8 (1.1 to 2.7) 99.9 (99.7 to 100.0)
Three tests
g
5199 1530 (29.4) 26 22 84.6 (65.1 to 95.6) 70.8 (69.6 to 72.1) 1.4 (0.9 to 2.2) 99.9 (99.7 to 100.0)
+ve, positive.
a Participants were not included as invited to any subsequent tests following a FIT positive test at the specified threshold.
b The round at which a participant completed their second FIT; for a particular participant this could be round 2 or 3.
c The round at which a participant completed their third FIT; equivalent to round 3 in participants who completed FIT at both prior rounds.
d Includes participants who completed at least two rounds of FIT or who were FIT positive at round 1; participants were classed as positive if FIT was positive at either of the first two
rounds at which they completed FIT.
e Includes participants who completed all three rounds of FIT or who were FIT positive at any round; participants were classed as positive if FIT was positive at any of the three rounds.
f Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
g Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at any of the three rounds.
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TABLE 5 Faecal immunochemical test sensitivity, specificity, PPV and NPV for AAs at various thresholds in participants who completed 1–3 tests and had at least one
colonic examination performed
FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
AAsb
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases, n
FIT +ve
cases, n
40
First 5199 326 (6.3) 443 78 17.6 (14.2 to 21.5) 94.8 (94.1 to 95.4) 23.9 (19.4 to 28.9) 92.5 (91.7 to 93.2)
Secondc 4837 233 (4.8) 363 38 10.5 (7.5 to 14.1) 95.6 (95.0 to 96.2) 16.3 (11.8 to 21.7) 92.9 (92.2 to 93.7)
Thirdd 4429 182 (4.1) 308 36 11.7 (8.3 to 15.8) 96.5 (95.8 to 97.0) 19.8 (14.3 to 26.3) 93.6 (92.8 to 94.3)
Cumulative test analysis
Two testse 5163 559 (10.8) 441 116 26.3 (22.3 to 30.7) 90.6 (89.8 to 91.4) 20.8 (17.5 to 24.4) 92.9 (92.2 to 93.7)
Three testsf 4988 741 (14.9) 424 152 35.8 (31.3 to 40.6) 87.1 (86.1 to 88.1) 20.5 (17.7 to 23.6) 93.6 (92.8 to 94.3)
Programme analysis
Two tests
g
5199 559 (10.8) 443 116 26.2 (22.1 to 30.5) 90.7 (89.8 to 91.5) 20.8 (17.5 to 24.4) 93.0 (92.2 to 93.7)
Three testsh 5199 741 (14.3) 443 152 34.3 (29.9 to 38.9) 87.6 (86.6 to 88.5) 20.5 (17.7 to 23.6) 93.5 (92.7 to 94.2)
30
First 5199 386 (7.4) 443 88 19.9 (16.2 to 23.9) 93.7 (93.0 to 94.4) 22.8 (18.7 to 27.3) 92.6 (91.8 to 93.3)
Secondc 4778 276 (5.8) 353 50 14.2 (10.7 to 18.2) 94.9 (94.2 to 95.5) 18.1 (13.8 to 23.2) 93.3 (92.5 to 94.0)
Thirdd 4330 220 (5.1) 287 44 15.3 (11.4 to 20.0) 95.6 (95.0 to 96.3) 20.0 (14.9 to 25.9) 94.1 (93.3 to 94.8)
Cumulative test analysis
Two testse 5164 662 (12.8) 441 138 31.3 (27.0 to 35.8) 88.9 (88.0 to 89.8) 20.8 (17.8 to 24.1) 93.3 (92.5 to 94.0)
Three testsf 4992 882 (17.7) 425 182 42.8 (38.1 to 47.7) 84.7 (83.6 to 85.7) 20.6 (18.0 to 23.5) 94.1 (93.3 to 94.8)
Programme analysis
Two testsg 5199 662 (12.7) 443 138 31.2 (26.9 to 35.7) 89.0 (88.1 to 89.9) 20.8 (17.8 to 24.1) 93.3 (92.5 to 94.0)
Three testsh 5199 882 (17.0) 443 182 41.1 (36.5 to 45.8) 85.3 (84.2 to 86.3) 20.6 (18.0 to 23.5) 94.0 (93.2 to 94.6)
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FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
AAsb
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases, n
FIT +ve
cases, n
20
First 5199 492 (9.5) 443 111 25.1 (21.1 to 29.4) 92.0 (91.2 to 92.7) 22.6 (18.9 to 26.5) 92.9 (92.2 to 93.7)
Secondc 4677 331 (7.1) 330 54 16.4 (12.5 to 20.8) 93.6 (92.9 to 94.3) 16.3 (12.5 to 20.7) 93.6 (92.9 to 94.4)
Thirdd 4182 267 (6.4) 260 40 15.4 (11.2 to 20.4) 94.2 (93.4 to 94.9) 15.0 (10.9 to 19.8) 94.4 (93.6 to 95.1)
Cumulative test analysis
Two testse 5169 823 (15.9) 441 165 37.4 (32.9 to 42.1) 86.1 (85.1 to 87.1) 20.0 (17.4 to 22.9) 93.6 (92.9 to 94.4)
Three testsf 5005 1090 (21.8) 425 205 48.2 (43.4 to 53.1) 80.7 (79.5 to 81.8) 18.8 (16.5 to 21.3) 94.4 (93.6 to 95.1)
Programme analysis
Two testsg 5199 823 (15.8) 443 165 37.2 (32.7 to 41.9) 86.2 (85.2 to 87.1) 20.0 (17.4 to 22.9) 93.6 (92.9 to 94.4)
Three testsh 5199 1090 (21.0) 443 205 46.3 (41.6 to 51.0) 81.4 (80.3 to 82.5) 18.8 (16.5 to 21.3) 94.2 (93.4 to 94.9)
10
First 5199 742 (14.3) 443 147 33.2 (28.8 to 37.8) 87.5 (86.5 to 88.4) 19.8 (17.0 to 22.9) 93.4 (92.6 to 94.1)
Secondc 4429 441 (10.0) 294 65 22.1 (17.5 to 27.3) 90.9 (90.0 to 91.8) 14.7 (11.6 to 18.4) 94.3 (93.5 to 95.0)
Thirdd 3837 347 (9.0) 216 42 19.4 (14.4 to 25.4) 91.6 (90.6 to 92.5) 12.1 (8.9 to 16.0) 95.0 (94.2 to 95.7)
Cumulative test analysis
Two testse 5171 1183 (22.9) 441 212 48.1 (43.3 to 52.8) 79.5 (78.3 to 80.6) 17.9 (15.8 to 20.2) 94.3 (93.5 to 95.0)
Three testsf 5020 1530 (30.5) 428 254 59.3 (54.5 to 64.0) 72.2 (70.9 to 73.5) 16.6 (14.8 to 18.6) 95.0 (94.2 to 95.7)
continued
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TABLE 5 Faecal immunochemical test sensitivity, specificity, PPV and NPV for AAs at various thresholds in participants who completed 1–3 tests and had at least one
colonic examination performed (continued )
FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
AAsb
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases, n
FIT +ve
cases, n
Programme analysis
Two tests
g
5199 1183 (22.8) 443 212 47.9 (43.1 to 52.6) 79.6 (78.4 to 80.7) 17.9 (15.8 to 20.2) 94.2 (93.5 to 94.9)
Three testsh 5199 1530 (29.4) 443 254 57.3 (52.6 to 62.0) 73.2 (71.9 to 74.4) 16.6 (14.8 to 18.6) 94.8 (94.1 to 95.5)
+ve, positive.
a Participants were not included as invited to any subsequent tests following a FIT positive test at the specified threshold.
b AAs were defined as adenomas (namely an adenoma, serrated adenoma, or mixed hyperplastic/dysplastic adenoma) which satisfied at least one of the following criteria: (1) ≥ 10mm in size,
(2) tubulovillous or villous histology or (3) high-grade dysplasia.
c The round at which a participant completed their second FIT; for a particular participant this could be round 2 or 3.
d The round at which a participant completed their third FIT; equivalent to round 3 in participants who completed FIT at both prior rounds.
e Includes participants who completed at least two rounds of FIT or who were FIT positive at round 1; participants were classed as positive if FIT was positive at either of the first two
rounds at which they completed FIT.
f Includes participants who completed all three rounds of FIT or who were FIT positive at any round; participants were classed as positive if FIT was positive at any of the three rounds.
g Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
h Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at any of the three rounds.
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threshold of 40 µg/g, 41.1% and 85.3% at a threshold of 30 µg/g, 46.3% and 81.4% at a threshold of
20 µg/g, and 57.3% and 73.2% at a threshold of 10 µg/g (see Table 5).
The PPVs of FIT were higher and NPVs lower for AAs than for CRC. For instance, at a threshold of
40 µg/g, the PPV of the first completed FIT for AAs was 23.9% and the NPV was 92.5%. At the same
threshold, the PPV and NPV for CRC were 2.5% and 99.6%, respectively.
Sensitivity, specificity, positive predictive value and negative predictive value of the
faecal immunochemical test for advanced colorectal neoplasia
Of the 5199 participants who underwent a colonic examination, 463 were diagnosed with ACN (Table 6);
437 (94.4%) with AAs but not CRC, 20 (4.3%) with CRC but not AAs and 6 (1.3%) with both AAs and CRC.
Sensitivities and specificities of FIT for ACN were similar to the values observed for AAs. For instance, for
the first completed FIT, sensitivity and specificity for ACN were, respectively, 17.9% and 94.9% at a
threshold of 40 µg/g, 20.5% and 93.9% at a threshold of 30 µg/g, 25.7% and 92.1% at a threshold of
20 µg/g, and 34.3% and 87.7% at a threshold of 10 µg/g (see Table 6).
As with CRC and AAs, sensitivity for ACN increased and specificity decreased with multiple FITs and lower
faecal haemoglobin thresholds. In cumulative test analysis after three tests, sensitivity and specificity for
ACN were, respectively, 37.5% and 87.3% at a threshold of 40 µg/g, 44.2% and 84.9% at a threshold of
30 µg/g, 49.8% and 80.9% at a threshold of 20 µg/g, and 60.5% and 72.5% at a threshold of 10 µg/g.
In programme analysis after three tests, sensitivity and specificity were, respectively, 35.6% and 87.8% at
a threshold of 40 µg/g, 42.1% and 85.5% at a threshold of 30 µg/g, 47.5% and 81.6% at a threshold of
20 µg/g, and 58.3% and 73.4% at a threshold of 10 µg/g.
The PPVs were higher and NPVs lower for ACN than for either AAs or CRC. For instance, for the first
completed FIT, the PPVs and NPVs for ACN were, respectively, 25.5% and 92.2% at a threshold of 40 µg/g,
24.6% and 92.4% at a threshold of 30 µg/g, 24.2% and 92.7% at a threshold of 20 µg/g, and 21.4% and
93.2% at a threshold of 10 µg/g. In comparison, PPVs and NPVs of the first completed FIT for AAs were,
respectively, 23.9% and 92.5% at a threshold of 40 µg/g, 22.8% and 92.6% at a threshold of 30 µg/g,
22.6% and 92.9% at a threshold of 20 µg/g, and 19.8% and 93.4% at a threshold of 10 µg/g. For CRC,
these values were, respectively, 2.5% and 99.6% at a threshold of 40 µg/g, 2.6% and 99.7% at a threshold
of 30 µg/g, 2.4% and 99.7% at a threshold of 20 µg/g, and 2.2% and 99.8% at a threshold of 10 µg/g.
Performance of the faecal immunochemical test by sex and age at invite
Of the 26 participants diagnosed with CRC, 13 were men (see Report Supplementary Material 7, Table 4).
Furthermore, 12 out of 26 (33.3%) participants with CRC were aged ≤ 65 years (see Report Supplementary
Material 8, Table 5). The number of CRCs when stratified by subgroup was small and, therefore, the
subgroup analyses lacked statistical power.
The sensitivity, specificity, PPV and NPV for CRC of the first completed FIT at a threshold of 40 µg/g were,
respectively, 38.5%, 93.0%, 2.0% and 99.8% in men, and 23.1%, 95.6%, 3.8% and 99.4% in women
(see Report Supplementary Material 7, Table 4). PPVs for CRC were consistently higher in women than in
men across all thresholds (e.g. in cumulative test analysis after three tests, PPVs in women compared
with men were, respectively, 4.6% vs. 1.6% at a threshold of 40 µg/g, 3.9% vs. 1.5% at a threshold of
30 µg/g, 3.8% vs. 1.3% at a threshold of 20 µg/g, and 2.5% vs. 1.0% at a threshold of 10 µg/g).
The sensitivity, specificity, PPV and NPV for CRC of the first completed FIT at a threshold of 40 µg/g were,
respectively, 16.7%, 94.7%, 1.5%, and 99.6% in participants aged ≤ 65 years, and 42.9%, 93.1%,
3.2%, and 99.7% in participants aged > 65 years (see Report Supplementary Material 8, Table 5).
Of the 443 participants with AAs, 311 (70.2%) were men (see Report Supplementary Material 9, Table 6)
and 202 (45.6%) were aged ≤ 65 years (see Report Supplementary Material 10, Table 7).
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TABLE 6 Faecal immunochemical test sensitivity, specificity, PPV and NPV for ACN at various thresholds in participants who completed 1–3 tests and had at least one colonic
examination performed
FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
ACNb
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases
FIT +ve
cases
40
First 5199 326 (6.3) 463c 83 17.9 (14.5 to 21.7) 94.9 (94.2 to 95.5) 25.5 (20.8 to 30.6) 92.2 (91.4 to 92.9)
Secondd 4837 233 (4.8) 376 44 11.7 (8.6 to 15.4) 95.8 (95.1 to 96.3) 18.9 (14.1 to 24.5) 92.8 (92.0 to 93.5)
Thirde 4429 182 (4.1) 313 38 12.1 (8.7 to 16.3) 96.5 (95.9 to 97.0) 20.9 (15.2 to 27.5) 93.5 (92.7 to 94.2)
Cumulative test analysis
Two testsf 5163 559 (10.8) 459 127 27.7 (23.6 to 32.0) 90.8 (90.0 to 91.6) 22.7 (19.3 to 26.4) 92.8 (92.0 to 93.5)
Three tests
g
4988 741 (14.9) 440 165 37.5 (33.0 to 42.2) 87.3 (86.3 to 88.3) 22.3 (19.3 to 25.4) 93.5 (92.7 to 94.2)
Programme analysis
Two testsh 5199 559 (10.8) 463 127 27.4 (23.4 to 31.7) 90.9 (90.0 to 91.7) 22.7 (19.3 to 26.4) 92.8 (92.0 to 93.5)
Three testsi 5199 741 (14.3) 463 165 35.6 (31.3 to 40.2) 87.8 (86.9 to 88.8) 22.3 (19.3 to 25.4) 93.3 (92.5 to 94.0)
30
First 5199 386 (7.4) 463 95 20.5 (16.9 to 24.5) 93.9 (93.1 to 94.5) 24.6 (20.4 to 29.2) 92.4 (91.6 to 93.1)
Secondd 4778 276 (5.8) 364 54 14.8 (11.3 to 18.9) 95.0 (94.3 to 95.6) 19.6 (15.1 to 24.7) 93.1 (92.3 to 93.8)
Thirde 4330 220 (5.1) 292 46 15.8 (11.8 to 20.4) 95.7 (95.0 to 96.3) 20.9 (15.7 to 26.9) 94.0 (93.2 to 94.7)
Cumulative test analysis
Two testsf 5164 662 (12.8) 459 149 32.5 (28.2 to 37.0) 89.1 (88.2 to 90.0) 22.5 (19.4 to 25.9) 93.1 (92.3 to 93.8)
Three testsg 4992 882 (17.7) 441 195 44.2 (39.5 to 49.0) 84.9 (83.8 to 85.9) 22.1 (19.4 to 25.0) 94.0 (93.2 to 94.7)
Programme analysis
Two testsh 5199 662 (12.7) 463 149 32.2 (27.9 to 36.6) 89.2 (88.2 to 90.0) 22.5 (19.4 to 25.9) 93.1 (92.3 to 93.8)
Three testsi 5199 882 (17.0) 463 195 42.1 (37.6 to 46.8) 85.5 (84.5 to 86.5) 22.1 (19.4 to 25.0) 93.8 (93.0 to 94.5)
20
First 5199 492 (9.5) 463 119 25.7 (21.8 to 29.9) 92.1 (91.3 to 92.9) 24.2 (20.5 to 28.2) 92.7 (91.9 to 93.4)
Secondd 4677 331 (7.1) 341 59 17.3 (13.4 to 21.7) 93.7 (93.0 to 94.4) 17.8 (13.9 to 22.4) 93.5 (92.7 to 94.2)
Thirde 4182 267 (6.4) 264 42 15.9 (11.7 to 20.9) 94.3 (93.5 to 95.0) 15.7 (11.6 to 20.7) 94.3 (93.6 to 95.0)
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FIT threshold (µg/g)
Completed
a FIT,a n
Tested
+ve, n (%)
ACNb
Sensitivity, % (95% CI) Specificity, % (95% CI) PPV, % (95% CI) NPV, % (95% CI)
Total
cases
FIT +ve
cases
Cumulative test analysis
Two testsf 5169 823 (15.9) 460 178 38.7 (34.2 to 43.3) 86.3 (85.3 to 87.3) 21.6 (18.9 to 24.6) 93.5 (92.7 to 94.2)
Three tests
g
5005 1090 (21.8) 442 220 49.8 (45.0 to 54.5) 80.9 (79.8 to 82.1) 20.2 (17.8 to 22.7) 94.3 (93.6 to 95.0)
Programme analysis
Two testsh 5199 823 (15.8) 463 178 38.4 (34.0 to 43.0) 86.4 (85.4 to 87.3) 21.6 (18.9 to 24.6) 93.5 (92.7 to 94.2)
Three testsi 5199 1090 (21.0) 463 220 47.5 (42.9 to 52.2) 81.6 (80.5 to 82.7) 20.2 (17.8 to 22.7) 94.1 (93.3 to 94.8)
10
First 5199 742 (14.3) 463 159 34.3 (30.0 to 38.9) 87.7 (86.7 to 88.6) 21.4 (18.5 to 24.6) 93.2 (92.4 to 93.9)
Secondd 4429 441 (10.0) 302 68 22.5 (17.9 to 27.7) 91.0 (90.0 to 91.8) 15.4 (12.2 to 19.1) 94.1 (93.4 to 94.8)
Thirde 3837 347 (9.0) 219 43 19.6 (14.6 to 25.5) 91.6 (90.6 to 92.5) 12.4 (9.1 to 16.3) 95.0 (94.2 to 95.7)
Cumulative test analysis
Two testsf 5171 1183 (22.9) 461 227 49.2 (44.6 to 53.9) 79.7 (78.5 to 80.8) 19.2 (17.0 to 21.6) 94.1 (93.4 to 94.8)
Three testsg 5020 1530 (30.5) 446 270 60.5 (55.8 to 65.1) 72.5 (71.1 to 73.7) 17.6 (15.8 to 19.7) 95.0 (94.2 to 95.7)
Programme analysis
Two testsh 5199 1183 (22.8) 463 227 49.0 (44.4 to 53.7) 79.8 (78.6 to 80.9) 19.2 (17.0 to 21.6) 94.1 (93.4 to 94.8)
Three testsi 5199 1530 (29.4) 463 270 58.3 (53.7 to 62.8) 73.4 (72.1 to 74.6) 17.6 (15.8 to 19.7) 94.7 (94.0 to 95.4)
+ve, positive.
a Participants were not included as invited to any subsequent tests following a FIT positive test at the specified threshold.
b ACN was defined as CRC or AA. AAs were defined as adenomas (namely an adenoma, serrated adenoma or mixed hyperplastic/dysplastic adenoma) which satisfied at least one of the
following criteria: (1) ≥ 10mm or (2) tubulovillous or villous histology or (3) high-grade dysplasia.
c A total of 463 participants had advanced neoplasia: 20 participants had CRC but no AAs, 437 participants had AAs but not CRC and six participants had both CRC and AAs.
d The round at which a participant completed their second FIT; for a particular participant this could be round 2 or 3.
e The round at which a participant completed their third FIT; equivalent to round 3 in participants who completed FIT at both prior rounds.
f Includes participants who completed at least two rounds of FIT or who were FIT positive at round 1; participants were classed as positive if FIT was positive at either of the first two
rounds at which they completed FIT.
g Includes participants who completed all three rounds of FIT or who were FIT positive at any round; participants were classed as positive if FIT was positive at any of the three rounds.
h Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at either of the first two rounds at which they completed FIT.
i Includes participants who completed at least one round of FIT; participants were classed as positive if FIT was positive at any of the three rounds.
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The sensitivity, specificity, PPV and NPV for AAs of the first completed FIT at a threshold of 40 µg/g were,
respectively, 19.0%, 94.1%, 24.0% and 92.1% in men, 14.4%, 96.2%, 23.8% and 93.2% in women,
17.8%, 95.7%, 26.5% and 93.1% in participants aged ≤ 65 years, and 17.4%, 93.9%, 22.1% and
92.0% in participants aged > 65 years.
Sensitivities for AAs were generally higher, and specificities lower, in men and older participants. For
instance, in cumulative test analysis after three tests, the sensitivity and specificity for AAs in men were,
respectively, 37.8% and 85.5% at a threshold of 40 µg/g, 45.6% and 82.8% at a threshold of 30 µg/g,
51.0% and 78.5% at a threshold of 20 µg/g, and 61.5% and 70.0% at a threshold of 10 µg/g. In women,
these values were 31.3% and 90.1% at a threshold of 40 µg/g, 36.4% and 88.2% at a threshold of
30 µg/g, 41.9%% and 84.8% at a threshold of 20 µg/g, and 54.3% and 76.5% at a threshold of 10 µg/g
(see Report Supplementary Material 9, Table 6).
Among participants aged ≤ 65 years, the sensitivity and specificity for AAs in cumulative test analysis after
three tests were, respectively, 33.5% and 88.2% at a threshold of 40 µg/g, 39.2% and 86.2% at a
threshold of 30 µg/g, 43.3% and 81.9% at a threshold of 20 µg/g, and 52.6% and 72.9% at a threshold
of 10 µg/g. In those aged > 65 years, these values were 37.8% and 86.0% at 40 µg/g, 45.9% and 83.3%
at a threshold of 30 µg/g, 52.4% and 79.5% at a threshold of 20 µg/g, and 65.1% and 71.5% at a
threshold of 10 µg/g (see Report Supplementary Material 10, Table 7).
Of the 463 participants with ACN, 321 were men (69.3%) (see Report Supplementary Material 11,
Table 8) and 211 (45.6%) were aged ≤ 65 years (see Report Supplementary Material 12, Table 9).
The sensitivity, specificity, PPV and NPV for ACN of the first completed FIT at a threshold of 40 µg/g were,
respectively, 19.6%, 94.2%, 25.6% and 92.0% in men, 14.1%, 96.3%, 25.0% and 92.7% in women
(see Report Supplementary Material 11, Table 8), 17.1%, 95.7%, 26.5% and 92.7% in participants
aged ≤ 65 years, and 18.7%, 94.1%, 24.7% and 91.7% in participants aged > 65 years (see Report
Supplementary Material 12, Table 9).
As with AAs, sensitivity for ACN was generally higher and specificity lower in men and older participants.
For instance, in cumulative test analysis after three tests, at a threshold of 10 µg/g, sensitivity and specificity
for ACN were, respectively, 62.3% and 70.2% in men, 56.5% and 76.9% in women, 53.7% and 73.1%
in participants aged ≤ 65 years, and 66.3% and 71.8% in participants aged > 65 years.
Characteristics of detected colorectal cancers and advanced adenomas
Information on CRC stage and site was available for 23 out of 26 participants with CRC (Table 7). Of the
23 CRCs with stage and site information, 11 were primary tumours (pT) 3 or pT4, 12 were proximal to the
descending colon and 11 were distal to the splenic flexure.
Characteristics of the 524 AAs diagnosed in 443 participants are detailed in Report Supplementary
Material 13, Table 10, including information on site, size, dysplasia and histology. AAs were most
frequently located in the sigmoid colon (28.6%) and the vast majority (93.7%) had low-grade dysplasia.
Approximately half of the AAs were ≥ 10 mm in size (n = 269; 51.3%). Histology was known for 510
(97.3%) AAs, and 357 (68.1%) were tubulovillous adenomas. Out of the 443 participants with at least
one AA diagnosed, 383 (86.5%) had a single AA and 49 (11.1%) had two AAs, whereas only 11 (2.4%)
participants had three or more AAs (see Report Supplementary Material 14, Table 11).
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TABLE 7 Characteristics of the 26 patients diagnosed with CRC
Age at
invite
(years) Sex
Cancer
TNM stage
Number
of FITs
completed
Faecal haemoglobin
count (µg/g)
Site Type
First
completed
FIT
Highest
observed
Proximal to the descending colon
67 F Caecum Adenocarcinoma pT4, N0, Mx 1 786 786
61 M Caecum Adenocarcinoma pT3, N0, Mx 3 0 0.4
69 M Appendix Carcinoid exgoblet cell pT3, N1, Mx 1 61.2 61.2
70 F Ascending colon Adenocarcinoma pT1, N1, Mx 2 6 502.4
68 F Ascending colon Adenocarcinoma pT1, N0, Mx 2 2.2 157.8
66 M Ascending colon Adenocarcinoma pT2, N1, Mx 2 38.4 42.6
70 F Ascending colon Adenocarcinoma pT3, N0, Mx 3 12.8 23.6
61 F Ascending colon Adenocarcinoma pT4, N1, Mx 1 184.8 184.8
71 F Transverse colon Adenocarcinoma pT1, Nx, Mx 3 1.2 2.6
64 M Transverse colon Adenocarcinoma pT4, N0, Mx 3 7.6 35
61 M Transverse colon Adenocarcinoma pT3, N0, Mx 2 0 112.8
63 F Transverse colon Adenocarcinoma pT1, N0, Mx 3 1.8 52
Distal to the splenic flexure
72 M Descending
colon
Adenocarcinoma pT1, N0, Mx 2 20.8 71
68 M Sigmoid colon Adenocarcinoma pT3, N0, Mx 1 271.4 271.4
65 M Sigmoid colon Adenocarcinoma pT4, N2, M1 1 1937.4 1937.4
68 F Sigmoid colon Adenocarcinoma pT1, Nx, Mx 1 51 51
63 M Sigmoid colon Adenocarcinoma pT3, N0, Mx 2 37.8 1522.6
65 F Sigmoid colon Adenocarcinoma pT3, N1, Mx 3 5.4 5409.6
67 M Rectosigmoid Adenocarcinoma pT1, N0, Mx 1 97.2 97.2
63 F Rectum Adenocarcinoma pT2, N1, Mx 2 11.2 95.4
61 F Rectum Neuroendocrine
tumour
pT1 (from
biopsy)
2 0.4 1.2
68 F Rectum Adenocarcinoma pT1, Nx, Mx 2 16.4 752
69 M Rectum Adenocarcinoma pT1, Nx, Mx 1 54.8 54.8
Unknown
67 F Unknown Adenocarcinoma Unknown 1 21.4 21.4
63 M Unknown Adenocarcinoma Unknown 2 0 0
65 M Unknown Unknown Unknown 1 14.4 14.4
F, female; M, male; TNM, tumour, node and metastasis (classification of malignant tumours).
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Chapter 4 Health psychology assessment
This chapter is partly reproduced from Bowyer et al.67 Patient attitudes towards faecal immunochemicaltesting for haemoglobin as an alternative to colonoscopic surveillance of groups at increased risk of
colorectal cancer. Journal of Medical Screening vol. 20, iss. 3, pp. 149–56. Copyright © 2013 by the
Authors. Reprinted by permission of SAGE Publications, Ltd. This property is the exclusive property of the
SAGE Publishing and is protected by copyright and other intellectual property laws. User may not modify,
publish, transmit, participate in the transfer or sale of, reproduce, create derivative works (including course
packs) from, distribute, perform, display, or in any way exploit any of the content of the file(s) in whole or
in part. Permission may be sought for further use from Publications Ltd., Rights & Permissions Department,
1, Oliver’s Yar, 55, City Road, London EC1Y 1SP, Email: permissions@sagepub.co.uk. By accessing the file(s),
the User acknowledges and agrees to these terms. URL: www.sagepub.co.uk.
Introduction
In this chapter, we present studies evaluating perceptions and preferences for FIT surveillance and summarise
the experience of participants in the main FIT for Follow-Up study. Colonoscopy surveillance is currently
considered the optimal test for individuals at intermediate or high risk of CRC.21 However, since the
introduction of the BCSP, there have been concerns about the implications for endoscopy departments and
the risk associated with repeat colonoscopies at regular intervals. These concerns are further compounded by
the modest diagnostic yield of surveillance colonoscopy.19,39 Another issue with surveillance colonoscopy is
that one in five individuals at intermediate or high risk of CRC do not attend the surveillance examinations,
which is comparable to the uptake of colonoscopy following an abnormal gFOBT in the BCSP.16,35,36 Factors
associated with non-attendance at colonoscopy include anxiety about having to prepare for the test with a
laxative, anxiety about the procedure itself (such as the risk of bowel perforation) and expectations of pain
and embarrassment.34
FIT might be a viable alternative as the primary surveillance test. FIT is administered at home, is non-invasive
and requires only a single stool sample, thereby significantly reducing the unpleasantness associated with
other home-based stool tests.67 As such, FIT is aligned with people’s preferences for CRC tests that are
non-invasive, avoid pain as much as possible and do not require bowel preparation, while offering high
levels of sensitivity and specificity.78 One study found that average-risk participants who were concerned
about procedural discomfort were more likely to choose FIT over colonoscopy as a screening modality.79
In these patients, FIT completion rates were higher than colonoscopy attendance, a finding supported in a
recent RCT.80 However, there is a lack of research into the perceptions of and preferences for different
forms of post-polypectomy surveillance among higher-risk individuals.
Here, we present the findings of the health psychology work stream nested within the FIT for Follow-Up
study. Its aim was to better understand what people think about FIT in the context of surveillance, to
monitor the actual participant-reported experience associated with an annual FIT and begin to investigate
what preferences people at intermediate risk have for their adenoma surveillance.
Study 1: patient attitudes towards the faecal immunochemical test
as an alternative to colonoscopy surveillance of groups at increased
risk of colorectal cancer – a qualitative discussion group study
The following is an executive summary of a study into public attitudes towards FIT. Its main aim was to
gain an early understanding of potential issues for the main study and to facilitate the design of participant
materials. A full summary has been published by Bowyer et al.67
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Methods
Recruitment
A total of 198 individuals aged 60–74 years who resided in the London Boroughs of Brent and Harrow
were identified by the BCSP London Hub and St Mark’s Hospital Endoscopy Unit. Participants varied
in CRC risk level and experience of gFOBT, baseline colonoscopy and colonoscopy surveillance.
Previous research has demonstrated that patient preferences differ according to perceived risk and prior
experience of colonoscopy surveillance.69,81–84
Average-risk groups included individuals with and without prior experience of colonoscopy, all of whom
had received a negative gFOBT result from the BCSP and were awaiting their next routine BCSP invitation.
Intermediate-risk surveillance-naive groups included individuals who were awaiting their first surveillance
colonoscopy, having been referred via the BCSP.
Intermediate-risk surveillance-experienced groups consisted of individuals who had been referred for
colonoscopy via their GP or as part of the UK Flexible Sigmoidoscopy Screening Trial.9 The study was
approved by the North London Research Ethics Committee (reference 10/H0717/82).
Discussion guide
The discussion groups were conducted in November 2011 and used a comprehensive stepwise discussion
guide (see Report Supplementary Material 15). After each information segment on CRC surveillance,
participants responded to the following question: ‘Consider the information you have just seen about
FIT replacing a routine colonoscopy. How would you feel about the offer of a FIT every year instead of a
three-yearly colonoscopy?’. They responded using an electronic response device, selecting an option on a
six-point scale from ‘very positive’ to ‘very negative’, before discussing each section as a group. Discussions
were transcribed and coded using thematic analysis.85
Results
Of the 198 people who were sent invitation letters, 45 (22.7%) agreed to participate. Of these, 28 people
eventually took part in one of five discussion groups. The type of risk profile had an important impact on
how information about the FIT was interpreted. There was agreement in all groups that a FIT would be
easier to complete and safer than a colonoscopy. However, there was concern among intermediate-risk
participants with a history of previous colonoscopy whether or not a FIT would be reliable. One female
from the surveillance-experienced group voiced her reservations:
Once you’ve had a colonoscopy you feel very reassured yourself because you’ve actually seen the
whole procedure . . . whereas with this FIT, does it work, does it not . . . you don’t know.
Female, surveillance-experience group
Interestingly, many of the concerns about FIT related to the test relying on a single sample:
I’m very comfortable with the FIT but it also has a down-side that it . . . wouldn’t detect as much as
providing three samples, possibly.
Female, average-risk group
This was further compounded by the belief that polyps might bleed only intermittently.
Discussion
Overall, FIT was preferred over colonoscopy by people who were at average risk or surveillance naive, who
cited the importance of being tested more frequently. By contrast, the surveillance-experienced group did
not endorse the idea of annual FIT replacing 3-yearly colonoscopy surveillance because of concerns about
the sensitivity of FIT. They would endorse FIT only in addition to, rather than instead of, 3-yearly colonoscopy
surveillance. The study had several limitations. It is possible that, among individuals who attend a focus
group, levels of anxiety about CRC are different from those in the general population. Unfortunately, we
were unable to test this possibility and how this would have affected preferences stated in the groups.
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Some patients had also previously undergone a colonoscopy with a high satisfaction rate so they might
have been more likely to prefer to have another in the future. This group may also have been told that
they need a colonoscopy for follow-up and so may have been biased. As discussed in General discussion in
more detail, future research should focus on individuals who have not yet undergone colonoscopy.
Study 2: acceptability of annual faecal immunochemical tests for
post-polypectomy surveillance – findings from the main study
Introduction
As part of the main study, we monitored experiences associated with FIT-based annual surveillance. The
key areas were (1) the psychological impact of annual surveillance, (2) acceptability of completing the test
kit and (3) preferences for future surveillance.
Methods
Baseline questionnaire
The baseline questionnaire was sent to people alongside the consent form and round 1 FIT kit (see Report
Supplementary Material 1). Participants were asked to complete the questionnaire and return it with the
consent form and FIT kit. Those who did not respond within 3 weeks of the invitation were sent a
reminder letter.
Participants were asked to rate their experience of their baseline colonoscopy (‘Was your overall experience
of your most recent colonoscopy?’) on a four-point scale ranging from ‘not at all acceptable’ (1) to ‘very
acceptable’ (4).
The baseline questionnaire assessed specific aspects of CRC-related worry [‘Over the last two weeks, how
often have you worried about having bowel polyps (how often have you thought about your own chance
of developing bowel cancer?’)] using a four-point scale ranging from ‘not at all’ (1) to ‘every day’ (4).
The questionnaire also assessed participants’ current emotional state using the STAI,86 which contains six
items (‘calm’, ‘tense’, ‘upset’, ‘relaxed’, ‘content’ and ‘worried’), using a scale ranging from ‘not at all’ (1) to
‘very much so’ (4). The scale met the standard threshold for internal reliability in each round (Cronbach’s
alpha = 0.80, 0.81, 0.81 and 0.79, respectively). Positive emotional items were reverse coded so that higher
scores reflected greater degrees of state anxiety.
Round 1 questionnaire
Questionnaires were administered at the same time as the test outcomes (i.e. a negative FIT result letter or
a covering letter once the participant had attended or declined the offer of an early surveillance colonic
examination). See Report Supplementary Material 2 for study questionnaires. Questionnaires were not
posted to participants who had been diagnosed with cancer to minimise distress.
The round 1 questionnaire for participants with a negative FIT result (round 1 FIT negative) repeated the
measurement of current emotional well-being and specific CRC-related beliefs and worry (as per the
baseline questionnaire). In addition, the questionnaire assessed motivation to take part in the study,
acceptability of the FIT invitation materials, clarity of instructions and ease of completing the FIT kit.
In the section on completing the test, participants rated the ease of ‘catching the bowel motion’, ‘removing
the stick from the sampling bottle’, ‘collecting the sample with the stick’, ‘reinserting the stick into the
sample bottle’ and ‘closing the sample bottle after use’, on a four-point scale ranging from ‘very difficult’
(1) to ‘very easy’ (4). Participants were also asked to respond to the following negative effects of completing
the FIT (‘Doing the FIT made me feel anxious’, ‘The thought of an abnormal result from the FIT scared me’,
‘After seeing the FIT, I was concerned about its ability to detect new polyps’) on a four-point scale ranging
from ‘strongly disagree’ (1) to ‘strongly agree’ (4). This question was administered only at round 1.
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Participants were asked in all three rounds how they felt when waiting for the FIT results and when
receiving the FIT results using a four-point scale ranging from ‘not worried’ (1) to ‘very worried’ (4).
The questionnaires for all three rounds also contained three items adapted from the emotional subscale
of the Positive Psychological Consequences of Screening questionnaire87 to ascertain the degree of
reassurance gained after each round of FIT surveillance: did the FIT . . . ‘reassure you that you did not have
bowel cancer?’, ‘make you feel more hopeful about the future?’, ‘make you feel less anxious about bowel
cancer?’. Participants responded to each item on a four-point scale ranging from ‘not at all’ (1) to ‘a great
deal’ (4). For participants with a positive FIT result, the item was modified to ‘Did your last colonoscopy. . .’
followed by the same response options. The scale had acceptable to good inter-reliability in the three
rounds with Cronbach’s alpha of 0.84, 0.80 and 0.76 in rounds 1–3, respectively, and will be referred to
as the Positive Consequences of Surveillance Scale (PCSS).
Round 2 questionnaire
The round 2 questionnaire repeated the assessment of emotional well-being and perceived CRC worry
(see Baseline questionnaire).
Participant questionnaires for faecal immunochemical test-positive participants in
rounds 1 and 2
Participants with a FIT positive result were given the same questionnaire for rounds 1 and 2 but with a
few additional items for round 2, including a question about how they felt about being invited to have a
follow-up test (in the vast majority of cases a colonoscopy) earlier than they had expected; for this they
could answer on a four-point scale ranging from ‘very dissatisfied’ (1) to ‘very satisfied’ (4). Participants
with a FIT positive result were also asked to state a preference between four potential options for future
surveillance: ‘Routine colonoscopy every 3 years’, ‘Routine colonoscopy every 3 years plus a FIT every year’,
‘FIT every year only’ or ‘No further surveillance’.
Round 3 questionnaire
End-of-study questionnaires (identical to those used in rounds 1 and 2) were sent to all participants
(irrespective of their round 3 FIT result) after they had attended their end-of-study colonic examination.
End-of-study interviews
A subsample of participants were invited to participate in an end-of-study interview with a research
assistant (see Report Supplementary Material 16 for the interview guide). Participants were invited for an
interview at the end of round 1 or 2 if they had received a positive FIT during these two rounds, or at the
end of the study if they had completed a round 3 FIT and attended their end-of-study colonic examination.
The aim of the interviews was to enrich the quantitative evaluation of participant-reported experience.
Surveillance outcomes
At the end of the study, participants fell into one of four groups. Respondents who had received three negative
FIT results were divided into two subgroups according to the outcome of the end-of-study colonic examination.
Respondents who had no CRC-related abnormality detected at their end-of-study examination were classified
as ‘true negative.’ In contrast, those who had some form of therapeutic intervention to remove a CRC-related
abnormality (e.g. polyps or adenoma) were classified as ‘false negative’. In the group of respondents who had
received a positive FIT result in rounds 1–3, the outcome of the diagnostic colonoscopy determined whether a
participant was classified as ‘true positive’ (when the diagnostic colonoscopy detected an AA or CRC-related
abnormality) or ‘false positive’ (when the diagnostic colonoscopy did not detect an AA or CRC-related
abnormality). Our criteria were based on previous research, which suggested that participants would
consider any form of CRC-related abnormality a significant clinical finding.67,88 These categories excluded
people who did not complete their end-of-study questionnaire and participants who had CRC detected
by whatever means. As a result, our definition of an abnormal result was different from the one used to
categorise clinical findings in the main study. For example, we classified any colonoscopy which detected a
CRC-related abnormality as abnormal, whereas in the main study the definition of abnormal was restricted
to colonoscopies which had detected AAs or CRC.
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Statistical analysis
Basic information on demographics (i.e. age, sex) and participant outcomes for FIT and diagnostic/surveillance
examinations were obtained from data recorded in the PMS. Initial analysis revealed that most responses were
skewed towards the upper end (in the case of acceptability) or the lower end (in the case of CRC-related worry
and risk) of the distribution. As a result, we used non-parametric tests of differences to compare between
different test outcomes and within individuals responding in repeated rounds. The Mann–Whitney U-test was
used for between-group comparisons and Wilcoxon signed-rank test for comparison across different rounds.
Chi-squared tests were used for individual items that had been collapsed into binary outcomes.
Results
Table 8 gives a demographic breakdown of responders in all three rounds. Of 5946 participants, 5879 (98.9%)
completed a baseline questionnaire with 5020 participants (84.4%) completing a round 1 questionnaire. Of
5350 participants, 4491 (83.9%) completed a round 2 questionnaire, and of 4646 participants, 3881 (83.5%)
completed a round 3 questionnaire.
Satisfaction with previous colonoscopy at baseline was extremely high, with 95.8% (5370/5604)
of participants responding to this question rating their baseline colonoscopy as acceptable (Table 9).
However, female participants were significantly more likely than male participants to report that their
colonoscopy was not acceptable (6.7% vs. 2.8% respectively; χ2 = 47.94; p < 0.001). There was no
significant difference by age (χ2 = 0.02; p = 0.89).
Participants unanimously reported that catching the bowel motion, removing the stick, collecting the
sample with the stick, reinserting the stick into the sampling bottle and closing the sampling bottle was
easy (94.9%, 99.0%, 97.1%, 95.4% and 99.3%, respectively; see Table 9). Participants aged > 65 years
were slightly more likely than those aged ≤ 65 years to find removing the stick from the sampling bottle
difficult (1.3% vs. 0.7%; χ2 = 4.56, p = 0.04). There were no other significant differences by age.
There were a number of small but significant differences by sex (see Table 9). Females were slightly more
likely than males to report difficulties with removing the stick from the bottle (1.4% vs. 0.7%, χ2 = 5.5;
p = 0.02), collecting the sample with the stick (3.8% vs. 2.4%, χ2 = 7.8; p = 0.006) and reinserting the
stick into the sampling bottle (7.3% vs. 4.0%; χ2 = 25.1; p < 0.001).
In terms of the psychological consequences of screening, 26.8% of participants in round 1 reported that
completing the FIT kit made them feel anxious (see Table 9), 48.3% reported that the thought of an
abnormal test result had scared them (see Table 9) and 7.3% reported being worried when waiting for the
round 1 FIT result (Table 10). A total of 29.2% reported being concerned about the ability of FIT to detect
new polyps (see Table 9).
TABLE 8 Demographic composition of questionnaire respondents at baseline and at each round
Variables
Time point
Baseline, n (%)
Round, n (%)
1 2 3
All participants 5879 5020 4491 3881
Gender
Female 2030 (34.5) 1751 (34.9) 1576 (35.1) 1319 (34.4)
Male 3849 (65.5) 3269 (65.1) 2915 (64.9) 2562 (65.6)
Age
≤ 65 years 2847 (48.4) 2364 (47.1) 2130 (47.4) 1866 (48.1)
> 65 years 3032 (51.6) 2656 (52.9) 2361 (52.6) 2015 (51.9)
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TABLE 9 Impact of annual FIT surveillance on CRC-related beliefs
Experience with previous colonoscopy at baseline
Variables na Not acceptable, n (%) Acceptable, n (%) χ2 p-value
All participants 5604 234 (4.2) 5370 (95.8)
Gender 47.94 < 0.001
Female 1933 130 (6.7) 1603 (93.3)
Male 3671 104 (2.8) 3567 (97.2)
Age (years) 0.02 0.894
≤ 65 2707 112 (4.1) 2595 (95.9)
> 65 2897 122 (4.2) 2775 (95.8)
How did you feel about being invited to have a colonoscopy earlier than you had expected?
Variables n Dissatisfied, n (%) Satisfied, n (%) χ2 p-value
All participants 450 34 (7.6) 416 (92.4)
Round 9.199 0.002
1 176 5 (2.8) 171 (97.2)
2 274 29 (10.6) 245 (89.4)
Gender 0.001 0.978
Female 105 8 (7.6) 97 (92.4)
Male 345 26 (7.5) 319 (92.5)
Age (years) 0.137 0.720
≤ 65 185 15 (8.1) 170 (91.9)
> 65 265 19 (7.2) 246 (92.8)
How did you find catching the bowel motion?
Variables n Difficult, n (%) Easy, n (%) χ2 p-value
All participants 4990 255 (5.1) 4735 (94.9)
Gender 1.084 0.312
Female 1736 81 (4.7) 1655 (95.4)
Male 3254 174 (5.3) 3080 (94.7)
Age (years) 0.186 0.699
≤ 65 2355 117 (5.0) 2497 (95.0)
> 65 2635 138 (5.1) 2497 (94.8)
How did you find removing the stick from the sampling bottle?
Variables n Difficult, n (%) Easy, n (%) χ2 p-value
All participants 4798 47 (1.0) 4751 (99.0)
Gender 5.529 0.016
Female 1670 24 (1.4) 1646 (98.6)
Male 3128 23 (0.7) 3105 (99.3)
Age (years) 4.562 0.039
≤ 65 2274 15 (0.7) 2259 (99.3)
> 65 2524 32 (1.3) 2492 (98.7)
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TABLE 9 Impact of annual FIT surveillance on CRC-related beliefs (continued )
How did you find collecting the sample with the stick?
Variables n Difficult, n (%) Easy, n (%) χ2 p-value
All participants 4790 137 (2.9) 4653 (97.1)
Gender 7.806 0.006
Female 1666 63 (3.8) 1603 (96.2)
Male 3124 74 (2.4) 3050 (97.6)
Age (years) 0.290 0.603
≤ 65 2269 68 (3.0) 2201 (97.0)
> 65 2521 69 (2.7) 2452 (97.3)
How did you find reinserting the stick into the sampling bottle?
Variables n Difficult, n (%) Easy, n (%) χ2 p-value
All participants 4801 246 (5.1) 4555 (94.9)
Gender 25.067 < 0.001
Female 1670 122 (7.3) 1548 (92.7)
Male 3131 124 (4.0) 3007 (96.0)
Age (years) 2.220 0.077
≤ 65 2271 105 (4.6) 2166 (95.4)
> 65 2530 141 (5.6) 2389 (94.4)
How did you find closing the sampling bottle?
Variables n Difficult, n (%) Easy, n (%) χ2 p-value
All participants 4801 36 (0.7) 4765 (99.3)
Gender 2.447 0.159
Female 1673 17 (1.0) 1656 (99.0)
Male 3128 19 (0.6) 3109 (99.4)
Age (years) 0.099 0.753
≤ 65 2275 18 (0.8) 2257 (99.2)
> 65 2526 18 (0.7) 2508 (99.3)
Doing the FIT made me anxious
Variables n Disagree, n (%) Agree, n (%) χ2 p-value
All participants 4877 3570 (73.2) 1307 (26.8)
Gender 31.253 0.001
Female 1675 1144 (68.3) 531 (31.7)
Male 3202 2426 (75.8) 776 (24.2)
Age (years) 1.010 0.316
≤ 65 2319 1682 (72.5) 637 (27.5)
> 65 2558 1888 (73.8) 670 (26.2)
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TABLE 9 Impact of annual FIT surveillance on CRC-related beliefs (continued )
The thought of an abnormal result from the FIT scared me
Variables n Disagree, n (%) Agree, n (%) χ2 p-value
All participants 4840 2500 (51.7) 2340 (48.3)
Gender 92.093 < 0.001
Female 1670 704 (42.2) 966 (57.8)
Male 3170 1796 (56.7) 1374 (43.3)
Age (years) 1.399 0.238
≤ 65 2301 1168 (50.8) 1133 (49.2)
> 65 2539 1332 (52.5) 2500 (52.5)
After seeing the FIT, I was concerned about its ability to detect new polyps
Variables n Disagree, n (%) Agree, n (%) χ2 p-value
All participants 4856 3440 (70.8) 1416 (29.2)
Gender 30.436 < 0.001
Female 1680 1107 (65.9) 573 (34.1)
Male 3176 2333 (73.5) 843 (26.5)
Age (years) 2.67 0.107
≤ 65 2304 1658 (72.0) 646 (28.0)
> 65 2552 1782 (69.8) 770 (30.2)
a Differences in ‘n’ figures are because of variations in the number of questionnaire respondents answering each item.
TABLE 10 Worried when waiting for result: variation by round, age and sex
Variables
Time point, how did you feel when waiting for the FIT results?
Round 1 Round 2 Round 3
Not worried,
n (%)
Worried,
n (%)
Not worried,
n (%)
Worried,
n (%)
Not worried,
n (%)
Worried,
n (%)
All participants 4628 (92.7) 362 (7.3) 4125 (92.4) 337 (7.6) 4125 (92.4) 337 (7.6)
Age (years)
≤ 65 2175 (92.4) 179 (7.6) 1962 (92.7) 155 (7.3) 1744 (94.2) 108 (5.8)
> 65 2453 (93.1) 183 (6.9) 2163 (92.2) 182 (7.8) 1889 (94.5) 111 (5.6)
p-value 0.368 0.579 0.579
Sex
Female 1554 (85.9) 182 (10.5) 1391 (88.9) 173 (11.1) 1191 (91.0) 118 (9.0)
Male 3074 (95.4) 180 (5.5) 2734 (94.3) 164 (5.7) 2442 (96.0) 101 (4.0)
p-value < 0.001 < 0.001 < 0.706
FIT result
Negative 4392 (93.2) 321 (6.8) 3975 (92.8) 310 (7.2) 3456 (5.6) 205 (5.6)
Positive 236 (85.2) 41 (14.8) 150 (84.7) 27 (15.3) 142 (92.2) 12 (7.8)
p-value < 0.001 < 0.001 0.283
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There were significant differences by sex but not by age in the responses to these items. Female responders
were significantly more likely to report being anxious when completing the test kit than male responders
(31.7% vs. 24.2%, χ2 = 31.25; p = 0.001; see Table 9). Female responders were also more likely to report
that the thought of an abnormal test result had scared them (57.8% vs. 43.3%, χ2 = 92.10; p < 0.001; see
Table 9) and were more likely than male responders to report being worried while waiting for the round 1
FIT results (10.5% vs. 5.5%, χ2 = 41.63; p < 0.001; see Table 10). Female responders were also more likely
than male responders to be concerned about the ability of FIT to detect new polyps (34.1% vs. 29.2%,
χ2 = 30.44; p< 0.001; see Table 9).
Spielberger State–Trait Anxiety Inventory scores across different rounds
Anxiety was highest at baseline (baseline = 9, round 1 = 7, round 2 = 7, round 3 = 7; Table 11).
Comparison across the four assessments of anxiety confirmed that anxiety at baseline was significantly
higher than at round 1 (p < 0.001), round 2 (p < 0.001) and round 3 (p < 0.001). There were, however,
no significant differences between rounds 1 and 2 (p = 0.36) or between rounds 2 and 3 (p = 0.18)
(see Table 11).
There was no significant difference in anxiety between people who had received FIT-positive versus FIT-
negative results in round 1 (FIT–ve = 7 vs. FIT+ve = 7; p = 0.37), round 2 (FIT–ve = 7 vs. FIT+ve = 6; p = 0.26) or
round 3 (FIT–ve = 7 vs. FIT+ve = 6; p = 0.10; see Table 11). There was a small but statistically significant trend
of males reporting slightly higher levels of anxiety than females across the three rounds (Table 12).
We observed a very similar pattern for CRC-related worry by round. The proportion of respondents worrying
more than once a week was 7.2%, 8.7% and 9.2% at baseline, round 1 and round 2, respectively, with a
decline at round 3 (3.0%) (p = 0.001; Table 13). There were no between-group differences. Furthermore,
the vast majority of participants who had a positive result in round 1 or 2 felt satisfied about being called
early for their colonoscopy as a result of a positive FIT (97.2% and 89.4%, respectively; see Table 9). However,
participants were significantly more likely to be dissatisfied about being called early for colonoscopy in round 2
than in round 1 (10.6% vs. 2.8%, χ2 = 9.20; p = 0.002; see Table 9).
TABLE 11 Psychological scales: outcome by FIT result at baseline and at each round
Psychological scale
Time point
Baseline Round 1 Round 2 Round 3
Median
FIT–ve
median
FIT+ve
median
FIT–ve
median
FIT+ve
median
FIT–ve
median
FIT+ve
median
STAI
I feel calm 2.00 1.00 1.00 1.00 1.00 1.00 1.00
I am tense 1.00 1.00 1.00 1.00 1.00 1.00 1.00
I am upset 1.00 1.00 1.00 1.00 1.00 1.00 1.00
I am relaxed 2.00 1.00 1.00 1.00 1.00 1.00 1.00
I feel content 1.00 1.00 1.00 1.00 1.00 1.00 1.00
I am worried 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Overall 9.00 7.00 7.00 7.00 6.00 7.00 6.00
PCSS
Reassurance – 4.00 4.00 4.00 4.00 4.00 4.00
More hope – 4.00 4.00 4.00 4.00 4.00 4.00
Less anxious – 3.00 3.00 3.00 3.00 3.00 3.00
Overall – 11.00 10.00 10.00 11.00 11.00 11.00
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TABLE 12 The STAI: variation by age and sex
Variables
Time point, median STAI score
Baseline Round 1 Round 2 Round 3
All participants 9.00 7.00 7.00 7.00
Age (years)
≤ 65 9.00 7.00 7.00 7.00
> 65 9.00 7.00 7.00 7.00
p-value 0.905 0.374 0.725 0.342
Sex
Female 9.00 6.00 7.00 7.00
Male 10.00 8.00 7.00 8.00
p-value 0.001 < 0.001 < 0.01 < 0.001
TABLE 13 Colorectal cancer-related worry: variation by round, age and sex
Variables
Time point, doing the FIT kit
Baseline Round 1 Round 2 Round 3
Not
worried,
n (%)
Worried,
n (%)
Not
worried,
n (%)
Worried,
n (%)
Not
worried,
n (%)
Worried,
n (%)
Not
worried,
n (%)
Worried,
n (%)
All participants 5213
(92.8)
404
(7.2)
4512
(91.3)
428
(8.7)
4007
(90.8)
407
(9.2)
3672
(97.0)
114
(3.0)
Age (years)
≤ 65 2499
(92.2)
212
(7.8)
2109
(90.3)
226
(9.7)
1898
(90.6)
197
(9.4)
1764
(96.7)
61
(3.3)
> 65 2714
(93.4)
192
(6.6)
2403
(92.2)
202
(7.8)
2109
(90.9)
210
(9.1)
1908
(97.3)
53
(2.7)
p-value 0.079 < 0.05 0.715 0.255
Sex
Female 1760
(90.9)
176
(176)
1518
(88.7)
194
(11.3)
1332
(86.1)
215
(13.9)
1214
(95.0)
64
(5.0)
Male 3453
(93.8)
228
(6.2)
2994
(92.8)
234
(7.2)
2675
(93.3)
192
(6.7)
2458
(98.0)
50
(2.0)
p-value < 0.001 < 0.001 < 0.001 < 0.001
FIT result
Negative NA 4275
(91.5)
398
(8.5)
3845
(90.7)
395
(9.3)
3495
(97.1)
301
(2.9)
Positive NA 237
(88.8)
30
(11.2)
162
(93.1)
12
(6.9)
143
(96.0)
6
(4.0)
p-value 0.145 0.348 0.172
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Positive consequences of faecal immunochemical test surveillance
Participants reported very high levels of reassurance (median = 4 out of 4), feeling more hopeful
(median = 4 out of 4) and being less anxious (median = 3 out of 4) as a result of taking part in the study
(see Table 10). There were no meaningful differences by round or FIT results (see Table 11).
Preferences for different types of adenoma surveillance
Table 14 offers a breakdown of surveillance preferences. As can be seen by the grand total, a majority of
participants (57.9%, n = 2478) preferred ‘Routine colonoscopy every three years plus a FIT every year
(RC + FIT)’, followed by ‘FIT every year with colonoscopy only for a positive result (FIT only)’ (31.5%,
n = 1347), ‘Routine colonoscopy every three years and no FIT (RC only)’ (8.9%, n = 379) and ‘No further
colonoscopies or FIT (No surveillance)’ (1.8%, n = 75).
Table 14 shows that there were some notable differences between female and male participants. For
example, females were more likely than males to prefer ‘FIT only’ (35.0% vs. 29.7%). Males were more
likely than females to opt for ‘RC only’ (10.4% vs. 5.8%). There were no significant differences in
preference by age.
TABLE 14 Preferences for surveillance: variation by round, age, sex and outcomes
Variables
Surveillance preference, n (%)
Routine colonoscopy
every 3 years and
no FIT (‘RC only’)a
Routine colonoscopy
every 3 years plus
a FIT every year
(‘RC+ FIT’)
FIT every year
with colonoscopy
only for a positive
result (‘FIT only’)
No further
colonoscopies
or FIT
(‘no surveillance’)
All participants 379 (8.9) 2478 (57.9) 1347 (31.5) 75 (1.8)
Sexb
Female 81 (5.8) 801 (57.1) 492 (35.0) 30 (2.1)
Male 298 (10.4) 1677 (58.3) 855 (29.7) 45 (1.6)
Age (years)
≤ 65 165 (8.1) 1175 (58.0) 655 (32.3) 31 (1.5)
> 65 214 (9.5) 1303 (57.8) 692 (30.7) 44 (2.0)
Roundb
1 41 (15.2) 105 (39.0) 118 (43.9) 5 (1.9)
2 22 (12.2) 82 (45.6) 73 (40.6) 3 (1.7)
3 15 (10.1) 81 (54.4) 52 (34.9) 1 (0.7)
Year 3 (FIT–ve) 300 (8.2) 2206 (60.0) 1104 (30.0) 66 (1.8)
Previous experience with baseline colonoscopyb
Not acceptable 12 (8.6) 56 (40.0) 68 (48.6) 4 (2.9)
Acceptable 347 (8.9) 2301 (58.7) 1201 (30.7) 68 (1.7)
Outcomesb
True negative (FIT–ve RC–ve) 122 (7.3) 908 (54.5) 602 (36.1) 66 (1.7)
False negative (FIT–ve RC+ve) 167 (8.5) 1275 (65.1) 485 (24.8) 34 (2.0)
False positive (FIT+ve RC–ve) 6 (11.8) 30 (58.8) 15 (29.4) 0 (0.0)
True positive (FIT+ve RC+ve) 10 (9.7) 54 (52.4) 38 (36.9) 1 (1.0)
RC, routine colonoscopy.
a Differences in ‘n’ figures are because of variations in the number of questionnaire respondents answering each item.
b p-value of χ2 < 0.005.
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Table 14 shows the pattern of preferences by screening round among FIT-positive participants. There were
notable differences to this pattern among respondents who received a FIT positive result in rounds 1–3.
In round 1, the largest proportion of respondents (43.9%, n = 118) opted for ‘FIT only’, followed closely
by ‘RC + FIT’ (39.0%, n = 105). One out of six respondents (15.2%, n = 41) opted for receiving ‘RC only’,
whereas a very small minority (1.9%, n = 5) preferred ‘No surveillance’. Interestingly, the proportion of
people choosing ‘FIT only’ as their preferred option reduced to 40.6%, (n = 73) in round 2 and to 34.9%
(n = 52) in round 3. By comparison, the proportion of respondents choosing ‘RC + FIT’ increased to 45.6%
(n = 82) in round 2 and to 54.4% (n = 81) in round 3. In contrast, participants who received consistent
FIT-negative results across the study and completed the end-of-study questionnaire in round 3 showed a
strong preference for ‘RC + FIT’ (60.0%, n = 2206) compared with ‘FIT only’ (30.0%, n = 1104), ‘RC only’
(8.2%, n = 300) and ‘No surveillance’ (1.8%, n = 66).
Preferences by satisfaction with baseline colonoscopy
Among participants with a negative experience at baseline colonoscopy, 48.6% (n = 68) preferred
‘FIT only’ compared with 30.7% (n = 1201) of respondents who had rated their baseline colonoscopy as
acceptable (χ2 = 23.01; p < 0.001; see Table 14).
Preferences by final diagnostic/surveillance outcome
Preference for ‘FIT-only’ surveillance was highest in the true-positive group (36.9%, n = 38) and true-negative
group (36.1%, n = 602), and was lowest among respondents who had a false-negative FIT result (24.8%,
n = 485) (see Table 14). In contrast, the option of ‘RC + FIT’ was most frequently chosen among those in the
false-negative group (65.1%, n = 1275).
End-of-study interviews
We invited 31 participants who had received a positive FIT result in round 1 to interview; 22 (71.0%) attended
(male, n = 17; female, n = 5). In round 2, 16 individuals with FIT-positive results were invited, of whom 13
(81.0%) agreed to be interviewed (male, n = 6; female, n= 7). In round 3, we conducted a further 24
interviews (60.0% response rate) with participants after their end-of-study colonic examination.
Acceptability of the faecal immunochemical test
Overall, participants were very satisfied with their experience of taking part in the study and particularly
remarked how much easier it was for them to complete the FIT than the gFOBT they completed in the
BCSP (Box 1).
Reassurance
Another frequently endorsed advantage was that the annual FIT provided more frequent reassurance and
helped to bridge the gap between 3-yearly colonoscopies. Interviewees frequently commented on the
fact that FIT required only a single stool sample. Some participants described this as a ‘mark of quality’,
whereas others thought that it might limit the ability of FIT to detect intermittently bleeding polyps
and cancers.
Test preferences by faecal immunochemical test outcomes
Participants who received a positive FIT result in round 1 or 2, and then had CRC-related abnormalities detected
at their colonic examination, often expressed surprise (Boxes 2 and 3 show quotations from ‘end-of-study
interviews’ in rounds 1 and 2). Importantly, some participants mentioned that any abnormalities detected in
round 1 would probably have been missed during the baseline colonoscopy (see Box 2). Participants who
received false-positive FIT results commonly mentioned feeling relieved by the negative result of their colonic
examination and did not express any concern or regret associated with having had a ‘false alarm’. Some of these
participants preferred to be offered an annual FIT and a 3-yearly colonoscopy, to ensure that any abnormalities
not detected by the FIT could be picked up by a more thorough examination (see Box 3).
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BOX 1 Overall acceptability of the FIT and final colonoscopy examination
The FIT was easy to administer and the instructions were clear
I mean if you’re prone to have these little polyps and things appear then you should be looking out for
them and if this is a way of finding that out fairly easily, simply and cost-effectively then I think it should
be done.
Participant 3: male, round 1, true positive
I’d say it comes, it’s very simple to do, it’s very easily . . . I mean, I’m quite a layperson. It is very simple to
do and the instructions are very clear. . . .
Participant 59: female, round 3, true negative
The FIT was easier and more hygienic to administer than the gFOBT
Well, it was a lot easier to do, it was not as messy as the other, err, you just have to take one sample, erm,
as I say, a hundred times better
Participant 6: male, round 1, true positive
Once it’s clean, far more hygienic . . . if you are hygienic yourself it doesn’t really matter, I suppose, but far
more pleasant than the previous way of testing and the fact that it had to be done three times.
Participant 28: female, round 2, false positive
Opinions about sensitivity of testing a single stool sample
Minor concerns, yes, for the reasons I mentioned. Three tests in a series might be better to highlight a
rogue reading, whereas the one test might be the rogue reading.
Participant 41: male, round 3, true negative
I thought well if they can pick something up from such a small sample as that, I think it’s a much more . . .
to me, it’s a much more accurate fine-tune test.
Participant 33: female, round 3, true positive
An annual FIT test provided more frequent reassurance
You think, well, although I tried not to think . . . oh well 3 years is quite a long time, actually, I suppose a
lot of something could happen in 3 years, whereas yearly it’s caught earlier, isn’t it?
Participant 30: female, round 2, true positive
Three years is quite a long time, and I understand that the polyps can actually turn cancerous, certain ones
can. So it’s [the FIT test] worth doing because if you have anything and anything shows up then you can
get someone to take a look or have another colonoscopy.
Participant 40: female, round 3, true negative
The colonoscopy was tolerable
The colonoscopy was fine, the staff were absolutely brilliant, the clinician that carried it out was
exceptionally good. The worst part was the . . . err, what’s the word I’m looking for . . . the substances I
had to take beforehand.
Participant 21: male, round 1, false positive
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Yes. I mean, it’s not comfortable, it’s not something you want to go through, like anything like that, but,
I mean, it wasn’t bad and they [medical staff] are all very nice and very supportive on both times I’ve had it
done. Very, very good. I couldn’t fault them.
Participant 32: female, round 2, true positive
Negative colonoscopy experiences
. . . and I felt really unpleasant for a good week. I had a lot of back trouble, and he said it was because
what they were having to do, and I believe what they removed this time was a little bit bigger.
Participant 2: female, round 1, true positive
. . . you have that horrendous solution to drink the night prior to the colonoscopy to flush your system
out. I found that really hard to get through, however many litres of water solution it was, to get it through
the system. That was quite gagging in some way, to drink it.
Participant 46: female, round 2, true positive
BOX 1 Overall acceptability of the FIT and final colonoscopy examination (continued)
BOX 2 Quotes representing common themes from end-of-study interviews in round 1
Shock that a polyp was found so soon
. . . well it did surprise me in a sense that, because they told me I wasn’t to have another check for 3 years,
you see what I mean?
Participant 5: male, true positive
Yeah, well with only being, you know, being told that 3 years . . . erm . . . before they want to see me
again, and then it’s within just over 12 months that, something has developed.
Participant 6: male, true positive
Relief that polyps were found and removed
No, not really, it’s just that, I mean, in a way it’s when they do find something, right, then it’s like a relief
when they take it away because you know they took it away.
Participant 5: male, true positive
Well, again, disbelief I suppose. But I suppose relieved that they’d removed whatever it was and again,
just get on with life, I mean what can you do, sit and worry and there’s no point in it.
Participant 2: female, true positive
Understood that polyps may have been missed during the first colonoscopy
. . . no problem, they just found a small, another small polyp, which they probably missed the first time.
Participant 5: male, true positive
I asked him why, err, err they had appeared again so sudden. He said most probably they might have just
left a bit of root in or something like that.
Participant 6: male, true positive
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Relief that no polyps were found during colonoscopy
I was very pleased, well relieved err and obviously you know you forget about it err once it’s been done
and you’re given the all clear you’re at ease.
Participant 14: male, false positive
Relieved. I would have been surprised because it was so quickly . . . so soon after the anterior resection,
err polyps growing . . . would not have grown that rapidly so I suspect any blood in the test was a result
of possible haemorrhoids or whatever.
Participant 21: male, false positive
Concerns about possible harms of colonoscopy
I just don’t think it’s a procedure that should be undertaken lightly, you know there are dangers attached
to it.
Participant 2: female, true positive
. . . if the experts in their wisdom have decided that this is the way to proceed and go ahead, with the
least amount of fuss but with the maximum amount of result it’s err, it’s got to be the way forward.
Participant 1: male, false positive
BOX 2 Quotes representing common themes from end-of-study interviews in round 1 (continued)
BOX 3 Quotes representing common themes from end-of-study interviews in round 2
Remaining positive after receiving a positive FIT result
It was a bit of a surprise, yes it was. But, as I say, I tried to stay positive thinking well, alright, something
has been picked up and it will be sort of dealt with further.
Participant 30: female, true positive
It was like here we go again, because obviously I’ve had the feeling twice now and it got, right, OK,
they’ve found something else, let’s hope it’s the same as the previous time and just go on from there.
Participant 28: female, false positive
Glad to be monitored annually
. . . well, because if I hadn’t have had that done and missed it for 3 years, if you hadn’t sent me that
follow-up one, I wouldn’t have had a normal bowel screening test possibly for 3 years and there might
have been a problem, which I will be eternally grateful for, that you did send me it again.
Participant 33: female, true positive
I feel grateful in a way that I’m being monitored at a close level sort of thing because if it had been left,
my dad didn’t know . . . we didn’t know my dad had it, we were told 3 days before he died.
Participant 34: female, true positive
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In round 3, all remaining participants received a colonoscopy regardless of their FIT outcome. Participants
who received true-positive FIT results at round 3 commonly mentioned being reassured by the accuracy of
the FIT in detecting CRC-related abnormalities, and feeling relieved when abnormalities were removed
during the colonoscopy. In contrast, participants who received false-negative FIT results mostly mentioned
feeling disappointed by having abnormalities found during the colonoscopy. Some participants mentioned
that they did not believe that abnormalities would bleed all the time, rendering a test relying on a single
stool sample unreliable (Box 4).
General discussion
Participant-reported satisfaction with the FIT for Follow-Up study was very high. This was probably in part
bolstered by the participants’ previous experience with gFOBT. Completing the FIT kit was unanimously
perceived as easier and more convenient, especially as it required only one stool sample. However, many
participants remained sceptical that a single sample stool kit would detect CRC reliably and preferred to
have the test in addition to, rather than as a replacement for, colonoscopy.
Although the act of completing the test kit and waiting for the results was associated with some anxiety,
this did not seem to have lasting effects as CRC-related worry or general anxiety was reported to be very
low, even for those who had received positive FIT results.
BOX 3 Quotes representing common themes from end-of-study interviews in round 2 (continued)
Relief that no polyps were found during their colonoscopy
Oh yes, I was pleased there was nothing there, yes.
Participant 25: male, false positive
Well obviously one was pleased, yes.
Participant 27: male, false positive
Concerns about harms of colonoscopy
I can’t say I’d queue up to have a colonoscopy. The FIT is the easier option, if it is accurate.
Participant 31: female, true positive
Yes, because there’s no point in having a colonoscopy if you don’t need to have one. Because it’s not
something you’d recommend to anybody but, having said that, that probably is only because of my
experience.
Participant 30: female, true positive
Reducing the risk of missing cancer
So yes, it probably would be best to run it in conjunction, when I think about it, just in case there is a
slip-up where it’s not detected in the yearly test. Yes, when I think about it, it probably would be nice for
the two things to run together.
Participant 28: female, false positive
On the safe side of things, if you can catch it early, at least you can do something about it.
Participant 26: female, false positive
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BOX 4 Quotes representing common themes from end-of-study interviews in round 3
Reassured by the accuracy of the test
It made me feel good because it had been picked up from there, and if I hadn’t have done the FIT,
that wouldn’t have happened. I had no reason or other symptoms to have gone to the doctor and ask.
So very positive.
Participant 39: female, true positive
Well, I’d probably just . . . It made me believe the FIT was actually a reasonably accurate test.
Participant 46: female, true positive
Reassured by the FIT that there was nothing sinister
I was very pleased that I’d done the FIT as well because I didn’t expect that there would be anything
seeing as I had done the test, so my mind was at ease before I went in because I’d done that one and
obviously she said it was all clear and there was no polyps or anything. So yes, I was really pleased.
Participant 40: female, true negative
I guess that the FIT, if it showed anything amiss, you would have . . . well you wrote to me and said, on
each occasion, that the test was satisfactory. I think that it was fine.
Participant 36: male, true negative
Understood bleeding could have been caused by other conditions
The explanation I got was that why I had a positive test and then nothing showed on the colonoscopy was
because something briefly had released blood into the faecal matter and then healed up.
Participant 50: male, false positive
Well I just put that down to an error in the system. As I said, I’ve got haemorrhoids. Not that they are that
bad, I’ve just had a bit of a bleed and some of the blood has got into the sample. I wasn’t particularly
concerned about it.
Participant 38: male, false positive
Awareness of intermittent bleeding
It must be necessary to have several tests because there are times when I was having blood in my stool
and there were times when I wasn’t. So I’m not entirely surprised that there are times when it shows and
there are times when it doesn’t show.
Participant 37: male, false negative
There was no blood. So the polyps were . . . They’re very, very small and they obviously weren’t bleeding.
Yes. That was fine.
Participant 53: male, false negative
Preference for only being offered a colonoscopy if an abnormal FIT result is found
I mean, the colonoscopy, it’s a very good thing, but it’s not very comfortable [laughs]. If you could get
away without having one of them I think I’d be quite happy.
Participant 40: female, true negative
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Overall, the main message from these studies seems to be that participants valued colonoscopy for
its ability to visually inspect the bowel and were concerned that a single stool sample test might miss
intermittently bleeding polyps and cancers. From a participant perspective, therefore, the FIT was
appreciated as offering a quick and easy way to gain additional reassurance rather than as a
stand-alone test.
There are limitations to bear in mind when interpreting these results. Despite the high level of recruitment,
our findings might not represent the entire surveillance population. Importantly, our end-of-study
preference data are restricted to participants who had undergone an end-of-study colonic examination,
excluding participants who withdrew during the study, failed to attend their end-of-study colonic
examination or did not return their final questionnaire. As a result, our findings might over-represent
people who are concerned about CRC and have positive attitudes towards colonoscopy.
Across all of our studies we were unable to record the ethnic mix of participants. If FIT for surveillance
were to be implemented, it would be vital to ensure active participation from patients from ethnically
diverse backgrounds. Future work should also investigate the views of patients who have not previously
been exposed to colonoscopy surveillance. In a recent hypothetical survey of 491 screening-naive
individuals, the majority (61%) stated a preference for a surveillance test resembling a home-based FIT,
whereas only 31% reported a preference for colonoscopy. Increased frequency of testing was a commonly
cited reason for the preference for FIT. Unfortunately, the response rate of the survey was only 16%,
limiting its generalisability. Future work should investigate whether or not the preference for FIT in
screening-naive individuals translates to greater adherence in the surveillance setting.89
Future research should try to identify the extent to which FIT might enable the small but substantial
proportion of people not attending surveillance colonoscopy to have adenoma surveillance. This study
also revealed that the key concerns about annual FIT surveillance are the lack of visual inspection and
the reliance on a single stool sample, which might miss intermittently bleeding polyps and cancers.
These concerns are based on complex beliefs, which need to be explored further.
Another important question for future research will be to determine what precise additional benefit people
expect to gain from annual FIT. In this study, it was interesting to observe the response from people who
had CRC-related abnormalities detected following a positive FIT result in round 1 or 2. Here, our end-of-
study interviews revealed ‘surprise’ or even ‘shock’, often combined with a realisation that abnormalities
detected so soon after the baseline colonoscopy would probably have been missed at that examination.
BOX 4 Quotes representing common themes from end-of-study interviews in round 3 (continued)
Avoiding the risk of false negatives
I know there’s no guarantees. There could have been blood and there could be nothing at all. Even if I
had the procedure and they found nothing, I’d rather be safe than sorry.
Participant 46: female, true positive
Not to have the colonoscopy, I think I would start to worry with the fact that polyps could be there but we
are not looking for them. Unless the polyps are bleeding then it’s not going to show up on the FIT, is it?
Participant 53: male, false negative
I think I’d have more faith in the colonoscopy than in the actual test. I think the test may just be, as I said,
an indicator but I feel the colonoscopy is more of an examination rather than just a test.
Participant 38: male, false positive
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The extent to which people value FIT for its ability to detect disease that has been missed previously should
be investigated further.
To conclude, these investigations have shown that, although there is enthusiasm for the use of FIT in CRC
surveillance, it is often restricted to the use of FIT as an additional rather than a stand-alone test. Future
research is needed to better understand the concerns of participants with regard to FIT missing polyps
and cancers.
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Chapter 5 Economic evaluation of faecal
immunochemical tests versus colonoscopy surveillance
Introduction
We investigated the incremental cost and cost-effectiveness of annual FIT versus colonoscopy at 3 years
post baseline colonoscopy for post-polypectomy surveillance of intermediate-risk patients.
As defined in the protocol, under the assumption that FIT was as accurate as colonoscopy surveillance, the
aim of the economic evaluation was to undertake a cost-minimisation analysis of annual FIT surveillance
versus colonoscopy surveillance at 3 years. In the event that the marginal effectiveness of FIT surveillance
was significantly less than that of colonoscopy surveillance, the analysis would instead comprise a cost and
cost-effectiveness analysis, balancing test costs against test outcomes.
Method
Overview of economic evaluation
Given the results of the main clinical analysis, we undertook both a cost analysis and cost-effectiveness
analysis comparing annual FIT surveillance with colonoscopy surveillance at 3 years. For the cost analysis,
we calculated the cost of each surveillance alternative. In the cost-effectiveness analysis, the outcomes
were the number of AAs detected and the number of CRCs detected. Cost-effectiveness was expressed in
terms of incremental saving per AA that was not detected by FIT versus colonoscopy surveillance, and per
CRC that was not detected by FIT versus colonoscopy surveillance (see Economic analysis).
The analysis took a UK NHS perspective.90 Costs were calculated in 2015 Great British pounds and inflated
when necessary.91 The time horizon was 3 years, reflecting the cycle time for colonoscopy surveillance, and
all costs were discounted at 3.5% for each year after the first year.
As stated in the protocol, a full lifetime cost-effectiveness model using quality-adjusted life-years (QALYs)
as the outcome measure was not conducted because this would have required separate data describing
the outcomes and treatment pathways associated with the two options.
There were no missing data for the analyses.
Generating a control group
The FIT for Follow-Up study was a single-arm trial, which meant that for the economic analysis we had to
generate a control arm (a pseudo-control group) to consider the cost and outcomes of people who would
have had routine 3-yearly colonoscopy surveillance in the absence of FIT.
In order to create this pseudo-control group, we assumed that all DNA participants for colonic
examinations scheduled because of positive FIT would also be DNA participants for routine colonoscopy
surveillance, and that those participants lost to follow-up during the study would also be lost to routine
colonoscopy surveillance. As a starting point, we defined the size of the intervention and control groups as
the 5946 participants who completed round 1 of the FIT regimen. To estimate the number of participants
receiving colonoscopy surveillance at 3 years in the absence of FIT, we used the sum of all participants
involved in the trial who had a colonic examination (4455 participants who had the routine 3-year colonic
examination, plus 744 participants who had an examination after having a FIT positive result, which
resulted in 5199 participants in total).
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The appropriateness of the size of the pseudo-control arm receiving colonoscopy surveillance at 3 years
can be confirmed by subtracting the participants who DNA their colonic examination and those who were
lost to follow-up from the original 5946 participants who completed round 1 of the FIT regimen (5946 minus
584 DNA participants for the 3-year colonic examination, minus 51 DNA participants for early colonic
examination after a FIT positive result, minus 112 participants who were lost to follow-up during the course
of the 3-year study period, which resulted in 5199 participants in total).
Figure 4 shows the actual number of study participants completing each round of FIT and the estimated
number undergoing colonoscopy surveillance at 3 years in the absence of FIT. Figure 5 shows the resulting
costs, number of colonoscopies, and AAs and CRCs detected in each group.
Resource use and costs
As specified in the study protocol, the costs used in the analyses were restricted to surveillance costs.
We did not include the cost of treating observed cases of disease, other than polypectomy during a
surveillance procedure, but we did include the costs of treating complications of colonoscopy. For every
participant, we calculated the cost of FIT kits92 and of all diagnostic testing that took place as a result of a
positive FIT (Table 15). Unit costs for diagnostic procedures were sourced from the NHS Reference Costs
2014 to 2015,93 and the average cost for each procedure was used. For the unit cost of CT colonography,
we took the weighted average of a CT scan of one area with pre contrast, post contrast and both. For
colonoscopy complications, we included the costs of treating bowel perforations and GI bleeding. The
probabilities of bowel perforation during colonoscopy without and with polypectomy were assumed to be
0.0008 and 0.0017,94 respectively, and the probability of GI bleeding following colonoscopy was assumed
to be 0.00439.94 Unit costs for dealing with these complications were taken from NHS Reference Costs
2014 to 201593 as above (see Table 15). In cases in which an AA was detected, the procedures were
Completed
FIT round 1
(n = 5946)
Enter into model after
completing FIT round 1
(n = 5946)
FIT arm Pseudo-control arm
Completed
FIT round 2
(n = 5350)
Completed
FIT round 3
(n = 5058)
Surveillance
group
(n = 5199)
Surveillance
DNA
(n = 584)
FIT-positive
scan DNA
(n = 51)
Lost to
follow-up
(n = 112)
FIGURE 4 Participants included in the economic analysis. FIT round completed data were drawn from the FIT for
Follow-Up study Consolidated Standards of Reporting Trials (CONSORT) diagram. The pseudo-control arm estimates
the number of surveillance colonoscopies that would have taken place in the absence of the FIT for Follow-Up study.
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FIT round 1
(n = 5946)
Enter into
model
(n = 5946)
FIT arm Pseudo-control arm
AAs, n = 78
CRCs, n = 8
Colonoscopies, n = 321
Cost (discounted) = £214,200
AAs, n = 37
CRCs, n = 8
Colonoscopies, n = 220
Cost (discounted) = £147,446
AAs, n = 37
CRCs, n = 2
Colonoscopies, n = 185
Cost (discounted) = £123,590
FIT arm totals:
Total AAs, n = 152
Total CRCs, n = 18
Total colonoscopies, n = 726
Total cost (discounted) = £485,236
Surveillance arm totals:
AAs, n = 443
CRCs, n = 26
Colonoscopies, n = 5199
Cost (discounted) = £2,633,382
FIT round 2
(n = 5350)
FIT round 3
(n = 5058)
Surveillance
group
(n = 5199)
FIGURE 5 Estimated costs and outcomes associated with annual FIT surveillance and 3-yearly colonoscopy surveillance.
TABLE 15 Unit cost parameters
Parameters Value Source
Colonoscopy £519.42 NHS Reference Costs 2014 to 2015,93 diagnostic, 19 years
and over
Colonoscopy with polypectomy £601.86 NHS Reference Costs 2014 to 2015,93 therapeutic, 19 years
and over
Diagnostic flexible sigmoidoscopy £381.61 NHS Reference Costs 2014 to 2015,93 diagnostic, 19 years
and over
Flexible sigmoidoscopy with polypectomy £480.76 NHS Reference Costs 2014 to 2015,93 therapeutic, 19 years
and over
CT colonography £87.92 NHS Reference Costs 2014 to 2015,93 Diagnostic Imaging
Cost of treating bowel perforation £5911.08 NHS Reference Costs 2014 to 2015,93 Major Large Intestine
Procedure, 19 years and over
Cost of treating GI bleed £2498.14 NHS Reference Costs 2014 to 2015,93 gastrointestinal bleed
with single intervention
FIT kit returned £5.14 Murphy and Gray,92 inflated to 2014/15
FIT kit not returned £1.66 Murphy and Gray,92 inflated to 2014/15
Probability of bowel perforation during
colonoscopy (without polypectomy)
0.0008 Atkin et al.94
Probability of bowel perforation during
colonoscopy (with polypectomy)
0.0017 Atkin et al.94
Probability of GI bleeding after colonoscopy 0.00439 Atkin et al.94
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costed with polypectomy, assuming that the adenoma would be excised during the procedure. For the
base-case analysis, participants who DNA their diagnostic procedures were assumed to incur no cost.
Outcome
The effectiveness of FIT surveillance was expressed in terms of the number of AAs and number of CRCs
that were detected. AAs are of relevance to CRC screening as they pose a high risk of malignancy.
Economic analysis
Mean costs per participant and the difference between the costs of FIT surveillance versus colonoscopy
surveillance were calculated. Incremental cost-effectiveness ratios (ICERs) were calculated in terms of the
incremental cost per additional AA detected and the incremental cost per additional CRC detected. These
were calculated as the costs of FIT surveillance minus the costs of colonoscopy surveillance divided by the
AAs (or CRCs) detected by FIT surveillance minus the AAs (or CRCs) detected by colonoscopy surveillance.
As FIT surveillance was both cheaper and less effective than colonoscopy surveillance, incremental cost-
effectiveness was presented in terms of incremental saving per AA and per CRC not detected. Note that in
this scenario, the numerator of the ICER (incremental costs) and the denominator (differences in AAs and
CRCs detected) are both negative so the ICER will be positive. In this case, higher positive values of the
ICER reflect better value for money as they represent a larger cost saving for each AA or CRC missed.
Calculations of net monetary benefit were not possible because there are no cost-effectiveness thresholds
for these outcomes.
Sensitivity analyses
We undertook a probabilistic sensitivity analysis.90 We varied the following parameters: number of FIT kits
returned at each round, number of colonoscopies required at each round, number of participants who
DNA their diagnostic procedure at each round, number of AAs and CRCs detected by FIT at each round,
and unit costs of colonoscopy, treating bowel perforations and treating GI bleeding following colonoscopy.
Distributions were assigned to the parameters to reflect the uncertainty associated with each parameter
value. We used probabilities to characterise the number of FIT kits returned, colonoscopies, DNAs for
diagnostic testing, and AAs and CRCs, and used beta distributions to model uncertainty in these
probabilities.95 We used uniform distributions to model uncertainty in unit costs, allowing the values to
vary randomly between ± 25% of the base-case value.
A random value from the corresponding distribution for each parameter was selected. This generated an
estimate of the mean cost and mean number of detected AAs and CRCs associated with FIT surveillance
for each of the 5000 simulations, and these were used to calculate the incremental costs, differences in
AAs and CRCs detected and ICERs for FIT versus colonoscopy surveillance. This was repeated 5000 times
and the results for each simulation were noted. The 95% uncertainty intervals were calculated as the 2.5th
and 97.5th percentiles of the simulated values.
We also undertook a deterministic sensitivity analysis. The effect on cost and cost-effectiveness of using
different faecal haemoglobin thresholds to denote FIT positivity was explored using data on the performance
of FIT at different thresholds, reported in Chapter 3. The study used a threshold of 40 µg/g, although lower
thresholds were considered in the analyses. The number of participants classed as positive was higher with
lower thresholds. Therefore, lower thresholds would increase costs associated with FIT surveillance as more
patients would be referred for colonic examinations. To explore the effect of lower thresholds on the
analysis, we assumed a linear relationship between the number of positive FIT results and overall costs of
FIT surveillance.
The impact of the diagnostic procedure unit costs was also explored using univariate sensitivity analysis.
We first assumed that all procedures were undertaken as elective inpatient procedures. We then assumed
that all procedures were undertaken on an outpatient basis. Weighted averages of the upper and lower
quartiles were used for the unit cost of CT colonography (for a procedure with pre contrast, post contrast
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and both). The effect of the unit cost of the FIT kits was analysed by increasing and decreasing the cost by
25%. We similarly varied the unit costs of treating bowel perforations and GI bleeding associated with
colonoscopy by ± 25%. The cost of managing DNA participants was also explored, valuing them at the
full cost of a colonoscopy without polypectomy, instead of at zero cost as in the base-case analysis.
Budget impact
We estimated the budget impact if FIT surveillance were to replace colonoscopy surveillance nationally
over a screening cycle by multiplying the incremental costs per patient as calculated above by the total
estimated eligible patients. We assumed that approximately 4.5 million people between 60 and 74 years
would be screened adequately for CRC in England over a 2.5-year cycle;96 2% would have an abnormal
screening result and be offered a colonic examination,97 uptake of which would be 88%,98 and 16% of
those attending a colonic examination would be diagnosed with intermediate-risk adenomas.99
Results
Costs and outcomes
For the cost analysis, we calculated the total cost of FIT surveillance over 3 years to be £485,236, using a
threshold of 40 µg/g, and the cost of colonoscopy surveillance over 3 years to be £2,633,382 (Table 16).
Hence, FIT surveillance produced a cost saving of £2,148,146 compared with colonoscopy surveillance.
The mean total cost per participant was £81.61 for FIT surveillance and £442.88 for colonoscopy
surveillance. For FIT surveillance, approximately 80% of the total cost was the cost of colonoscopies
undertaken for a positive FIT result, with the remainder split between the cost of FIT kits, complications
of colonoscopy and the cost of alternative diagnostic tests (flexible sigmoidoscopy and CT colonography).
For colonoscopy surveillance, 100% of the cost was accounted for by colonoscopies undertaken.
The FIT surveillance detected fewer AAs and CRCs (n = 152 and n = 18, respectively) than colonoscopy
surveillance (n = 443 and n = 26, respectively).
Cost-effectiveness analysis
The mean incremental cost per participant for FIT versus colonoscopy surveillance was –£361 (95% uncertainty
interval –£386 to –£321) over the 3-year period. FIT surveillance detected 291 fewer (i.e. –291) AAs than
colonoscopy surveillance (95% uncertainty interval –312 to –269) and eight fewer CRCs (95% uncertainty
interval –15 to 1) using a threshold of 40 µg/g (Table 17). These findings suggest that FIT surveillance was less
costly than colonoscopy surveillance and was also less effective at detecting AAs. The point estimate for the
difference in number of CRCs detected suggests that FIT surveillance was less effective at detecting CRCs
than colonoscopy surveillance; however, the size of the 95% uncertainty interval indicates that there is a
chance that FIT surveillance was not less effective. The incremental cost-effectiveness of FIT surveillance versus
colonoscopy surveillance was £7382 (95% uncertainty interval £6475 to £8191) per AA not detected and
£268,518 (95% uncertainty interval –£868,248 to £1,718,956) per CRC not detected.
TABLE 16 Absolute costs and outcomes for 3-yearly colonoscopy surveillance and annual FIT surveillance at
different FIT thresholds
Absolute costs and
outcomes of regimen
Surveillance
Colonoscopy
FIT threshold (µg/g)
40 30 20 10
Cost £2,633,382 £485,236 £568,601 £693,148 £956,602
AAs detected 443 152 182 205 254
CRCs detected 26 18 19 21 22
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Faecal immunochemical test positivity threshold sensitivity analysis
The effect of varying the FIT positivity threshold on cost and cost-effectiveness was explored, relative to
the base case threshold of 40 µg/g. The numbers of AAs and CRCs that would have been detected using
different thresholds were estimated based on the data reported in Chapter 3. Tables 16 and 17 show
the results of this sensitivity analysis. Qualitatively, the findings were similar to the base case threshold of
40 µg/g, indicating that FIT surveillance was less costly than colonoscopy surveillance and less effective
at detecting AAs and CRCs, with the 95% uncertainty interval indicating that there is a chance that FIT
was not less effective at detecting CRCs. However, the absolute cost difference between FIT surveillance
and colonoscopy surveillance fell as the threshold was lowered, and the incremental cost-effectiveness
increased (i.e. improved) as fewer AAs and CRCs were missed. At a threshold of 10 µg/g, the incremental
cost per participant for FIT versus colonoscopy surveillance was –£282 (95% uncertainty interval
–£419 to £70); the 95% uncertainty interval indicates that there is a chance that FIT was not less costly
than colonoscopy surveillance.
Sensitivity analysis if did-not-attend participants were valued at full cost
When valuing the diagnostic procedures of DNA participants at the full cost of a colonoscopy without
polypectomy (instead of at zero cost as in the base-case analysis), the total difference in cost of FIT versus
colonoscopy surveillance was –£2,429,331 over the 3-year period. This corresponds to an incremental cost
per participant for FIT versus colonoscopy surveillance of –£409. The incremental cost-effectiveness of FIT
versus colonoscopy surveillance was £8348 per AA not detected and £303,666 per CRC not detected
(Table 18).
Diagnostic procedure cost sensitivity analysis
The effect of unit costs on the incremental cost and cost-effectiveness was explored in a sensitivity analysis.
Table 18 shows the results of this sensitivity analysis. Incremental cost and cost-effectiveness was largely
insensitive to changes in unit costs, with the exception of the cost of colonoscopies. The cost of FIT kits did
not have an appreciable effect on the analysis.
TABLE 17 Economic evaluation of 3-yearly colonoscopy surveillance vs. annual FIT surveillance at different
FIT thresholds
Output parameter
FIT positivity threshold
Base case (40 µg/g) 30 µg/g 20 µg/g 10 µg/g
Absolute difference in
cost compared with
surveillance colonoscopy
–£2,148,146
(–£2,292,629 to
–£1,911,004)
–£2,064,780
(–£2,230,445 to
–£1,817,489)
–£1,940,234
(–2,127,787 to
–£1,687,479)
–£1,676,779
(–£2,494,145 to
£415,940)
Difference in number of
AAs detected
–291 (–312 to –269) –261 (–284 to –238) –238 (–263 to –213) –189 (–213 to –166)
Difference in number of
CRCs detected
–8 (–15 to 1) –7 (–14 to 3) –5 (–13 to 5) –4 (–9 to 2)
Incremental cost per
participant
–£361
(–£386 to –£321)
–£347
(–£375 to –£306)
–£326
(–£358 to –£284)
–£282
(–£419 to £70)
Incremental
cost-effectiveness
per AA not detected
£7382
(£6475 to £8191)
£7911
(£6823 to £8983)
£8152
(£6884 to £9478)
£8872
(–£2341 to £13,884)
Incremental
cost-effectiveness
per CRC not detected
£268,518
(–£868,248 to
£1,718,956)
£294,969
(–£1,786,046 to
£2,546,573)
£388,047
(–£2,766,964 to
–£3,844,425)
£419,195
(–£3,495,732 to
£3,822,391)
Figures in parentheses are 95% uncertainty intervals, calculated as the 2.5th and 97.5th percentiles of the simulated values.
ECONOMIC EVALUATION OF FAECAL IMMUNOCHEMICAL TESTS VERSUS COLONOSCOPY SURVEILLANCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
62
Budget impact analysis
Based on the assumptions and data described above, we estimated that up to 12,777 individuals would be
eligible for FIT surveillance. Given a cost saving per participant for FIT versus colonoscopy surveillance of –£361
(–£386 to –£321) for the base-case FIT threshold of 40 µg/g, the budget impact from replacing colonoscopy
surveillance with FIT surveillance would be –£4.6M (95% uncertainty interval –£4.9M to –£4.1M). If the FIT
threshold was amended to 30 µg/g, 20 µg/g or 10 µg/g, the resulting cost savings per participant for FIT versus
colonoscopy surveillance would be –£347 (95% uncertainty interval –£375 to –£306), –£326 (95% uncertainty
interval –£358 to –£284) or –£282 (95% uncertainty interval –£419 to £70), respectively, while the budget
impact would be –£4.4M (95% uncertainty interval –£4.8M to –£3.9M), –£4.2M (95% uncertainty interval
–£4.6M to –£3.6M) or –£3.6M (95% uncertainty interval –£5.4M to £0.9M), respectively. As noted, these
figures do not include the costs of treating missed AAs and CRCs.
Discussion
Our economic analysis to evaluate the cost-effectiveness of annual FIT surveillance versus 3-yearly
colonoscopy surveillance showed that FIT surveillance was cheaper than colonoscopy surveillance, but also
less effective at detecting AAs and CRCs. Sensitivity analysis suggested that the cost of DNAs did have an
effect on the analysis, as did the cost of colonoscopies.
The total cost associated with FIT surveillance was sensitive to the faecal haemoglobin threshold selected
to define FIT positivity. This is not surprising, as more people would be classed as positive and referred for
colonic examination with lower thresholds. In all cases, annual FIT surveillance was less costly than 3-yearly
colonoscopy surveillance; however, at the lowest threshold (10 µg/g), there is a chance that FIT surveillance
TABLE 18 Sensitivity analysis of the effect of costs of DNA participants and diagnostic procedure unit costs on the
economic evaluation
Input parameters
Incremental cost
per participant
Incremental cost-effectiveness
Per AA not detected Per CRC not detected
Base case –£361 £7382 £268,518
DNAs valued at full cost –£409 £8348 £303,666
High-cost colonoscopy –£572 £11,692 £425,280
High-cost colonoscopy with polypectomy –£378 £7719 £280,777
High-cost flexible sigmoidoscopy –£359 £7341 £267,045
High-cost computed tomographic colonography –£361 £7380 £268,448
High cost of treating bowel perforation –£362 £7400 £269,175
High cost of treating GI bleed –£363 £7421 £269,939
FIT kit cost +25% –£358 £7312 £265,961
Low-cost colonoscopy –£263 £5375 £195,531
Low-cost colonoscopy with polypectomy –£342 £6983 £254,000
Low-cost flexible sigmoidoscopy –£362 £7395 £268,983
Low-cost computed topographic colonography –£361 £7384 £268,604
Low cost of treating bowel perforation –£358 £7315 £266,088
Low cost of treating GI bleed –£354 £7237 £263,260
FIT kit cost –25% –£365 £7452 £271,075
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was not less costly than colonoscopy surveillance. The incremental cost-effectiveness per AA and CRC not
detected increased significantly (i.e. reflecting better value for money) at lower thresholds. This is because,
despite higher diagnostic costs associated with higher numbers of colonic examinations at lower thresholds,
FIT surveillance would miss fewer participants with AAs and CRC at these lower thresholds. This is despite
the increase in diagnostic costs associated with the higher numbers of colonic examinations that would be
performed. The findings suggest that using FIT as an alternative to colonoscopy for surveillance could result
in significant financial savings, although this would mean missing a number of AAs and CRCs.
Limitations of the economic analysis and further research
Our analysis had two main limitations. The first was that the study was based on a single-arm trial and,
therefore, to undertake the economic analysis, we had to create a pseudo-control group for colonoscopy
surveillance. This is a suboptimal alternative to using a separate control group in a RCT. However, we did
test the impact of the assumptions made in generating the pseudo-control group and showed that the
conclusions of the economic analysis did not change.
The second main limitation, also stemming from the study design, was that our analysis included only the
short-term costs and outcomes associated with surveillance. In particular, we were not able to estimate
lifetime costs and QALYs associated with FIT and colonoscopy surveillance, including the long-term costs
and outcomes associated with undiagnosed CRCs. As stated in the study protocol, such an analysis was
not planned because it would require separate data describing the outcomes and treatment pathways
associated with FIT and colonoscopy surveillance. However, this meant that we could not include the
treatment costs for CRCs that were detected, meaning we are underestimating the total cost of both
surveillance regimens. This underestimation might be particularly pronounced for FIT surveillance given
the potential cost implications of undiagnosed CRCs.
In the light of these limitations, further research would be beneficial, in particular a cost–utility analysis of
annual FIT versus 3-yearly colonoscopy surveillance in terms of the lifetime incremental costs per QALYs
gained. Ideally, such an analysis would be undertaken within a full RCT, enabling a direct comparison
between a treatment and control group and thereby removing the need to generate control group data,
as was done in the present study. Such an analysis would account for costs of treatment associated with
FIT and colonoscopy surveillance, and would also include the costs of treating diagnosed and undiagnosed
CRCs. It would also account for the impact of both surveillance regimens on survival and health-related
quality of life.
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Chapter 6 Discussion
In the UK, individuals deemed to be at intermediate-risk of developing CRC or AAs after polypectomy arecurrently recommended 3-yearly surveillance colonoscopy.22 Although colonoscopy is the most sensitive
examination for colorectal neoplasia, there are disadvantages to its use in this context. Most intermediate-
risk individuals undergoing surveillance colonoscopy will not have CRC or AAs.100–102 Colonoscopy is an
uncomfortable procedure that carries a small risk of serious adverse events.33,103 Furthermore, colonoscopy
is expensive and surveillance colonoscopy is putting a growing strain on already overburdened endoscopy
services.29 In the light of these issues, we developed the FIT for Follow-Up study to examine the diagnostic
accuracy, acceptability and cost-effectiveness of annual FIT as an alternative to colonoscopy for surveillance
of patients at intermediate risk of CRC or AAs following polypectomy.
Main findings
In our study, the sensitivity of FIT was greater for CRC than for AAs and depended strongly on the faecal
haemoglobin threshold applied and the number of completed FIT rounds. The sensitivity of the first
completed FIT at a threshold of 40 µg/g was only half that estimated at a threshold of 10 µg/g (30.8%
vs. 61.5% for CRC and 17.6% vs. 33.2% for AAs). Sensitivity was even higher at 10 µg/g in those who
completed all FITs offered (91.7% and 59.3% for CRC and AAs, respectively, in cumulative test analysis).
Although using a low threshold and multiple rounds of FITs reduced the number of CRCs and AAs missed,
this came at a cost of reduced specificity and an increase in cumulative positivity and requirement for
colonoscopy. However, even when the lowest threshold of 10 µg/g was applied, 71% of participants did
not test positive at any round. Therefore, using three rounds of annual FIT as an alternative to the first
surveillance colonoscopy at year 3 would considerably reduce the number of colonoscopies performed.
The FIT positivity declined by round of testing, reducing from approximately 6% at the first round to 4%
at the third round with a threshold of 40 µg/g, and from 14% to 9% with a threshold of 10 µg/g. The
decrease in positivity is not surprising given that participants who would have tested positive at a given
threshold would have been offered an early colonoscopy and, therefore, would not have been invited to
subsequent FIT rounds.
Sensitivity also declined by round of testing; for example, at a threshold of 40 µg/g, sensitivity for ACN was
estimated to be 17.9% for the first completed FIT, 11.7% for the second FIT and 12.1% for the third FIT.
At 10 µg/g, sensitivity for ACN was 34.3% for the first FIT, 22.5% for the second FIT and 19.6% for the
third FIT. A possible explanation for this is that participants with an AA or CRC that caused high faecal
haemoglobin levels were likely to test positive at an early round.
There were differences in the performance of FIT by age and sex. FIT positivity was higher in older and
male participants. This reflects the prevalence of ACN, which, in both this study and more generally,
increases with age and is higher in men.104,105 However, sensitivity for AAs and CRC was also generally
higher, and specificity lower, in older participants and men. The reasons for these differences in FIT
positivity and sensitivity between older and younger patients, as well as between men and women, are
not yet fully understood.
Looking at the stage distribution of the CRCs detected during the study, 11 were pT stage three or four.
Considering that these were detected within 3 years following colonoscopy, it is likely that they were
present but missed during the baseline examination. Although advanced-stage CRCs are more likely to be
detected by FIT than early-stage CRCs,75 our reported sensitivities for FIT are not likely to be significantly
inflated compared with what would be achieved in clinical practice; colonoscopy is not perfectly sensitive
and a small proportion of CRCs, including those at advanced stages, are routinely missed.106–108
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A surveillance programme employing annual FIT would therefore help to speed detection of missed CRCs
compared with a programme adopting surveillance colonoscopy at 3 years. Indeed, in our study, FIT
detected 8 of the 11 pT3/4 CRCs at 40 µg/g and 10 out of the 11 at 10 µg/g, with seven detectable
in round 1 or 2 at either threshold.
Comparison with other studies of faecal immunochemical tests
in surveillance
The FIT for Follow-Up study is, to our knowledge, the largest study to date to have examined the
performance of FIT in post-polypectomy surveillance. In our study, 5199 participants completed at least
one FIT and attended colonoscopy in the study period, during which time 26 CRCs and 443 AAs
were diagnosed.
Estimated sensitivity for CRC of a single FIT at the lowest studied threshold (10 µg/g) was lower in our
study (61.5%) than in previous studies of both qualitative and quantitative FIT in a surveillance setting.
Robinson et al.57 reported the sensitivity for CRC of a qualitative FIT (Hemeselect, SmithKline Diagnostics,
San Jose, CA, USA) before surveillance colonoscopy to be 70.0% (7/10). Terhaar sive Droste et al.46
reported the sensitivity for CRC of a single quantitative FIT (OC-Sensor) to be 80.0% (4/5) at 10 µg/g.
Hazazi et al.59 found the sensitivity of three consecutive quantitative FITs (OC-Micro at 10 µg/g) for CRC
before surveillance colonoscopy to be 100.0% (8/8). Low numbers of CRCs in each study limited the
precision of these estimates. One potential reason for lower sensitivity in our study might be that the first
FIT was completed 2 years prior to, rather than immediately before, the year 3 planned surveillance
colonoscopy. Faecal haemoglobin concentration may have increased over time as neoplasia progressed.
The sensitivity for AAs or ACN of a single FIT at 10 µg/g was not markedly different in our study (33.2% for
AAs and 34.3% for ACN) to figures reported in previous studies of FIT in surveillance. Robinson et al.57 noted
a sensitivity of 44.4% (16/36) of a qualitative FIT for large adenomas (i.e. sized ≥ 10mm). Hazazi et al.59 found
the sensitivity for ACN of three consecutive quantitative FITs at 10 µg/g to be 44.4% (32/72). Terhaar sive Droste
et al.46 reported the sensitivity for AAs of a single FIT at 10 µg/g to be 27.7% (28/101).
The study conducted by Lane et al.60 is the only other study to have examined the sensitivity of annual FIT
in a surveillance setting. Annual qualitative FIT (median of two rounds) identified 12 out of 14 patients
with CRC (sensitivity of 85.7%) and 60 of 96 patients with AAs (sensitivity of 64.5%). Comparable, but
slightly lower, sensitivity was observed in our study with three annual FIT rounds and a threshold of 10 µg/g
(programme analysis: 84.6% for CRC and 57.3% for AAs).
Comparison with other studies of faecal immunochemical tests
in screening
More extensive research has been conducted into the use of FIT for CRC screening. A systematic review
commissioned by the US Preventive Services Task Force,56 published in 2016, reported the sensitivity of a
single FIT for CRC, from studies using a FDA-approved qualitative or quantitative FIT and colonoscopy as
reference standard, to be in the range 73–88% and specificity to be in the range 90–98%. Sensitivity of
a single FIT for AAs was reported to be in the range 22–40% and specificity to be in the range 91–97%.
An earlier systematic review with meta-analysis of FIT for CRC screening calculated a pooled sensitivity and
specificity for CRC of FIT at 20 µg/g of 86% (95% CI 75% to 92%) and 91% (95% CI 89% to 93%),
respectively.55
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The sensitivity of FIT for CRC reported by these systematic reviews is higher than was observed in our
study. One potential explanation for this may be differences in the size, site and stage of CRCs detected
through surveillance relative to screening. A systematic review with meta-analysis by Hirai et al.109 found
lower sensitivity of FIT for proximal than distal CRC. Furthermore, faecal haemoglobin levels appear to be
higher in patients with larger AAs and in those with a greater number of AAs.110
Health psychology assessment
Participants generally reported high levels of satisfaction with the FIT for Follow-Up study. Although
completing the test was associated with some increased anxiety, this did not seem to have a long-lasting
effect. Participants also reported that FIT was easier and more convenient than the three stool sample
gFOBT (hema-screen™; Immunostics, Eatontown, NJ, USA) used at the time in the BCSP.
There was some scepticism about whether or not FIT alone would detect cancer reliably, particularly with
only one stool sample. Although participants were generally in favour of the use of FIT in surveillance,
most preferred annual FIT in addition to colonoscopy every 3 years (57.9%, 2478/4279), with a lower
proportion (31.5%, 1347/4279) preferring annual FIT alone. Many participants valued annual FIT in
addition to colonoscopy for the more frequent reassurance this provided them.
Health economic assessment
In incremental cost and cost-effectiveness analyses, annual FIT surveillance was cheaper than 3-yearly
colonoscopy surveillance. At a threshold of 40 µg/g, the cost of FIT surveillance for the 5946 study
participants was estimated to be £485,236, compared with £2,633,382 for colonoscopy surveillance.
However, compared with colonoscopy surveillance, FIT surveillance resulted in eight missed CRCs (8/26)
and 291 missed AAs (291/443).
Reducing the FIT threshold increased the cost of FIT surveillance and reduced the number of colorectal
lesions missed. With a threshold of 10 µg/g, the cost of FIT surveillance was estimated to be £956,602,
with 4 out of 26 CRCs missed and 189 out of 443 AAs missed. Incremental cost-effectiveness per AA and
per CRC not detected increased (i.e. improved) with lower thresholds. These findings demonstrate that
low-threshold annual FIT could be a cheaper alternative strategy for surveillance of intermediate-risk
patients following the removal of adenomas. However, further economic analysis would be beneficial to
understand the cost implications of AAs and CRCs missed by FIT, and the impact on expected QALYs lost.
Strengths and limitations
Our study had a number of strengths, including a relatively large sample size, a well-defined population
comprised solely of individuals undergoing surveillance for intermediate-risk adenomas, and results from
multiple rounds, rather than a single round, of FIT.
The study also had limitations. One possible limitation is that we assumed that the population with ACN was
static, such that any ACN detected was present and would remain present and unchanged in the absence of
colonic examination at years 1, 2 and 3. This is a reasonable assumption as it is widely thought that annual
polyp progression rates are low. A systematic review of the natural history of small polyps (i.e. sized < 10mm)
found that, in the few studies that have been conducted, the majority of untreated polyps did not progress to
become an AA over 2–3 years.111 Furthermore, in a study of 226 patients with large untreated polyps (i.e. sized
≥ 10mm), the risk of CRC at 5 years post-baseline assessment was only 2.5%.112
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Under the assumption of a static ACN population and with a constant FIT sensitivity, we would expect the
number of neoplasms detected to decrease with each round. The detection of eight CRC cases at round 1,
eight CRC cases at round 2 and two CRC cases at round 3 is consistent with a static population assumption
for CRC. However, the detection of 78 AAs at the first round and 37 at each of the second and third
rounds is less consistent with a static population of AAs, and suggests that even within the study period of
3 years, there is some movement in and out of this population. However, if anything, the static population
assumption is likely to lead to conservative results with respect to the effect of FIT at the various thresholds,
as it takes no account of the improved outcome associated with lesions detected earlier.
A further limitation of the study is that we assumed that the colonic surveillance examination had perfect
sensitivity for AAs and CRCs. Most participants attending colonic examination received a colonoscopy
(98.0%, 5097/5199). Although considered the ‘gold-standard’ colonic examination, colonoscopy occasionally
misses polyps and, on rare occasions, CRCs.113,114 A small proportion of participants attending colonic
examination did not receive colonoscopy but did receive CT colonography. A randomised trial of CT
colonography and colonoscopy in 1610 symptomatic patients found little difference in the detection rate of
CRC and large polyps between the examinations.115 In a study of 2531 asymptomatic participants undergoing
CT colonography followed by colonoscopy, sensitivity of CT colonography for adenomas or CRCs ≥ 10mm
in size was 90% relative to colonoscopy.116 Flexible sigmoidoscopy has lower sensitivity than CT colonography
or colonoscopy as the proximal colon is not examined. However, in our study, only two participants received
flexible sigmoidoscopy without additional colonoscopy or CT colonography (0.04%, 2/5199).
The generalisability of our findings was limited to an extent by the inclusion criteria, which stipulated that
all participants had to return a first round FIT to be included. Uptake of FIT at rounds 2 and 3 is likely to
be higher in our study than if participants who did not respond to the first FIT invitation had also been
reinvited. Participation was slightly higher in older invitees (75.6% among invitees aged > 65 years and
72.9% among invitees aged ≤ 65 years) and in men (74.6% of male invitees participated and 73.6% of
female invitees participated). Given that we stratified our findings by age and sex, the negative consequences
of this are limited.
The generalisability of the findings from the health psychology assessment are limited in a similar way, as
questionnaires and interviews were administered only to individuals participating in the main study. The
attitudes of these individuals towards FIT and surveillance are likely to have been more favourable than
those of individuals who did not agree to participate.
A further potential issue of generalisability is that we evaluated just one FIT brand (OC-Sensor). Evidence
from a recent study of nine different quantitative FITs does, however, suggest that this is not a significant
limitation.117 When directly compared in a single screening cohort, different FIT brands achieved near-equal
sensitivities when thresholds were set to yield defined rates of test positivity.
As noted, the economic evaluation was limited as it was based on a single-arm trial and did not consider
the cost implications of missed AAs and CRCs and impact on QALYs.
In addition, although we hoped to model the potential of FIT screening to replace colonoscopy surveillance
for groups at intermediate risk of developing CRC, including those with a personal or family history of
CRC, we unfortunately were not able to realise this aim in the study period. A cost-effectiveness analysis
of different CRC screening and surveillance strategies has recently been conducted, using data from the
Dutch general population.118 The analysis used the Adenoma and Serrated pathway to Colorectal Cancer
(ASCCA) model, populated with Dutch data for colorectal lesion prevalence rates and CRC incidence
and mortality rates, to compare no screening or surveillance, FIT screening alone and FIT screening plus
surveillance colonoscopy. It was revealed that both FIT screening alone and FIT screening with surveillance
colonoscopy were more effective and cost saving than no screening or surveillance. FIT screening with
surveillance colonoscopy was not, however, cost-effective compared with FIT screening alone (using the
Dutch cost-effectiveness threshold).
DISCUSSION
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Implications for clinical practice
Our findings suggest that a programme of low-threshold annual FIT could perform a useful role in the
surveillance of intermediate-risk patients. However, in a recent study examining heterogeneity of CRC
incidence in intermediate-risk patients, we identified a lower-risk subgroup, for whom the value of
colonoscopy surveillance was unclear, and a higher-risk subgroup for whom colonoscopy surveillance
was clearly beneficial.102 The utility of FIT surveillance may differ dependent on risk subgroup.
Currently, most patients deemed at intermediate risk following polypectomy cease surveillance after two
negative surveillance colonoscopies.22 We have examined the performance of FIT relative to the initial
surveillance colonoscopy but we do not have sufficient data on the performance of FIT in the longer term.
FIT might also perform a useful role in patients diagnosed with high-risk adenomas instead of the first
12-month surveillance examination or after the first surveillance colonoscopy.
Recommendations for research
1. Further research on FIT-based surveillance is needed to examine the implications of missed ACN,
considering effects on QALYs.
2. The identification of subgroups among intermediate-risk patients102 requires further research into the
performance and value of FIT by subgroup.
3. The efficacy, safety and cost-effectiveness of FIT in longer-term surveillance, as well as in high-risk
patients, should be evaluated in RCTs.
4. Future studies should aim to determine whether molecular stool testing in addition to FIT could improve
sensitivity further. This is important as the diagnostic accuracy of FIT is to some extent limited given
that, as it is a test for occult blood in stool, non-bleeding lesions will not be detected. Although van
Lanschot et al.119 are currently evaluating FIT and a stool DNA test performed separately in a surveillance
setting, the sensitivity of these tests in combination requires investigation.
5. Finally, effort should be placed on building a natural history model of CRC, similar to the ASCCA
model,118 which incorporates data from the British population and from intermediate-risk patients. This
would enable evaluation of the potential to replace 3-yearly colonoscopy surveillance with annual
FIT surveillance.
Conclusion
This study has demonstrated the potential value of FIT for the surveillance of patients deemed to be at
intermediate risk following polypectomy. Annual rounds of FIT, using a low faecal haemoglobin threshold
and with colonoscopy in positive cases, achieved high cumulative sensitivity for CRC, was well accepted by
patients, and would be cost saving compared with 3-yearly colonoscopy surveillance. However, with higher
thresholds, FIT surveillance could miss 15–30% of CRCs and 40–70% of AAs, and most participants
preferred annual FIT in combination with 3-yearly colonoscopy. Further research is needed to define a clear
role for FIT in post-polypectomy surveillance. A full RCT with cost–utility analysis that addresses the cost
and health implications of AAs and CRCs that were not detected is recommended.
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